{
    "GP006 Management of Bartholins Cyst Abscess N.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the management of Bartholin\u2019s cyst/abscess:  \n\n### **Key Pathological Terms:**  \n- **Bartholin\u2019s cyst**  \n- **Bartholin\u2019s abscess**  \n- **Sterile mucous accumulation**  \n- **Duct blockage**  \n- **Acute inflammatory reaction**  \n- **Cellulitis**  \n- **Vulval abscess**  \n- **Recurrent Bartholin\u2019s abscess**  \n- **Diabetes mellitus (screening in recurrent cases)**  \n\n### **Clinical Presentation:**  \n- **Soft, fluctuant, painless mass (cyst)**  \n- **Acute pain, inflammation, swelling (abscess)**  \n\n### **Management Approaches:**  \n- **Surgical intervention (abscess)**  \n- **Outpatient management (Word catheter)**  \n- **Marsupialisation (with biopsy if >40 years)**  \n- **Incision and drainage (larger abscesses)**  \n- **Excision of gland (consultant-led)**  \n\n### **Procedures & Interventions:**  \n- **Word catheter**  \n  - Outpatient procedure  \n  - No fasting required  \n  - 97% success rate at 6 months  \n  - Risk of catheter falling out  \n- **Marsupialisation**  \n  - Requires **general anaesthesia**  \n  - **Biopsy** if patient >40  \n  - 5-15% recurrence rate  \n  - Higher post-op pain  \n\n### **Antibiotic & Adjunctive Therapy:**  \n- **IV antibiotics (if cellulitis)**  \n- **No routine antibiotics (unless cellulitis/PID/STI suspected)**  \n- **Analgesia**  \n- **Warm compress (small abscesses)**  \n\n### **Follow-up & Discharge:**  \n- **Discharge plan with follow-up**  \n- **Nurse-led discharge (post-op)**  \n- **Consult senior clinician (recurrent cases)**  \n\n### **Operational Notes:**  \n- **CEPOD pathway**  \n- **Day Surgery Unit (ext. 7242)**  \n- **General anaesthesia (marsupialisation)**  \n\nThese terms encapsulate the core clinical, diagnostic, and therapeutic aspects of managing Bartholin\u2019s cyst/abscess as per the guideline.",
    "MP005 Perinatal Care for Transgender  Non-Binary People.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and importance:\n\n### **Core Concepts & Key Principles**  \n- **Trans and non-binary individuals**  \n- **Gender identity**  \n- **Gender expression**  \n- **Gender dysphoria**  \n- **Pronouns & preferred name**  \n- **Trauma-informed care**  \n- **Privacy & dignity**  \n- **Inclusive communication**  \n\n### **Clinical Care & Procedures**  \n- **Perinatal care**  \n- **Pre-conception care**  \n- **Antenatal care**  \n- **Intrapartum care**  \n- **Postnatal care**  \n- **Hormone therapy (testosterone, implications for pregnancy/postpartum)**  \n- **Lower surgery (urethral lengthening, catheter considerations)**  \n- **Top surgery (chestfeeding implications, mastitis risk)**  \n- **Catheterisation (aseptic technique, urethral anatomy considerations)**  \n- **Vaginal examination (language preferences)**  \n\n### **Postnatal & Postpartum Considerations**  \n- **Postnatal depression (higher risk with testosterone history)**  \n- **Infant feeding (chestfeeding/breastfeeding post-top surgery)**  \n- **Testosterone resumption postpartum**  \n- **Contraception for birthing parents**  \n- **Birth registration (\"Mother\" legal requirement)**  \n\n### **Communication & Documentation**  \n- **Pronoun stickers**  \n- **\"My Language Preferences\" sheet**  \n- **Anatomical vs. preferred terms (e.g., \"chest\" vs. \"breasts\")**  \n- **Misgendering (harmful effects)**  \n\n### **Legal & Ethical References**  \n- **NICE CG190 (respect in labour)**  \n- **NMC The Code (dignity, communication, individual choice)**  \n- **Gender reassignment discrimination**  \n- **Transphobia & victimisation**  \n\n### **Specific Clinical Considerations**  \n- **Shared wards vs. side-room preference**  \n- **Mastitis risk post-top surgery**  \n- **Urethral lengthening & catheter selection**  \n- **Aseptic non-touch technique (catheterisation)**  \n\nThese terms encapsulate the critical aspects of the guideline, ensuring healthcare providers understand the unique needs of trans and non-binary individuals in perinatal care.",
    "CG12035 Neonatal Jaundice.txt": "Clinical significance terms and keywords:\n- Neonatal jaundice\n- Midwives\n- Neonatal staff\n- Paediatricians\n- Nursery nurses\n- Evidence-based guidance\n- Recognition\n- Management\n- Bilirubin levels\n- Antenatal care\n- Postnatal care\n- Risk factors\n- Visual inspection\n- Gestational age\n- Family history\n- Early jaundice\n- Serum bilirubin\n- Gas bilirubin\n- Phototherapy\n- Exchange transfusion\n- Intravenous immunoglobulin\n- Conjugated bilirubin\n- FBC (Full Blood Count)\n- Blood group determination\n- DAT (Direct Antiglobulin Test)\n- ETCOc (End-tidal carbon monoxide)\n- IVIG (Intravenous Immunoglobulin)",
    "BMS - 2024 - Management of unscheduled bleeding on HRT.txt": "- Unscheduled bleeding\n- HRT\n- Endometrial cancer risk factors\n- Investigation\n- Adjusting HRT\n- Assessment\n- Cancer risk factors\n- Endometrial assessment\n- Ultrasound\n- Progestogen\n- Regimen\n- Compliance\n- Risk factors\n- Endometrial protection\n- Levonorgestrel 52 mg intra-uterine device\n- Micronised progesterone\n- Endometrial hyperplasia\n- Clinical pathways\n- Conservative management\n- Referral\n- Endometrial biopsy\n- Hysteroscopy\n- Hormone replacement therapy\n- Progestogen type\n- Non-hormonal alternatives\n- Weight management\n- Lifestyle adjustments\n- Contraceptive needs\n- Perimenopausal women\n- Desogestrel\n- Combined oral contraceptives\n- Surgical options\n- Hysterectomy\n- Resource utilization\n- Gender identity\n- Gynaecological services\n- Reproductive services\n- Inclusive care\n- Clinical assessment\n- BMI assessment\n- History taking\n- Examination\n- Abdominal assessment\n- Vulvo-vaginal assessment\n- Cervical appearance assessment\n- Genital tract swabs\n- Cervical screening\n- Pregnancy test\n- Expert review panel\n- Evidence-led recommendations\n- Consensus review\n- Efficient resource utilization\n- Audit\n- Endometrial thickness\n- TVS\n- Blind or targeted endometrial biopsy\n- Hyperplasia\n- RCOG endometrial hyperplasia guideline",
    "MP031 Pre-term labour.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance:\n\n### **Core Concepts**  \n- **Preterm birth**  \n- **Adverse infant outcome**  \n- **Survival and quality of life**  \n\n### **Diagnosis & Assessment**  \n- **Threatened preterm labour**  \n- **Regular and painful uterine contractions**  \n- **Cervical change before 37 weeks**  \n- **Fetal Fibronectin testing (22+0 to 34+6 weeks)**  \n- **Obstetric review and management**  \n- **Ultrasound scan (fetal growth assessment)**  \n- **Blood tests, ultrasound scans, sensitivities monitoring**  \n\n### **Interventions & Treatments**  \n- **Antenatal corticosteroids (23-34+6 weeks)**  \n  - Reduces **neonatal respiratory distress**  \n- **Tocolytics** (for **preterm rupture of membranes**)  \n- **Magnesium sulfate** (for **fetal neuroprotection**, **cerebral palsy prevention**)  \n- **Mode of delivery discussion** (consultant obstetrician)  \n- **Caesarean section not routinely recommended for preterm breech**  \n\n### **Neonatal Care**  \n- **Neonatal support at delivery**  \n- **Avoid opiates in labor**  \n\n### **Associated Conditions & Guidelines**  \n- **Preterm prelabour rupture of membranes (PPROM)**  \n- **Prevention of early-onset neonatal Group B Streptococcal Disease**  \n- **NICE guidelines (antenatal and intrapartum care)**  \n- **Diabetes mellitus in pregnancy**  \n\n### **Special Considerations**  \n- **Perinatal management of extreme preterm birth (<27 weeks)**  \n- **Appendices for parents of very premature babies**  \n\nThese terms encapsulate the critical clinical aspects of the guideline, ensuring a clear understanding of diagnosis, management, and interventions for preterm birth.",
    "Releasing placentas to parents form.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, which are critical for understanding the guidance:  \n\n### **Key Clinical & Safety Terms:**  \n1. **Placenta handling**  \n2. **Sealed in 2 bags**  \n3. **Leak-proof container**  \n4. **Storage in fridge (without food)**  \n5. **48-72 hours storage**  \n6. **Standard hygiene precautions**  \n7. **Infection risk reduction**  \n8. **Avoid blood contact with skin breaks**  \n9. **Home burial (following local guidelines)**  \n10. **1 meter burial depth**  \n11. **Prevent contamination**  \n12. **Remove plastic cord clamps**  \n13. **No non-biodegradable containers**  \n14. **Avoid water supply contamination**  \n15. **Prohibited disposal in domestic waste**  \n16. **Hospital return option for disposal**  \n\nThese terms cover the essential **safety, hygiene, storage, and disposal** instructions for parents handling placentas. Let me know if you need further refinement!",
    "SOP001 Consultant Ward Round East UHS Maternity.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance:  \n\n### **General Terms:**  \n- **Standard Operating Procedure (SOP)**  \n- **Consultant-led ward rounds**  \n- **On-call consultant**  \n- **Patient care**  \n- **Safety and quality of care**  \n- **RCOG standards** (Royal College of Obstetricians and Gynaecologists)  \n- **Ockenden Immediate Essential Actions**  \n\n### **Clinical & Operational Terms:**  \n- **Obstetric admissions**  \n- **Gynaecology ward round**  \n- **Acute obstetric review (within 14 hours)**  \n- **Escalation to consultant**  \n- **Labor ward presence**  \n- **Clinical condition monitoring**  \n- **Social circumstances**  \n- **Psychological wellbeing**  \n\n### **Roles & Responsibilities:**  \n- **Consultant Obstetricians and Gynaecologists**  \n- **Chief of service**  \n- **Obstetric lead**  \n- **Clinical director**  \n- **Trainees**  \n\n### **Procedural Details:**  \n- **Twice-daily ward rounds**  \n- **Timings for different sites/days**  \n- **Daily gynaecology ward round**  \n- **Escalation guidelines**  \n\nThese terms encapsulate the core clinical, operational, and governance aspects of the guideline.",
    "GP007 Ovarian Hyperstimulation Syndrome (OHSS) V2.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance on **Ovarian Hyperstimulation Syndrome (OHSS)**:\n\n### **Core Concepts & Definitions**  \n- **Ovarian Hyperstimulation Syndrome (OHSS)**  \n- **Iatrogenic condition**  \n- **Fertility treatment**  \n- **Vasoactive products**  \n- **Systemic disease**  \n\n### **Diagnosis & Assessment**  \n- **Ovarian stimulation history**  \n- **Abdominal distension**  \n- **Abdominal pain**  \n- **Nausea & vomiting**  \n- **Differential diagnosis** (ovarian cyst, pelvic infection, intra-abdominal hemorrhage, ectopic pregnancy, appendicitis)  \n- **Severity classification** (mild, moderate, severe, critical)  \n\n### **Clinical Management**  \n- **Supportive management**  \n- **Symptomatic relief** (pain, nausea)  \n- **Outpatient management** (mild/moderate cases)  \n- **Inpatient management** (severe/critical cases)  \n- **IV rehydration therapy**  \n- **Indwelling catheter** (fluid balance)  \n- **Paracentesis** (if necessary)  \n- **Pain relief & antiemetics**  \n\n### **Monitoring & Reporting**  \n- **Early consultant involvement**  \n- **Ultrasound & necessary tests**  \n- **Documentation of severity**  \n- **Confidential Enquiries into Maternal Deaths** (reporting deaths)  \n\n### **Discharge & Follow-Up**  \n- **Discharge letter**  \n- **Patient information leaflets**  \n- **Contact numbers for concerns**  \n- **Emotional support & reassurance**  \n\n### **Guideline References**  \n- **RCOG Green-top guideline (2006)**  \n\nThese terms encapsulate the essential clinical, diagnostic, and management aspects of OHSS as outlined in the protocol.",
    "GP012 Ovarian Cysts (v1.0).txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and category:\n\n### **General Terms**  \n- **Asymptomatic ovarian cysts**  \n- **Pre-menopausal women**  \n- **Post-menopausal women**  \n- **Ovarian masses**  \n- **Benign vs. malignant**  \n- **Risk of Malignancy Index (RMI)**  \n\n### **Definitions & Types of Cysts**  \n- **Simple ovarian cyst** (thin-walled, anechoic, no flow)  \n- **Haemorrhagic ovarian cyst** (reticular echoes, no internal flow)  \n- **Complex cysts** (requires referral regardless of menopausal status)  \n\n### **Diagnostic & Imaging Terms**  \n- **Transvaginal ultrasound** (preferred imaging)  \n- **CA-125** (tumour marker, interpret with caution)  \n- **Alpha fetoprotein (AFP)** (for women <40 with complex mass)  \n- **Human chorionic gonadotropin (HCG)** (for women <40 with complex mass)  \n- **IOTA Group ultrasound rules** (classification of benign vs. malignant masses)  \n\n### **Menopausal Status & Cyst Management**  \n#### **Premenopausal Women:**  \n- **Cysts \u22643cm** (normal, no follow-up)  \n- **Cysts >3cm \u22645cm** (describe, no immediate action)  \n- **Cysts >5cm** (rescan in 6 months)  \n\n#### **Postmenopausal Women:**  \n- **Cysts \u22641cm** (clinically inconsequential)  \n- **Cysts >1cm \u22645cm** (describe, repeat scan in 6 months)  \n- **Cysts >5cm** (gynaecology referral)  \n\n### **Management & Referral Criteria**  \n- **All complex cysts** \u2192 **gynaecology referral**  \n- **Moderate/high RMI** \u2192 **discuss with gynaecological oncologist**  \n- **Persistent/increasing cysts** \u2192 **surgical management**  \n- **Aspiration not recommended** (high recurrence risk)  \n- **Surgical removal** (avoid spillage, consider oophorectomy)  \n\n### **Key Clinical Considerations**  \n- **Last menstrual period (LMP)**  \n- **Hormonal status**  \n- **Family/personal history of cancer**  \n- **Previous investigations/sc",
    "CG14021 Birth Centre guideline.txt": "- Birth Centre\n- Maternity staff\n- Supporting women\n- Place of birth\n- Care\n- Senior midwives\n- Obstetric Consultants\n- Guidelines Group\n- Supervisors of Midwives\n- Antenatal Care\n- Risk Assessment\n- Labour\n- Homebirth\n- Approval date\n- Criteria for Admission\n- Low-risk\n- High-risk factors\n- Central Labour Suite\n- Obstetric indicators\n- Neonatal indicators\n- Emergency transfer\n- Postnatal Transfer\n- Monitoring\n- NICE intrapartum care Quality Standards\n- Preterm birth\n- Retained placenta\n- Fetal Complications\n- Fetal growth restriction\n- Macrosomia\n- Fetal heart rate\n- Doppler studies\n- Anhydramnios\n- Oligohydramnios\n- Polyhydramnios\n- Reduced fetal movements\n- Meconium\n- Major anomalies\n- Gynaecological history\n- Myomectomy\n- Hysterotomy\n- Uterine abnormalities",
    "UHSussex - Fetal Heart Monitoring Guideline.txt": "- Fetal Heart Monitoring\n- Antenatal Period\n- Intrapartum Fetal Monitoring\n- Electronic Fetal Monitoring (EFM)\n- Computerised CTG (cCTG)\n- Gestational Age\n- Short Term Variation (STV)\n- Baseline Rate (BLR)\n- Decelerations\n- Accelerations\n- Normal, Suspicious, Pathological\n- Conservative Measures\n- Maternal Position\n- Hypotension\n- Oxytocin\n- Obstetric Review\n- Neonatal Support\n- Bradycardia\n- Fetal Acidosis\n- Fresh Eyes\n- Continuous Monitoring\n- Intermittent Auscultation\n- Obstetrician\n- Midwife\n- Labour\n- Homebirth\n- CTG Trace\n- Risk Factors\n- Intrauterine Hypoxia\n- Acidaemia\n- Normal Trace\n- Clinical Scenario\n- Cardiotocography\n- Systematic Assessment\n- Multidisciplinary Team\n- Fetal Viability\n- Holistic Assessment\n- Maternal Pulse\n- Fetal Condition Assessment\n- High-Risk Pregnancies\n- Birthing Companions\n- Wireless Transducers\n- Wired Transducers\n- FHR\n- Intrapartum Risk Factors\n- Sepsis\n- Meconium\n- Uterine Blood Flow\n- Cord Compression\n- Left Lateral Position\n- Anaesthetist",
    "GP004 Diagnosis and Management of Gestational Trophoblastic Disease (GTD).txt": "- Gestational Trophoblastic Diseases (GTD)\n- Trophoblastic tissue proliferation\n- Irregular uterine bleeding\n- Hyperemesis\n- Early pregnancy failure\n- Excessive uterine enlargement\n- Ultrasound examination\n- Complete Moles\n- Partial Moles\n- Histological examination\n- Trophoblastic neoplasia\n- Evacuation of molar pregnancy\n- Anti-D prophylaxis\n- Follow-up testing\n- Future Pregnancy\n- Contraceptive Advice\n- Gestational Trophoblastic Neoplasia (GTN)\n- \u03b2hCG\n- Twin Pregnancy\n- Fetal Medicine Centre\n- Prenatal invasive testing",
    "GP020 Urogynaecology Specialist  Nurse-Led Clinic (1).txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and category:\n\n### **General Clinic Terms**  \n- Urogynaecology Specialist Nurse-Led Clinics  \n- Protocol  \n- Professional judgement  \n- Consent, Confidentiality, Documentation  \n- Audit, Research, Training  \n- Care quality  \n\n### **Clinic Types & Procedures**  \n- Urinary Incontinence Triage Clinic  \n- Free Flowmetry and Residual Volume Clinic  \n- Telephone Urinary Incontinence Follow Up Clinic  \n- Pessary Replacement Clinic  \n- Post-operative Follow Up Clinic  \n- Trial Without Catheter (TWOC) Clinic  \n- Posterior Tibial Nerve Stimulation (PTNS) Clinic  \n- Intra-vesical Instillation Clinic  \n\n### **Clinical Conditions & Assessments**  \n- Stress incontinence  \n- Overactive bladder (OAB)  \n- Detrusor Overactivity (confirmed via Urodynamic assessment)  \n- Painful bladder syndrome  \n- Refractory detrusor overactivity  \n- Post-void Bladder Volume measurement  \n\n### **Treatments & Interventions**  \n- Conservative measures (counseling, behavioral therapy)  \n- Pessary replacement (size/type adjustments)  \n- Botulinum Toxin \"A\" bladder wall injection  \n- Percutaneous Tibial Nerve Stimulation (PTNS)  \n- Intravesical instillation treatment (Hyacyst sheet)  \n\n### **Key Clinical Standards & Actions**  \n- **Trial Without Catheter (TWOC):**  \n  - Catheter removal & voided volume measurement  \n  - Discharge criteria (>100ml voided, <100ml residual)  \n  - TWOC sheet documentation  \n\n- **Urodynamic assessment** for refractory OAB  \n- **Multidisciplinary Team (MDT) discussion** for PTNS  \n- **Consultant referral** for complications/unusual features  \n\n### **Quality & Compliance**  \n- Audit for safe/effective practice  \n- Research opportunities  \n- Monitoring compliance  \n\nThese terms encapsulate the critical aspects of the guideline, ensuring a clear understanding of clinical workflows, responsibilities, and treatment pathways.",
    "BJOG - 2018 - Denison - Care of Women with Obesity in Pregnancy.txt": "- Obesity\n- Pregnancy\n- BMI\n- Antenatal care\n- Gestational weight gain\n- Folic acid supplementation\n- Vitamin D deficiency\n- Maternal disease\n- Gestational diabetes\n- Blood pressure measurements\n- Venous thromboembolism\n- Caesarean section\n- Prophylactic antibiotics\n- Postpartum contraception\n- Bariatric surgery\n- Fetal surveillance\n- Induction of labor\n- VBAC\n- Postpartum weight loss\n- Breastfeeding\n- Mental health\n- Macrosomia\n- Stillbirth\n- Neonatal death\n- Postpartum hemorrhage\n- Wound infection\n- Gestational diabetes\n- Hypertensive disorders\n- Shoulder dystocia\n- Neonatal intensive care unit\n- Stillbirth",
    "CG13026 Epilepsy Management in Pregnancy.txt": "- Epilepsy\n- Pregnancy\n- Seizures\n- Antiepileptic drugs (AEDs)\n- Folic Acid\n- Valproate\n- Antenatal monitoring\n- Maternal medicine clinic\n- Fetal growth scans\n- Enzyme-inducing AEDs\n- Vitamin K supplementation\n- Labor\n- Breastfeeding\n- Contraception\n- Carbamazepine\n- Levetiracetam\n- Sodium level\n- Dose adjustment",
    "BJOG - 2020 -  Management of Gestational Trophoblastic Disease.txt": "- Gestational Trophoblastic Disease\n- Molar Pregnancy\n- Vaginal Bleeding\n- Positive Pregnancy Test\n- Ultrasonographic Evidence\n- Hyperemesis\n- Uterine Enlargement\n- Hyperthyroidism\n- Pre-eclampsia\n- Abdominal Distension\n- Theca Lutein Cysts\n- Haemoptysis\n- Seizures\n- Metastatic Disease\n- Histological Examination\n- Suction Curettage\n- Ultrasound Guidance\n- Perforation\n- Anti-D Prophylaxis\n- Cervical Preparation\n- Oxytocic Infusions\n- Hemorrhage\n- Repeat Surgical Removal\n- Trophoblastic Neoplasia\n- Human Chorionic Gonadotrophin (hCG)\n- Ectopic Pregnancy\n- Biopsy\n- Fetal Medicine Center\n- Perinatal Morbidity\n- Chemotherapy\n- FIGO Scoring System\n- Preterm Birth\n- Stillbirth\n- Premature Menopause\n- Hormone Replacement Therapy\n- Support Groups\n- Research\n- Pathophysiology\n- Sonographic Diagnosis\n- Clinical Presentation\n- Pathology\n- Expert Opinion\n- Guidelines\n- Educational Tools\n- Local Deviations",
    "GTG 2012 - Initial Mx of Chronic Pelvic Pain.txt": "- Chronic pelvic pain\n- Women\n- Management\n- Investigation\n- Symptom\n- Diagnosis\n- Referral\n- Specialist\n- Red flag symptoms\n- Sexual assault\n- Pain diary\n- Function\n- IBS\n- Gastrointestinal symptoms\n- STIs\n- TVS\n- MRI\n- Laparoscopy\n- Hormonal treatment\n- Antispasmodics\n- Self-management techniques\n- Adenomyosis\n- Leiomyomas\n- Ovarian suppression\n- Dietary modifications\n- Myofascial pain syndrome\n- Musculoskeletal factors\n- Physical therapy\n- Coping\n- Abuse history\n- Psychological distress\n- Multidisciplinary pain treatment\n- Psychosomatic group treatment\n- Ultrasound\n- Magnetic resonance imaging\n- Endometriosis\n- Laparoscopy\n- Gonadotropin-releasing hormone agonist therapy\n- Opioids\n- Anticonvulsant drugs\n- Uterosacral nerve ablation\n- Rome III criteria\n- Red flag symptoms\n- Grades of recommendations\n- Classification of evidence levels",
    "MP079 Newborn Blood Spot Screening.txt": "Here are the most clinically significant terms and keywords extracted from the clinical guideline text, organized by category for clarity:\n\n### **1. Protocol & Scope**  \n- Protocol  \n- Measurable standards  \n- Professional judgement  \n- BSUH NHS Trust  \n- First year of life  \n\n### **2. Responsibilities**  \n- Midwives  \n- Obstetricians  \n- Accessing & following guidance  \n\n### **3. Screening Overview**  \n- Newborn Blood Spot Screening  \n- Conditions screened:  \n  - Phenylketonuria (PKU)  \n  - Congenital hypothyroidism (CHT)  \n  - MCADD (Medium-chain acyl-CoA dehydrogenase deficiency)  \n  - Sickle Cell Disease (SCD)  \n  - Cystic Fibrosis (CF) (if under 8 weeks)  \n  - Maple Syrup Urine Disease (MSUD)  \n  - Homocystinuria (HCU)  \n  - Isovaleric Acidaemia (IVA)  \n  - Glutaric Aciduria Type 1 (GA1)  \n\n### **4. Consent & Declination**  \n- Parental consent  \n- Right to decline  \n- Decline form  \n- Potential complications of declining  \n- Letter confirming decision  \n- \"NO RESEARCH CONTACT\" (if parents refuse future research use)  \n\n### **5. Sample Collection Procedures**  \n- Day 5 of life (Day 5-8 in exceptional cases)  \n- Heel prick  \n- Automated incision device  \n- Clean heel with plain water  \n- Fill all 4 circles (single drops, no layering)  \n- Expiry date check  \n- NHS number on card  \n- Barcoded label  \n- Block capitals for additional info  \n- Maternity code  \n\n### **6. Documentation & Communication**  \n- Record in maternity notes & PCHR (Personal Child Health Record)  \n- Double-check before posting  \n- Courier services (if disruptions)  \n- Transport within 24 hours  \n- First-class Royal Mail  \n- Maximum 5 cards per envelope  \n- Record sheets to central collection point  \n\n### **7. Special Circumstances**  \n- **Preterm babies (<32 weeks):**  \n  - Routine sample on day 5  \n  - Additional sample at 28 days or discharge  \n- **NICU/SCBU admission:**  \n  - Pre-transfusion spot on admission (1 spot)  \n  - Routine screening delayed until 72h post-transfusion  \n",
    "UHSussex - MP019 - Hypertension and Pre-eclampsia in Pregnancy.txt": "- Hypertension\n- Preeclampsia\n- Proteinuria\n- Antihypertensive drugs\n- Chronic hypertension\n- Blood pressure\n- Gestational hypertension\n- Labetalol\n- Nifedipine\n- Methyldopa\n- Pre-eclampsia management\n- Magnesium sulphate\n- Fetal monitoring\n- Cardiotocography\n- Ultrasound\n- Doppler velocimetry\n- Intrapartum care\n- Fluid balance\n- Indwelling urinary catheter\n- Oliguria\n- Urinalysis\n- MSU\n- VIP Scoring",
    "CG1128 Neonatal Resuscitation.txt": "- Neonatal Resuscitation Guideline\n- Equipment requirements\n- Trained personnel\n- Communication protocol\n- Resuscitation equipment\n- Corrected gestation\n- Oral ETT\n- Adrenaline\n- Bicarbonate\n- Glucose\n- Sodium chloride\n- Pre-term labor\n- Caesarean section\n- Survival focused care\n- Resuscitaire checklist\n- Oxygen cylinders\n- Face mask\n- Suction tubing\n- Laryngoscopes\n- ETT sizes\n- Umbilical cord clamp\n- Hats",
    "CG1116 Fetal Heart Monitoring & Sampling.txt": "Keywords and clinically significant terms:\n- Fetal heart monitoring\n- Antenatal and intrapartum period\n- Intermittent auscultation\n- Continuous electronic fetal monitoring\n- Fetal blood sampling\n- Cord blood sampling\n- Dawes Redman Criteria\n- CTG monitoring\n- Induction of labor\n- Pinard's stethoscope\n- Intelligent intermittent auscultation\n- Antepartum hemorrhage\n- Breech presentation\n- Hypertension\n- TREND Analysis Function\n- Oxygen therapy\n- IV fluid boluses\n- Second stage of labor\n- Escalation of concerns\n- Poor CTG quality\n- Fetal blood sampling criteria\n- Contraindications to FBS\n- Paired cord sampling\n- Care Analysis feature\n- FM800E fetal monitor\n- Gestational age\n- Analysis outcomes\n- Criteria met/not met\n- Reason codes\n- Clinical picture\n- Obstetric review\n- Documentation requirements\n- Human factors\n- Effective communication\n- Adverse outcomes\n- Instrumental birth\n- Sepsis\n- Prematurity\n- Maternal and birthing parent infection\n- Meconium\n- Cord prolapse\n- Uterine rupture\n- Placental abruption\n- Sinusoidal trace\n- Fetal hemorrhage\n- Fetal bleeding disorders\n- Heritable bleeding disorders\n- Paired cord blood gases\n- Optimal cord clamping\n- Pediatric opinion\n- Gas analyzer\n- Universal precautions\n- Heparinized syringes\n- Base excess\n- Local protocols",
    "CG1105 Maternal Antenatal Screening tests guideline.txt": "- Maternal and birthing parent antenatal screening tests\n- Screening tests\n- Timescales\n- Results\n- Subsequent miscarriages\n- Infectious diseases\n- Sickle cell\n- Thalassaemia testing\n- Down's syndrome\n- Edward's syndrome\n- Patau's syndrome\n- Fetal anomalies\n- Anomaly scan\n- Abnormal scan\n- Screening for SCT\n- Haemoglobin variants\n- HIV\n- Hepatitis B\n- Hepatitis C\n- Syphilis\n- Screening failsafes\n- Training\n- Quality monitoring standards",
    "CG14005 Water Birth guideline.txt": "- Water birth\n- Pain relief\n- Pregnant women/people\n- Shorter labors\n- Criteria\n- Low-risk pregnancy\n- Singleton pregnancy\n- Spontaneous onset of labor\n- Management\n- Pool temperature\n- Monitoring\n- Delivery\n- Hands-off\n- Cord\n- Post-delivery care\n- Maternal and fetal observations\n- Indications\n- Maternal pyrexia\n- Hypertension\n- Meconium-stained liquor\n- Blood loss\n- Fetal heart rate\n- Opioid analgesia\n- Epidural\n- Prolonged first or second stage\n- Excessive contamination\n- Obstetric emergency\n- Maternal collapse\n- Emergency evacuation\n- Audit\n- Antenatal discussions\n- Pool water temperature\n- Perineal suturing",
    "CG1106 Latent phase of labour guideline.txt": "- Midwives\n- Latent phase of labor\n- Emotional support\n- Physical support\n- Established first stage of labor\n- Responsibilities of staff\n- Clinical assessment\n- Antenatal education\n- Telephone advice\n- Fetal heart rate auscultation\n- Pain management techniques\n- Breathing exercises\n- Immersion in water\n- Massage\n- Aromatherapy\n- Yoga\n- Acupressure\n- TENS machine\n- Distractions\n- Hot water bottles\n- Breathing techniques\n- Analgesia\n- Paracetamol\n- Codeine-based tablets\n- Opiates\n- Side effects\n- Sedatives\n- Temazepam\n- Symptoms\n- Healthcare providers",
    "BJOG - 2019 - Thomson - Care of Women Presenting with Suspected Preterm Prelabour Rupture of Membranes from 24 0 Weeks of.txt": "- Spontaneous rupture of membranes\n- Diagnosis\n- Sterile speculum examination\n- IGFBP-1\n- PAMG-1\n- Amniotic fluid\n- Antibiotic (erythromycin)\n- PPROM\n- Corticosteroids\n- Gestation\n- Chorioamnionitis\n- Expectant management\n- Intravenous magnesium sulfate\n- Neonatologists\n- Latency\n- Preterm birth\n- Ultrasound\n- Nitrazine\n- Microbiological testing\n- White cell count\n- C-reactive protein\n- Vital signs\n- Tocolysis\n- Amnioinfusion\n- Emotional support\n- Obstetrician\n- Support groups\n- Royal College of Obstetricians and Gynaecologists\n- Little Heartbeats\n- Green-top Guideline\n- RCOG\n- National Guideline Alliance\n- Birth Trauma Association\n- Women's Network\n- British Association of Perinatal Medicine",
    "CG20011 Maternity Pressure Area Care Guideline.txt": "- Maternity Pressure Area Care Guideline\n- intrapartum\n- postnatal women\n- skin integrity\n- pressure area damage\n- risk assessment\n- care planning\n- surface pressure-reducing equipment\n- skin assessment\n- documentation\n- pressure ulcers\n- limited mobility\n- diabetes\n- poor circulation\n- medical devices\n- nutritional monitoring\n- Family Assist\n- incontinence pads\n- cleansing foam\n- barrier cream\n- mobilization\n- blood sugars\n- hygiene\n- moisture lesions\n- tissue viability team\n- NICE Clinical Guideline CG179\n- audit\n- performance board\n- pressure ulcer prevention\n- elective caesarean section\n- antenatal\n- intrapartum\n- postnatal\n- skin inspection\n- care plan\n- Trust guideline\n- moisture lesion\n- pressure ulcer category\n- tissue viability referral\n- repositioning\n- incontinence care\n- nutrition assessment\n- hydration assessment\n- patient education",
    "Lone worker checklist.txt": "Here are the most clinically significant terms and keywords extracted from the **Lone Worker Checklist v1.0**, critical for understanding the guidance:  \n\n### **General Safety & Compliance**  \n- **Mandatory training** (conflict resolution)  \n- **Contact details** (up to date, accessible)  \n- **Risk assessment** (homebirth/home visit)  \n- **MIS (Management Information System)** (alerts, documentation)  \n- **GP surgery alerts**  \n- **Team Leader/Community Manager** (reporting concerns)  \n\n### **Pre-Visit Planning**  \n- **Homebirth risk assessment** (documented on MIS)  \n- **Community office awareness** (visit timing, completion confirmation)  \n\n### **During Visit Safety Measures**  \n- **Mobile phones** (switched on)  \n- **ID badge** (visible)  \n- **Warning signs of aggressive behavior**  \n- **Risk situation** (leave quickly and safely)  \n- **Entrances/exits awareness** (quick escape)  \n- **Equipment positioning** (potential harm)  \n- **Security measures** (mobile phones, car trackers)  \n\n### **Parking Safety**  \n- **No visible personal possessions**  \n- **Park near street lamps/junctions** (visibility)  \n- **Car facing exit direction**  \n\n### **Emergency Protocol**  \n- **No contact at agreed time**  \n  - Call staff member  \n  - **Wellbeing check** (passwords)  \n  - **Police (999)** (if no contact within 30 minutes or concerns)  \n\nThese terms encapsulate the **key safety, compliance, and emergency response measures** essential for lone workers conducting home visits.",
    "BJOG - 2022 - Shennan - Cervical Cerclage.txt": "- Cervical cerclage\n- Singleton pregnancies\n- Preterm births\n- Spontaneous second trimester loss\n- Cervix length\n- Transvaginal cerclage\n- Transabdominal cerclage\n- Emergency cerclage\n- Delayed birth\n- Gestation\n- Prophylactic intervention\n- Fetal loss\n- Ultrasound\n- History-indicated cerclage\n- Transvaginal ultrasound\n- Risk factors\n- Laparotomy\n- Laparoscopy\n- Maternal pyrexia\n- Chorioamnionitis\n- PPROM\n- Complications\n- Suture material\n- Polyester braided thread\n- Mersilene tape\n- RCT\n- Adjuvant management\n- Serial sonographic surveillance\n- Fetal fibronectin testing\n- Progesterone supplementation\n- Cervical occlusion\n- Abstinence\n- Removal of cerclage\n- Maternal/fetal sepsis\n- Chorioamnionitis\n- Genitourinary fistulas\n- Proteomic biomarkers\n- Amniocentesis\n- Infection\n- Labor\n- C-reactive protein\n- Preterm prelabour rupture of membranes\n- Viable extreme preterm birth\n- Neonatal outcomes\n- Cervical insufficiency\n- Change in cervical length\n- Transvaginal ultrasonographic evaluation\n- Reinforcing cerclage\n- Fetal fibronectin\n- Vaginal progesterone\n- Multi-center randomized controlled trial.",
    "MP007 Antenatal Screening Infectious Diseases Syphilis.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance:\n\n### **Core Screening Concepts**  \n- **Antenatal screening for syphilis**  \n- **Congenital syphilis**  \n- **Maternal syphilis infection**  \n- **Early identification and management**  \n- **Transmission risk reduction**  \n\n### **Screening Process & Logistics**  \n- **Universal screening (all pregnant women)**  \n- **Pre-screening informed choice**  \n- **Late/unbooked pregnancy screening**  \n- **Declining screening (optional but documented)**  \n- **Blood samples at booking**  \n- **Sample labeling & documentation**  \n- **Unacceptable samples (repeat within 10 days)**  \n- **Results availability (5 working days, ICE/phone)**  \n- **Follow-up results within 10 days**  \n\n### **Clinical Management & Pathways**  \n- **Negative result (no protection, repeat possible)**  \n- **Positive result (confirmatory testing & treatment)**  \n- **Penicillin treatment (benefits for mother & baby)**  \n- **Penicillin allergy (specialist consultation)**  \n- **Referral for positive serology**  \n- **Joint pediatric management (suspected congenital syphilis)**  \n\n### **Documentation & Governance**  \n- **Reasons for delays (>10 days) documented**  \n- **Missing results (document at next appointment)**  \n- **Booking blood results at dating scan (if missing)**  \n- **Minimum auditable standards**  \n- **Incident reporting & governance**  \n- **Training requirements for midwives**  \n\n### **Associated Screening & Tests**  \n- **Group & Rhesus**  \n- **Hb (hemoglobin)**  \n- **Sickle & thal (sickle cell & thalassemia)**  \n- **Rubella**  \n- **HIV**  \n- **Hep B (hepatitis B)**  \n- **Downs screen (Down syndrome screening)**  \n- **Anomaly scan**  \n\nThese terms encapsulate the critical aspects of the guideline, ensuring clarity on screening protocols, clinical actions, and governance requirements.",
    "CG12027 PCA (Remifentanil) in Labour guideline.txt": "- Remifentanil PCA\n- Labor\n- Analgesic\n- Epidural analgesia\n- Contraindicated\n- Midwifery care\n- Lockout period\n- Indications\n- Contraindications\n- Absolute requirements\n- Complications\n- Monitoring\n- SaO2 monitoring\n- CTG monitoring\n- Respiratory rate monitoring\n- Anaesthetist\n- Loading dose\n- Background infusion\n- Maximum dose\n- Dedicated cannula\n- Naloxone\n- Oxygen supplementation\n- Bolus dose\n- Sedation\n- Nausea and vomiting\n- Pruritus\n- Side effects\n- Babies\n- Prescription\n- Observation Chart\n- Staff details\n- Solution\n- PCA setting\n- Sedation scores\n- Management of side effects\n- Timing\n- Fast-acting\n- Safety\n- Complete observations",
    "MP015 Substance Use in Pregnancy.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and category:\n\n### **General Principles & Care Pathways**  \n- **Substance use in pregnancy**  \n- **Non-judgmental approach**  \n- **Harm reduction**  \n- **One Stop Clinic**  \n- **Drug and Alcohol Service**  \n- **Electronic maternity record**  \n- **Care pathway**  \n- **Safeguarding referral**  \n- **Neonatal abstinence syndrome (NAS)**  \n- **Child protection concerns**  \n\n### **Substances & Their Management**  \n- **Alcohol** (Fetal Alcohol Syndrome, Fetal Alcohol Spectrum Disorder)  \n- **Benzodiazepines** (respiratory depression, neonatal dependence)  \n- **Stimulants**  \n- **Opioids** (heroin, morphine, codeine \u2013 respiratory depression, neonatal dependence)  \n- **Cannabis (THC)** (psychopathology risk, accumulation in neonate)  \n- **Hallucinogens** (LSD, PCP, Ketamine \u2013 avoid breastfeeding)  \n\n### **Clinical Interventions & Monitoring**  \n- **Urine toxicology** (mother/parent & neonate)  \n- **Methadone starting dose**  \n- **Opioid Substitution Therapy (OST)**  \n- **Abrupt cessation risks** (alcohol, benzodiazepines, opioids)  \n- **Intra-partum withdrawal** (2-6 weeks post-birth)  \n- **Neonatal monitoring** (for withdrawal symptoms)  \n\n### **Breast/Chest Feeding & Postnatal Care**  \n- **Breastfeeding contraindications** (codeine, hallucinogens)  \n- **Express and discard milk** (if toxicology pending)  \n- **Avoid mother-baby separation** (unless safety concerns)  \n- **Health visitor notification**  \n\n### **Key Services & Follow-Up**  \n- **Community Midwife (CMW)**  \n- **Substance Use Midwives**  \n- **Neonatologist/Obstetrician consultation**  \n- **Drug and Alcohol Service referral**  \n- **Discharge planning** (address, follow-up with community teams)  \n\n### **Guideline-Specific Terms**  \n- **\"One Stop Clinic birth plan\"** (in electronic records)  \n- **\"Late maternal/parental disclosure\"** (of substance use)  \n- **\"Harm reduction messages\"** (clean needles, safer",
    "BJOG - 2017 -  Management of Breech Presentation.txt": "- Breech presentation\n- External cephalic version (ECV)\n- Mode of delivery\n- Perinatal mortality\n- Apgar scores\n- Long-term morbidity\n- Complications in future pregnancies\n- Stillbirth\n- Skilled birth attendants\n- Continuous fetal monitoring\n- Cesarean section\n- Neonatal morbidity\n- Preterm breech birth\n- Twin pregnancy\n- Management protocol\n- All-fours position\n- Pelvimetry\n- Epidural analgesia\n- Auditable topics\n- Clinical guidelines\n- Evidence-based\n- Guidelines Committee\n- RCOG",
    "MP034 Vaginal Birth after Caesarean Section (VBAC).txt": "Here are the most clinically significant terms and keywords extracted from the VBAC guideline, organized by category for clarity:\n\n### **Core Concepts**  \n- Vaginal Birth after Caesarean Section (VBAC)  \n- Elective Repeat Caesarean Section (ERCS)  \n- Uterine rupture  \n- Hypoxic ischaemic encephalopathy (HIE)  \n- Transient respiratory morbidity  \n\n### **Contraindications**  \n- Previous classical uterine incision  \n- History of uterine rupture  \n- \u22653 previous lower segment caesarean sections (LSCS)  \n\n### **Special Considerations**  \n- VBAC with 2 previous uncomplicated caesareans (case-by-case)  \n\n### **Clinical Management**  \n- Birth Options clinic (Consultant Obstetrician-led)  \n- Continuous fetal monitoring (intrapartum)  \n- Induction of labour (discussed at 40 weeks)  \n- Birthing pool use (with monitoring)  \n\n### **Risks & Outcomes**  \n#### **VBAC Risks/Benefits:**  \n- 72\u201375% success rate  \n- 0.5% uterine rupture risk  \n- 5% anal sphincter injury risk  \n- 4/100,000 maternal mortality  \n- 8/10,000 HIE risk in infants  \n- 2\u20133% transient respiratory morbidity  \n\n#### **ERCS Risks/Benefits:**  \n- Virtually no uterine rupture risk  \n- 13/100,000 maternal mortality  \n- <1/10,000 perinatal death/HIE risk  \n- 4\u20135% transient respiratory morbidity  \n- Future placenta previa/accreta risk  \n\n### **Documentation & Compliance**  \n- Badgernet (electronic records)  \n- Mode/place of labor discussion (documented)  \n- Monitoring compliance (audit referenced)  \n\n### **Key Phrases for Decision-Making**  \n- \"Women\u2019s preferences prioritized\"  \n- \"Evidence-based information provision\"  \n- \"Increased likelihood of future vaginal birth after VBAC\"  \n\nThese terms encapsulate the critical clinical, procedural, and risk-assessment elements of the VBAC guideline.",
    "MP071 Provisions and Schedules of Postnatal Care.txt": "- Postnatal care\n- Protocol\n- Professional judgement\n- Skin-to-skin contact\n- Breastfeeding\n- VTE risk\n- Oral fluids\n- Neonatal examination\n- Individualized care plan\n- Communication support\n- Rooming in\n- Transitional care\n- Poor outcome\n- Emotional support\n- Religious/spiritual support\n- Discharge\n- Community setting\n- Newborn check\n- Support services\n- Mental health\n- Vaccinations\n- Follow-up appointments\n- Perineum care\n- Breastfeeding support\n- Postnatal depression\n- Infant feeding\n- Sudden Infant Death prevention\n- Parenting support\n- Birth preferences\n- Medical problems\n- Bloodspot screening\n- Health visiting service\n- Social services\n- Children's Centres",
    "Uptodate - 2025 - Uterine fibroids (leiomyomas) Treatment overview - UpToDate.txt": "- Uterine fibroids\n- Abnormal uterine bleeding\n- Pressure or bulk symptoms\n- Fertility issues\n- Pain\n- Expectant management\n- Hysteroscopic fibroid resection\n- Medical therapy\n- Estrogen-progestin contraceptives\n- Progestin-releasing intrauterine devices\n- GnRH agonists\n- GnRH antagonists\n- Uterine artery embolization\n- Tranexamic acid\n- Elagolix\n- Relugolix\n- Linzagolix\n- Laparoscopic myomectomy\n- Open abdominal myomectomy\n- Hysterectomy\n- UAE (Uterine artery embolization)\n- Focused ultrasound surgery\n- Endometrial ablation\n- Aromatase inhibitors\n- Androgenic compounds\n- Ovarian reserve\n- LIBERTY randomized withdrawal study\n- MYFEMBREE\n- Yselty\n- Endometrial polyps\n- Pregnancy rates\n- Intrauterine insemination\n- Leiomyomas\n- Anti-M\u00fcllerian Hormone Levels\n- Health-Related Quality of Life\n- Tung's Acupuncture\n- Classification system",
    "CG1147 Maternal Sepsis.txt": "Keywords and clinically significant terms:\n- Maternal or birthing person sepsis\n- Pregnancy and puerperium\n- Sepsis prevention and management\n- Timely recognition and treatment\n- Life-threatening condition\n- Antibiotics\n- Minority ethnic backgrounds\n- Deprived areas\n- Group A Streptococcus\n- Modified Early Warning Score\n- Postpartum Hemorrhage\n- Septic shock\n- Hypotension\n- Obesity\n- Diabetes\n- Anaemia\n- Group B streptococcal infection\n- Diagnosis of sepsis\n- Symptoms and signs\n- Influenza\n- Assessment and recognition\n- Urgent transfer to hospital\n- High-risk sepsis\n- Intravenous antibiotics and fluids\n- Lactate levels\n- Critical Care Unit\n- Moderate risk sepsis\n- Neonatal referral pathway\n- Third International Consensus Definitions for Sepsis and Septic Shock\n- Surviving Sepsis Campaign\n- Antiviral medication\n- UK Health Security Agency\n- UK Sepsis Trust\n- World Health Organization\n- COVID-2019.",
    "NICE Guideline - 2021 - IOL.txt": "- Inducing labour\n- NICE guideline\n- Pregnant women\n- Induction of labour\n- Assessment\n- Monitoring\n- Pain relief\n- Complications\n- Fetal monitoring\n- Preterm prelabor rupture of membranes\n- Group B streptococcus\n- Cesarean birth\n- Breech position\n- Fetal growth restriction\n- Precipitate labor\n- Intrauterine fetal death\n- Membrane sweep\n- Bishop score\n- Dinoprostone\n- Misoprostol\n- Hyperstimulation\n- Amniotomy\n- Oxytocin infusion\n- Uterine activity\n- Fetal condition\n- Mechanical methods\n- Pharmacological methods\n- Expectant management\n- Cord prolapse\n- Macrosomia\n- Informed decision-making\n- Uterine rupture\n- Healthcare professionals\n- Patients\n- Recommendations\n- Research recommendations\n- Environmental impact\n- Equality of opportunity\n- Health inequalities\n- Individual preferences\n- Information sharing\n- Decision-making\n- Monitoring and assessment\n- Support and care",
    "CG1129 Newborn Feeding.txt": "- Newborn feeding\n- Breastfeeding\n- UNICEF Baby Friendly Initiative\n- Skin-to-skin contact\n- Breast milk substitutes\n- Colostrum\n- Finger feeding\n- Cup feeding\n- Formula feeding\n- Skin-to-skin contact\n- Feeding cues\n- Safe sleeping practices\n- Parent-infant attachment\n- Rooming in\n- Breastfeeding support\n- Tongue ties\n- Training in breastfeeding support\n- Compliance with guidance\n- Breastfeeding frequency\n- Optimal positioning and attachment\n- Laid back position\n- Nipple confusion\n- Overfeeding\n- Formula supplementation\n- Breast milk supply\n- Gut infections\n- Cow's milk allergy\n- Teat confusion\n- Medical reasons for formula supplementation",
    "MP038 Fetal Blood Sampling.txt": "Here are the most clinically significant terms and keywords extracted from the **Fetal Blood Sampling (FBS) Maternity Protocol: MP038**:  \n\n### **Key Clinical Terms & Keywords:**  \n1. **Fetal Blood Sampling (FBS)** \u2013 The primary procedure.  \n2. **FHR (Fetal Heart Rate) trace** \u2013 Indication for FBS when concerning/abnormal.  \n3. **Abnormal FHR trace** \u2013 Primary reason to perform FBS.  \n4. **Contraindications for FBS:**  \n   - **Cervical dilatation <3cm**  \n   - **Maternal infection**  \n   - **Fetal bleeding disorders**  \n   - **Prematurity**  \n5. **Interpretation of FBS results:**  \n   - **Normal**  \n   - **Borderline**  \n   - **Abnormal**  \n6. **Documentation on Badgernet** \u2013 Mandatory recording.  \n7. **Paired Cord Blood Samples** \u2013 Required if neonatal concerns exist.  \n\nThese terms are critical for understanding when, why, and how FBS should be performed, as well as key contraindications and documentation requirements.",
    "GP003 Pelvic Inflammatory Disease (PID).txt": "- Pelvic Inflammatory Disease (PID)\n- Ascending infection\n- Endocervix\n- Endometritis\n- Parametritis\n- Oophoritis\n- Tubo-ovarian abscess\n- Pelvic peritonitis\n- Sexually transmitted diseases\n- STI\n- Gonorrhoea\n- Chlamydia trachomatis\n- Anaerobes\n- Mycoplasma\n- Lower abdominal pain\n- Dyspareunia\n- Vaginal bleeding\n- Vaginal discharge\n- Abdominal tenderness\n- Adnexal tenderness\n- Cervical motion tenderness\n- Fever\n- Urinalysis\n- Blood tests\n- Pelvic ultrasound\n- Antibiotics\n- IV antibiotics\n- Oral antibiotics\n- Penicillin allergy\n- Paracetamol\n- Analgesia\n- Anti-emetics\n- Patient information leaflet\n- Long term sequelae\n- Sexual partners\n- Complicating factors\n- NSAIDs\n- Ibuprofen\n- Congenital defects\n- Spontaneous abortions\n- Ceftriaxone\n- Doxycycline\n- Metronidazole\n- Ofloxacin\n- Azithromycin\n- IUCD\n- Follow-up\n- Monitoring\n- Treatment compliance\n- Training\n- Protocol compliance",
    "BJOG - 2017 -  Prevention of Early\u2010onset Neonatal Group B Streptococcal Disease.txt": "- Prevention\n- Early-onset Neonatal Group B Streptococcal Disease\n- Pregnant women\n- Information leaflet\n- Bacteriological screening\n- Clinical risk factors\n- GBS disease\n- IAP (Intrapartum Antibiotic Prophylaxis)\n- GBS carriage\n- Antenatal treatment\n- Membrane sweeping\n- Planned caesarean sections\n- Labor\n- Pyrexial women\n- Broad-spectrum antibiotics\n- Preterm labor\n- Polymerase chain reaction testing\n- Water birth\n- Postnatal antibiotic prophylaxis\n- Breastfeeding\n- Abnormal behavior\n- EOGBS disease\n- Indicators of infection\n- Testing\n- Benzylpenicillin\n- Cephalosporin\n- Adverse effects\n- Vaginal cleansing\n- Monitoring\n- Incidence\n- Postnatal antibiotic prophylaxis\n- Signs of infection\n- Penicillin\n- Gentamicin\n- Trendy alternative\n- Rectovaginal\n- Immediate delivery\n- Expectant management\n- Fetal serum\n- Chemoprophylaxis\n- Ampicillin\n- Intestinal microbiota\n- Gut microbiota\n- Childhood outcomes\n- Educational outcomes\n- Vaginal chlorhexidine\n- Neonatal sepsis\n- Clinical indicators\n- Red flags\n- RCOG Guidelines",
    "UHSx Role of the RN within Maternity.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance:  \n\n### **Core Clinical & Professional Terms:**  \n- **Registered Nurse (RN)**  \n- **Maternity Services**  \n- **Antenatal care**  \n- **Postnatal care**  \n- **Newborn care**  \n- **Patient assessments**  \n- **Care planning & implementation**  \n- **Infection control**  \n- **Drug administration**  \n- **Infant feeding support**  \n- **Modified Early Obstetric Warning Score (MEOWS)**  \n- **Newborn Early Warning Trigger & Track (NEWTT)**  \n- **SBAR (Situation, Background, Assessment, Recommendation)**  \n\n### **Managerial & Operational Terms:**  \n- **Standard Operating Procedure (SOP)**  \n- **Workload organization**  \n- **Equipment checks**  \n- **Ward security**  \n- **Compliance monitoring**  \n\n### **Professional & Legal Terms:**  \n- **Nursing & Midwifery Council (NMC)**  \n- **Trust policies**  \n- **Documentation of care**  \n- **Incident reporting (accidents/complaints)**  \n- **Professional portfolio**  \n\n### **Training & Development Terms:**  \n- **Clinical knowledge updates**  \n- **Appraisal & development planning**  \n- **Health promotion**  \n- **Baby Friendly Initiative (BFI)**  \n\nThese terms encapsulate the key clinical, operational, and professional aspects of the guideline, ensuring clarity and adherence to best practices in maternity nursing.",
    "MP041 (2024) Delay in Labour and use of Oxytocin v4.1.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance:\n\n### **General Protocol Terms**  \n- **Delay in labour**  \n- **Oxytocin use**  \n- **Maternity protocol (MP041)**  \n- **Professional judgment**  \n- **Obstetric-led care**  \n\n### **Diagnosis & Assessment**  \n- **Cervical dilation**  \n- **Fetal head position**  \n- **Assessment before oxytocin**  \n- **Fetal well-being**  \n- **Contraindications to oxytocin**  \n- **Full clinical examination**  \n\n### **Oxytocin Administration & Monitoring**  \n- **Low-dose infusion**  \n- **Gradual increase**  \n- **Uterine contractions**  \n- **Hyperstimulation management**  \n- **Dose adjustments**  \n- **30-minute monitoring intervals**  \n- **Water intoxication**  \n- **Electrolyte imbalance**  \n- **Continuous fetal heart rate (CTG) monitoring**  \n- **Uterine activity monitoring**  \n\n### **Documentation & Timeframes**  \n- **Maternal BadgerNet record**  \n- **CTG tracing documentation**  \n- **Six-hour limit for inadequate progress**  \n- **Consultant discussion for prolonged use**  \n\n### **Second Stage of Labour**  \n- **Delay in second stage**  \n- **Interventions based on timeframes**  \n- **Augmentation in second stage**  \n- **Recommended infusion rate**  \n- **Instrumental birth (if fetal concern/prolonged stage)**  \n\n### **Third Stage of Labour**  \n- **Active management of third stage**  \n- **Discontinuation of oxytocin post-delivery**  \n\n### **Key Responsibilities**  \n- **One-to-one midwifery care**  \n- **Obstetrician review before oxytocin**  \n- **Individualized management plans**  \n\nThese terms encapsulate the critical clinical, monitoring, and decision-making aspects of the guideline.",
    "Appendix 12 aSSKINg sticker.txt": "- aSSKINg CARE BUNDLE\n- Assess Risk\n- Skin\n- Pressure areas\n- Surface\n- Static foam mattress\n- Alternating pressure redistribution mattress\n- Static pressure redistribution cushion\n- Off load heels\n- Keep Moving\n- Position changes\n- Slide Sheets\n- Incontinence\n- Senset foam\n- Medi-honey barrier cream\n- Proshield barrier cream\n- Nutrition\n- MUST score\n- Dietitians\n- Pressure prevention information leaflet",
    "MP049 Assisted Vaginal Birth.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by category for clarity:\n\n### **General Concepts**  \n- Assisted Vaginal Birth  \n- Operative Vaginal Birth  \n- Protocol  \n- Professional judgement  \n- Informed consent (verbal/written)  \n\n### **Scope & Responsibilities**  \n- Midwives & Obstetricians  \n- Management  \n- Fetal compromise  \n- Malposition  \n- Inadequate progress  \n\n### **Contraindications**  \n- Ventouse contraindications (face presentation, <34 weeks gestation)  \n- Forceps indications (alternative to ventouse)  \n- Bony fracture history  \n- Medical conditions  \n\n### **Conditions & Prerequisites**  \n- Experienced operators (especially for rotational births)  \n- Assessment & instrument choice  \n- Neonatal resuscitation personnel  \n\n### **Risks & Complications**  \n- Maternal trauma (higher with forceps)  \n- Fetal risks (higher with ventouse failure)  \n- Perineal/vaginal trauma  \n- Urinary retention/incontinence  \n\n### **Procedure-Specific Terms**  \n- **Ventouse/Kiwi Assisted Delivery**  \n- **Non-Rotational Forceps**  \n- **Rotational Forceps (Keilland forceps)**  \n- **Episiotomy (Mediolateral)**  \n\n### **Preparation & Execution**  \n- Clear communication & documentation  \n- Pain relief (epidural, spinal, pudendal block)  \n- Bladder care (in-out catheter)  \n- Location (birth room vs. theatre)  \n\n### **Post-Delivery Care**  \n- Perineal repair  \n- Antibiotics  \n- Analgesia  \n- Bladder care (first void monitoring)  \n- Debriefing (indication, complications, future birth advice)  \n\n### **Documentation Requirements**  \n- Benefits/risks discussion  \n- Instrument count  \n- Sequential instruments used/reason for abandonment  \n- Birth time interval  \n- Postnatal support for traumatic experiences  \n\nThese terms encapsulate the critical clinical and procedural aspects of the guideline. Let me know if you'd like further refinement!",
    "MP017 DNA Appointments.txt": "Here are the most clinically significant terms and keywords extracted from the clinical guideline text, which are critical for understanding the guidance:\n\n### **Key Clinical Terms & Keywords:**  \n1. **DNA Appointments (Did Not Attend)**  \n2. **Protocol**  \n3. **Professional judgement**  \n4. **Non-attendance / No access**  \n5. **Maternal & fetal complications**  \n6. **Maternal death**  \n7. **Antenatal & postnatal care**  \n8. **Vulnerable groups**  \n9. **Multidisciplinary team (MDT) / Specialist agencies**  \n10. **Individual care plan**  \n11. **Follow-up process**  \n12. **Community antenatal clinic / Hospital antenatal clinic**  \n13. **Missed DAU/Triage/Labour ward appointment**  \n14. **Missed Obstetric Scan Appointment**  \n15. **Ultrasonographer / Clinic lead midwife**  \n16. **Three missed appointments**  \n17. **Activity audit**  \n18. **MBRRACE-UK / Confidential Enquiry into Maternal Deaths**  \n\n### **Key Staff Roles Mentioned:**  \n- Midwives  \n- Obstetricians  \n- Clinic Lead Midwife  \n- Area Manager  \n- Team Leader  \n- Appropriate Specialist  \n- Ward Clerks  \n\n### **Critical Actions & Processes:**  \n- **Flexible & individual care plan** at booking  \n- **Active follow-up** for non-attendance  \n- **Referral to MDT/specialist agencies** for vulnerable groups  \n- **Notification process** after **3 missed appointments**  \n- **Submission of carbon copy** for activity audit  \n\nThese terms encapsulate the core clinical, procedural, and administrative aspects of the guideline. Let me know if you'd like further refinement!",
    "Sensitive Disposal of Fetal Remains Under 24 Weeks.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance:  \n\n### **Key Clinical and Procedural Terms:**  \n- **Sensitive disposal of fetal remains**  \n- **Pregnancy loss under 24 weeks**  \n- **Respectful disposal**  \n- **Fetal remains**  \n- **Recognisable fetus**  \n- **Non-recognisable fetus**  \n- **Cremation (hospital or private)**  \n- **Private burial / home burial**  \n- **Consent for disposal**  \n- **Post-mortem procedures**  \n- **Cytogenetic investigations**  \n- **Mortuary transfer**  \n- **Waterproof pad & box**  \n- **Registration forms**  \n- **Annual audit for compliance**  \n\n### **Key Stakeholders & Staff Roles:**  \n- **Mortuary staff**  \n- **Histopathology staff**  \n- **Crematorium personnel**  \n- **Gynaecology Matron**  \n- **Theatre Sister**  \n- **Midwife**  \n- **Heads of Nursing**  \n- **Doctors**  \n- **A&E staff**  \n- **Theatre staff**  \n- **Surgical Ward Nursing & HCA staff**  \n- **Early Pregnancy & Gynae Day Unit staff**  \n\n### **Critical Processes & Responsibilities:**  \n- **Information giving to families**  \n- **Obtaining consent (disposal, post-mortem, cytogenetics)**  \n- **Transfer to mortuary (wrapping, waterproof box, forms)**  \n- **Sending remains for cytogenetic testing**  \n- **Accessing forms & information leaflets**  \n- **Annual guideline compliance audits**  \n\nThese terms encapsulate the core clinical, procedural, and ethical aspects of the guideline.",
    "GP019 Management of Recurrent Miscarriages.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance:  \n\n### **General Terms:**  \n- Recurrent Miscarriage  \n- Protocol  \n- Professional judgement  \n- Guideline scope  \n- Nursing staff & Gynaecologists  \n- Management responsibilities  \n\n### **Patient Selection Criteria:**  \n- 3 or more consecutive first-trimester miscarriages  \n- One or more second-trimester miscarriages  \n- 2 consecutive first-trimester miscarriages (age >38)  \n- Antiphospholipid syndrome (APLS) markers  \n\n### **Investigations & Testing:**  \n- Antiphospholipid antibodies (blood test)  \n- EPU (Early Pregnancy Unit) clinic  \n- Recurrent Miscarriage Clinic follow-up  \n- Antiphospholipid Syndrome (APLS) screening  \n  - Lupus anticoagulant  \n  - Anticardiolipin antibodies  \n- Cytogenetics (karyotyping) \u2013 3rd miscarriage  \n- Product of conception (tissue analysis)  \n\n### **Thrombophilia & Treatment:**  \n- Thrombophilia screen (second-trimester miscarriage only)  \n- LMWH (Low Molecular Weight Heparin)  \n- Consultant discussion for treatment initiation  \n\n### **No Abnormality Detected:**  \n- Reassurance  \n- Early EPU contact  \n- Anti-D administration (refer to miscarriage guideline)  \n\nThese terms encapsulate the key clinical, diagnostic, and management aspects of the guideline.",
    "RCOG - Birth After Previous Caesarean Section - 2015.txt": "- Birth After Previous Caesarean Birth\n- Antenatal care\n- VBAC (Vaginal Birth After Cesarean)\n- ERCS (Elective Repeat Cesarean Section)\n- Uterine rupture\n- Placenta previa\n- Placenta accreta\n- Induction of labor\n- Perinatal outcomes\n- Maternal morbidity\n- Neonatal morbidity\n- Decision-making tools\n- Risk factors\n- Success rates\n- Antenatal counseling\n- Respiratory morbidity\n- Perioperative care\n- Thromboprophylaxis\n- Stillbirth\n- Obstetric outcomes\n- Prediction models\n- Trial of labor\n- Uterine dehiscence\n- Perinatal mortality\n- Neonatal mortality\n- Intrapartum care\n- Guidelines\n- Evidence-based recommendations",
    "MP074 Assessment and Management of babies accidently dropped in Hospital.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, categorized for clarity:  \n\n### **General Protocol Terms**  \n- Protocol  \n- Objective standards  \n- Professional judgement  \n- Clinical context  \n\n### **Scope & Population**  \n- Babies (neonates/infants)  \n- Hospital setting  \n- Excludes children >1 year  \n\n### **Key Personnel**  \n- Midwives  \n- Obstetricians  \n- Neonatologists  \n\n### **Rationale & Risks**  \n- Accidental dropping  \n- Significant harm  \n\n### **Prevention Measures**  \n- Avoid co-sleeping (bed/chair)  \n- Never leave baby unattended (bed/sofa/changing table)  \n\n### **Clinical Management**  \n- Immediate review by staff  \n- Full set of observations  \n- Urgent neonatal doctor assessment  \n\n### **Imaging (CT Scan) Criteria**  \n- Suspicion of non-accidental injury  \n- Post-traumatic seizure  \n- Suspected skull fracture  \n- Other concerning signs  \n\n### **Safeguarding & Legal Concerns**  \n- Non-accidental injury (NAI)  \n- Escalation to safeguarding team  \n\nThese terms capture the essential clinical, procedural, and safety aspects of the guideline.",
    "PID Proforma - June 2011v2.txt": "Here are the most clinically significant terms and keywords extracted from the clinical guideline text, which are critical for understanding the guidance:  \n\n### **Key Clinical Terms:**  \n1. **Referral source** (GP/A&E/Other)  \n2. **Presenting complaint**:  \n   - Abdominal Pain  \n   - Abnormal Bleeding  \n   - Vaginal Discharge  \n   - Dyspareunia  \n3. **Allergies**  \n4. **Suspected Pelvic Inflammatory Disease (PID) Protocol**  \n5. **Sexual History**  \n6. **Previous Gynaecological History**  \n7. **General Examination**  \n8. **Investigations**  \n9. **Management Plan**  \n10. **Treatment Prescribed**  \n11. **2-week follow-up**  \n12. **Counselling prior to discharge**  \n13. **Consent for Health Advisor to proceed with partner notification**  \n14. **Patient Consent** (critical for confidentiality and legal compliance)  \n15. **Claude Nicol Clinic** (destination for faxed proforma)  \n\n### **Administrative/Procedural Keywords:**  \n- **Signed** (documentation)  \n- **Patient\u2019s Name** (identification)  \n- **Date** (record-keeping)  \n- **Contact no(s)** (follow-up)  \n- **SHO Name** (responsibility)  \n- **Fax proforma** (communication protocol)  \n\nThese terms are essential for clinicians to assess, diagnose, manage, and document cases of suspected **Pelvic Inflammatory Disease (PID)** while ensuring proper **consent, partner notification, and follow-up**.",
    "NICE Guidance - 2010 - Hysterectomy for Endometrial Cancer.txt": "- Laparoscopic hysterectomy\n- Endometrial cancer\n- Clinical governance\n- Consent\n- Audit\n- Multidisciplinary gynaecological oncology team\n- Advanced laparoscopic skills\n- Less invasive option\n- Shorter recovery times\n- Conversion to laparotomy\n- Postoperative complications\n- Long-term outcomes",
    "CG1127 Neonatal Abstinence Scoring.txt": "- Neonatal Abstinence Syndrome (NAS)\n- Birth parents\n- Prescribed substances\n- Non-prescribed substances\n- Signs and symptoms\n- Assessment tools\n- Drug dependency\n- Foetal alcohol syndrome\n- Premature birth\n- Intrauterine growth restriction\n- Placental abruption\n- Cleft palate\n- Low birth weight\n- Antenatal care\n- Hepatitis B vaccine\n- Social services\n- Opiate withdrawal\n- Naloxone\n- Immunoglobulin\n- Neonatal unit\n- Scoring chart\n- Pharmacological treatment\n- Morphine\n- Breastfeeding\n- Alcohol withdrawal\n- Benzodiazepine withdrawal\n- Barbiturate withdrawal\n- Discharge planning\n- Patient information\n- Audit/Monitoring",
    "CG1139 Obesity in Pregnancy.txt": "- Obesity\n- Pregnancy\n- Labor\n- Postnatal\n- Complications\n- Management\n- Guidelines\n- Midwives\n- Obstetricians\n- Anaesthetists\n- Support staff\n- Risks\n- Miscarriage\n- Gestational diabetes\n- Pre-eclampsia\n- BMI classifications\n- Care pathways\n- Thromboembolism\n- Thromboprophylaxis\n- Manual handling\n- Tissue viability assessments\n- Equipment\n- Fetal scalp monitoring\n- CS suturing\n- PICO dressings\n- Venous access\n- Oral intake\n- Postnatal period\n- Weight management\n- Healthy Eating Services\n- Birth outcome.",
    "Management of Acute Pelvic Inflammatory Disease.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by section for clarity:  \n\n### **General Terms**  \n- **Pelvic Inflammatory Disease (PID)**  \n- **Acute PID**  \n- **Guideline**  \n- **Management**  \n\n### **4.0 Introduction**  \n- **Endocervical infection**  \n- **Complications**  \n- **Infertility**  \n- **Delayed treatment**  \n\n### **5.0 Risk Factors**  \n- **Age**  \n- **Sexual activity**  \n- **History of PID/STD**  \n- **Recent medical procedures**  \n\n### **6.0 Clinical Features**  \n- **Abdominal tenderness**  \n- **Abnormal vaginal discharge**  \n- **Fever**  \n- **Dyspareunia (painful intercourse)**  \n\n### **7.0 Differential Diagnoses**  \n- **Ectopic pregnancy**  \n- **Appendicitis**  \n\n### **8.0 Investigations**  \n- **Ultrasound**  \n- **Swabs (cervical/vaginal)**  \n\n### **9.0 Management**  \n- **Outpatient antibiotic therapy**  \n- **Inpatient antibiotic therapy**  \n- **Counseling**  \n\n### **10.0 PID in Pregnancy**  \n- **Diagnosis in pregnancy**  \n- **Antibiotic therapy in pregnancy**  \n\n### **11.0 Complications**  \n- **Fitz-Hugh-Curtis syndrome**  \n- **Intrauterine contraceptive device (IUCD) management**  \n\n### **12.0 Sexual Partners**  \n- **Partner treatment**  \n- **Avoidance of intercourse during treatment**  \n\n### **13.0 Follow-up**  \n- **Follow-up appointments**  \n- **Persistent infection testing**  \n\n### **14.0 Auditable Standards**  \n- **Maternity standards**  \n\nThese terms capture the essential clinical and management aspects of PID as outlined in the guideline.",
    "Tongue-tie Division CG12033.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance:\n\n### **General Terms**  \n- **Tongue Tie (Ankyloglossia)**  \n- **Congenital anomaly**  \n- **Lingual frenulum**  \n- **Breastfeeding difficulties**  \n- **Bottle-feeding concerns**  \n\n### **Clinical Assessment & Management**  \n- **Full breastfeeding assessment**  \n- **Correct positioning and attachment**  \n- **Tongue Tie Assessment and Division Clinic form**  \n- **Frenulotomy Safety Checklist**  \n- **Maternal and birth history**  \n- **Family history**  \n- **Tongue structure and function**  \n- **Clinical judgment**  \n- **IM vitamin K** (Intramuscular)  \n- **Oral vitamin K (2 doses)**  \n\n### **Contraindications & Referrals**  \n- **Unusually thick frenulum**  \n- **Presence of blood vessels**  \n- **Referral to specialist center**  \n- **Neonatal surgeon**  \n\n### **Procedure Details**  \n- **Frenulotomy** (Tongue Tie Division)  \n- **No anaesthetic required**  \n- **Emergency call system access**  \n- **Hand washing facilities**  \n- **Direct light and privacy**  \n- **Pressure to stop bleeding**  \n- **Observe feed post-procedure**  \n- **Correct latch if needed**  \n\n### **Post-Procedure Care**  \n- **Feeding immediately to stop bleeding**  \n- **Persistent bleeding \u2192 medical attention**  \n- **Post-procedure information leaflet**  \n- **Follow-up care arrangements**  \n- **Documentation in red book/MIS**  \n\n### **Staff & Training**  \n- **Midwives, Neonatal staff, Maternity assistants, Maternity support workers**  \n- **Training required for assessment & division**  \n- **Inpatient ad-hoc divisions (if workload allows)**  \n\n### **Audit & Compliance**  \n- **Infant Feeding Team monitors outcomes**  \n\nThese terms encapsulate the essential clinical, procedural, and administrative aspects of the guideline.",
    "MP037 Fetal Heart Monitoring guideline 2023_Final.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and category:\n\n### **General Terms**  \n- Fetal Heart Monitoring  \n- Antenatal fetal monitoring  \n- Intrapartum fetal monitoring  \n- Hypoxia  \n- Acidaemia  \n- CTG (Cardiotocography)  \n- cCTG (Computerized CTG)  \n- DR analysis (Doppler Resistance analysis)  \n- STV (Short-Term Variation)  \n- Conservative measures  \n- Expedite birth  \n\n### **Monitoring Methods & Indications**  \n- **Electronic fetal monitoring (EFM)**  \n- **Intermittent auscultation** (for low-risk pregnancies)  \n- **Continuous CTG monitoring** (for high-risk pregnancies)  \n- **Telemetry** (when necessary)  \n- **Fetal scalp stimulation**  \n- **Fresh eyes assessment** (periodic re-evaluation)  \n\n### **Risk Factors Requiring Continuous CTG**  \n- Sepsis  \n- Epidural analgesia  \n- Oxytocin use  \n- Maternal tachycardia (>120 bpm)  \n- Maternal fever (\u226537.5\u00b0C)  \n- Vaginal bleeding  \n- Previous cesarean birth  \n- Hypertension  \n- Pre-existing diabetes  \n- Gestational age >42 weeks  \n- Fetal heart abnormalities  \n- Reduced fetal movements  \n- Meconium-stained liquor  \n- Non-cephalic presentation  \n- IUGR/SGA (Intrauterine Growth Restriction/Small for Gestational Age)  \n- Abnormal liquor volume  \n\n### **CTG Interpretation & Classification**  \n- **Baseline fetal heart rate**  \n- **Variability**  \n- **Decelerations** (Early, Variable, Late)  \n- **Accelerations** (\u226515 bpm for \u226515 sec)  \n- **Bradycardia** (single prolonged deceleration \u22653 min)  \n- **White/Amber/Red classification**  \n  - **Normal** (No amber/red features)  \n  - **Suspicious** (1 amber or 2+ amber features)  \n  - **Pathological** (1 red feature)  \n\n### **Actions Based on CTG Classification**  \n- **Normal CTG**: Hourly reassessment  \n- **Suspicious CTG**:  \n  - Escalate to obstetrician  \n  - Maternal position change  \n  - Consider fetal scalp stimulation  \n- **Pathological CTG**:  \n  - Urgent obstetric review  \n",
    "SP22003 Maternity Telephone Triage SOP.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance:  \n\n### **Key Clinical Terms & Keywords:**  \n1. **Maternity Telephone Triage**  \n2. **Standard Operating Procedure (SOP)**  \n3. **UH Sussex SRH & WH** (University Hospitals Sussex, St. Richard\u2019s & Worthing Hospitals)  \n4. **Consistency in care delivery**  \n5. **Midwives & medical staff**  \n6. **Quality, safety, patient satisfaction**  \n7. **Professional judgment**  \n8. **Triage calls (NetCall system)**  \n9. **Labor ward diversion**  \n10. **Care pathway determination**  \n11. **Documentation (MIS \u2013 Maternity Information System)**  \n12. **Third call rule (advise to come in unless no concerns)**  \n13. **Escalation pathways**  \n14. **Telephone triage assessment card**  \n15. **Referral point assessment**  \n16. **SP22003 Maternity Telephone Triage SOP v1.1 (July 2023)**  \n\nThese terms encapsulate the core clinical, procedural, and documentation aspects necessary for effective telephone triage in maternity services.",
    "UHSussex - MP044 - Failed intubation in the Obstetric patient.txt": "- Failed Intubation\n- Obstetric Patient\n- Protocol\n- Measurable\n- Objective standards\n- Professional judgment\n- Peri-partum period\n- Anaesthetists\n- Midwives\n- Obstetricians\n- Management Team\n- Maternal physiology\n- Fetal status\n- Human factors\n- Difficult airway\n- Algorithmic approach\n- OAA/DAS\n- Unanticipated difficult airway",
    "GP001 - Management of Miscarriage.txt": "- Management of Miscarriage\n- Diagnosis\n- Ultrasound\n- Conservative Management\n- Medical Management\n- Surgical Management\n- Anti-D rhesus prophylaxis\n- Follow-up\n- Terminology\n- Patient Information Leaflet\n- Memorial Service\n- Funeral arrangements\n- Contact Numbers\n- Support Groups\n- Counseling",
    "CG1152 Birth After Caesarean (BAC) Guideline.txt": "- Birth after Caesarean Section (BAC)\n- VBAC (Vaginal birth after caesarean)\n- ERCS (Elective Repeat Caesarean Section)\n- Antenatal Management\n- Intrapartum Management\n- Continuous electronic fetal monitoring\n- Epidural analgesia\n- Active management of the third stage of labor\n- Uterine rupture\n- Informed decision-making\n- Audit standards\n- Contraindications for BAC\n- Management Plan for labour\n- Fetal Monitoring\n- Preterm labor\n- Spontaneous labor\n- Induction of Labor (IOL)\n- Augmentation\n- Consultant Obstetrician",
    "GTG 2011 - APH.txt": "- Antepartum haemorrhage\n- Placenta praevia\n- Placental abruption\n- Perinatal and maternal mortality\n- Preterm delivery\n- Cerebral palsy\n- Clinical shock\n- Blood loss\n- Spotting\n- Major haemorrhage\n- Massive haemorrhage\n- Recurrent APH\n- Domestic violence\n- Triage\n- Maternal resuscitation\n- Fetal wellbeing\n- Antenatal corticosteroids\n- Tocolytic therapy\n- Fetal monitoring\n- Caesarean section\n- Induction of labor\n- Postpartum hemorrhage\n- Anti-D Ig\n- Coagulopathy\n- Neonatal assessment\n- Thromboprophylaxis\n- Obstetric skill drills\n- Audit topics\n- Areas for future research\n- Massive APH\n- Clinical shock\n- Delivery of the fetus\n- Communication\n- Resuscitation\n- Monitoring\n- Investigation\n- Fluid replacement\n- Blood products\n- DIC\n- Fluid therapy\n- Hemoglobin\n- Platelets\n- Prothrombin time\n- Fibrinogen",
    "GP001 - Management of Confirmed Ectopic Pregnancy.txt": "Keywords and clinically significant terms:\n\n- Ectopic pregnancy\n- NICE (National Institute for Health and Care Excellence)\n- RCOG (Royal College of Obstetricians and Gynaecologists)\n- Clinical stability\n- hCG levels\n- Expectant management\n- Medical management\n- Methotrexate\n- Surgical management\n- Laparoscopic surgery\n- Salpingectomy\n- Salpingotomy\n- Anti-D rhesus prophylaxis\n- Kleihauer test\n- Foeto-maternal haemorrhage\n- Debriefing\n- Early Pregnancy Assessment Clinic\n- Trophoblast\n- Follow-up arrangements\n- Safety netting\n- Emergency surgery\n- HCG numbers",
    "CG14009 PCEA (Epidural) in Labour Guideline.txt": "- Anaesthetic\n- Midwifery\n- Obstetric\n- PCEA (Patient Controlled Epidural Analgesia)\n- Local anesthetic\n- Motor block\n- Levobupivacaine\n- Fentanyl\n- Mobile epidurals\n- Epidural pain relief\n- Epidural opioids\n- 1:1 midwife care\n- Maternal and fetal monitoring\n- Peanut ball\n- Cesarean birth\n- Pressure area damage\n- Cervical dilatation\n- Anaesthetist referral\n- Postpartum management\n- Change Log\n- Patient information sheets\n- Yellow band\n- Clorhexidine\n- Pressure area care",
    "UHSx Maternity Education Policy.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and category:\n\n### **Policy & Governance**  \n- Maternity Education Policy  \n- Trust Statutory and Mandatory Training  \n- National Maternity Agenda  \n- Compliance Monitoring  \n- Due Regard Assessment Screening  \n- Governance Leads  \n- Action Plans  \n- Version Control  \n\n### **Staff Roles & Responsibilities**  \n- Maternity Rota Leads  \n- Maternity Administrators  \n- Maternity Education Administrator  \n- Non-Substantive Staff (Bank Midwives)  \n- Locum Doctors  \n- Student Midwives  \n- Fetal Monitoring Team  \n- Practice Education Facilitators  \n- Preceptorship Midwife  \n- Clinical Skills Facilitators  \n- Maternity Care Assistants (MCAs)  \n- Maternity Support Workers  \n- Nursery Nurses  \n- Non-Registered Staff (Band 2-4)  \n- PDT Administrators  \n- Roster Coordinators  \n\n### **Training & Competency Requirements**  \n- Mandatory Training  \n- Statutory Training  \n- Annual Training  \n- Competency Assessments  \n- Fetal Monitoring Training  \n- Care Certificate (for Band 2-4 staff)  \n- Preceptorship Programme  \n- Clinical Skills Training  \n- Simulation Training  \n- Online Learning  \n- Classroom Teaching  \n\n### **Compliance & Monitoring**  \n- Training Needs Analysis  \n- Attendance Reporting  \n- Protected Training Time  \n- Annual Appraisal  \n- Dissemination & Implementation Plan  \n- Incident Learning Integration  \n\n### **Key Processes**  \n- Training Bookings  \n- Staff Group Lists  \n- Justification for Missing Training (Extreme Circumstances)  \n- Policy Review (National Recommendations, Service User Input, Local Learning)  \n\nThese terms capture the essential clinical, administrative, and governance aspects of the maternity education policy. Let me know if you'd like further refinement!",
    "MP046 Management of Breech and ECV.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and category:\n\n### **General Definitions & Epidemiology**  \n- Breech presentation  \n- Longitudinal lie  \n- Perinatal mortality/morbidity  \n- Incidence (20% at 28 weeks, 16% at 32 weeks, 3\u20134% at term)  \n\n### **Types of Breech Presentation**  \n- Frank (extended) breech  \n- Complete (flexed) breech  \n- Footling breech  \n- Kneeling breech  \n\n### **Management & Referral**  \n- External cephalic version (ECV)  \n- Success rate (~50%)  \n- Contraindications (absolute contraindications to vaginal birth)  \n- Day Assessment Unit (DAU) referral (>36 weeks)  \n- RCOG leaflet: *A Breech Baby at the End of Pregnancy*  \n\n### **Delivery Options & Counseling**  \n- Elective LSCS (caesarean section at ~39 weeks)  \n- Vaginal breech birth (assessment required)  \n- Risks/benefits discussion (ECV, vaginal breech, LSCS)  \n\n### **Risk Factors for Vaginal Breech Birth**  \n- Hyperextended neck  \n- High/low estimated fetal weight  \n- Footling presentation  \n- Antenatal fetal compromise  \n\n### **Intrapartum Care & Birth Plan**  \n- Multidisciplinary team approach  \n- Immediate caesarean access & neonatal support  \n- Induction of labor (not recommended unless specific criteria)  \n- Continuous monitoring  \n- Lower tolerance for slow progress in breech labor  \n\n### **Second Stage of Labor & Delivery Techniques**  \n- Passive second stage before active pushing  \n- Progressive descent monitoring  \n- Hands-poised/hands-off approach  \n- **Maneuvers:**  \n  - Mauriceau-Smellie-Veit (for after-coming head delay)  \n  - Assisted vaginal breech maneuvers  \n- **Positions:**  \n  - Semirecumbent  \n  - All-fours  \n- **Key warnings:**  \n  - No traction on breech  \n  - Selective episiotomy  \n  - Signs requiring intervention (lack of tone/color, delay)  \n\n### **Special Cases & Governance**  \n- Preterm breech \u2192 LSCS recommended  \n- Twin pregnancy (breech presenting twin \u2192 LSCS)  \n- Undiagnosed breech in labor (consider",
    "UHSussex - MP056 - Obstetric High Dependency Care.txt": "- Obstetric High Dependency Care\n- Protocol\n- Professional judgement\n- Intensive care\n- Obstetric event/care\n- Midwives\n- Obstetricians\n- Management\n- Trust\n- National recommendations\n- Life threatening\n- Maternity unit\n- Level of care\n- Nursing/midwifery care\n- Critical Care Outreach team\n- Anaesthetists\n- Equipment\n- Transfer decision\n- Discharge\n- Senior staff\n- Clinical conditions\n- Guidelines",
    "GP011 Referral criteria for Outpatient Hysteroscopy.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by category for clarity:\n\n### **1. Protocol & Responsibilities**  \n- Protocol (measurable, objective standards)  \n- Professional judgement  \n- Responsibilities: Nurses, Midwives, Obstetricians & Gynaecologists  \n- Management Team (review & accessibility)  \n\n### **2. Outpatient Hysteroscopy (OPH) Service**  \n- OPH service (PRH site)  \n- Consultants & trained nurses  \n- Written patient information & consent  \n\n### **3. Referral Criteria (Indications for OPH)**  \n- Abnormal uterine bleeding  \n- Endometrial pathology  \n- Abnormal bleeding on Tamoxifen  \n- Irregular/heavy uterine bleeding  \n- Postmenopausal bleeding  \n- Fertility patients  \n- Recurrent pregnancy loss  \n\n### **4. Patient Suitability**  \n- **Suitable patients:** All women meeting criteria  \n- **Unsuitable patients:**  \n  - Unable to tolerate speculum/pelvic exam  \n  - History of PID (pelvic inflammatory disease)  \n  - Pregnancy  \n  - Other pelvic pathology  \n  - Patient unwillingness  \n\n### **5. Referral Pathways**  \n- **GOPD referrals:** Require consultant approval  \n- **GP & BICS referrals:** Direct referrals accepted after triage (GK or EK)  \n\n### **6. Diagnostic & Triage Protocol**  \n- **USS (Ultrasound Scan) protocol:** Used for triaging further investigations  \n\n### **7. Procedure & Pain Management**  \n- Adequate analgesia  \n\n### **8. Clinic Appointments & Follow-Up**  \n- Allocated time slots  \n- Clear management plan post-procedure  \n\n### **9. Communication & Results**  \n- Letter to referring consultant & GP  \n- Histology reports sent to GP promptly  \n\nThese terms capture the essential clinical, procedural, and administrative aspects of the guideline. Let me know if you'd like further refinement!",
    "CG1196 Care in labour.txt": "- Care in labour\n- Evidence-based practices\n- Pregnant women\n- Birthing people\n- Low-risk individuals\n- Decision-making\n- Midwives\n- Obstetricians\n- Initial assessment\n- Fetal movements\n- Risk assessments\n- Timely referrals\n- Normal birth\n- Avoiding unnecessary interventions\n- Clinical picture\n- Obstetric history\n- Medical history\n- Anaesthetic history\n- Risk factors\n- Social lifestyle\n- Routine observations\n- Referral\n- Delay in labor\n- Biomechanics\n- Monitoring progress\n- Amniotomy\n- Complications\n- Pain management\n- Monitoring maternal and fetal condition\n- Second stage of labor\n- Pushing\n- Delay in progress\n- Third stage of labor\n- Active management\n- Physiological management\n- Uterotonic\n- Postpartum hemorrhage\n- Placenta\n- Cord drainage\n- Skin-to-skin contact\n- Breastfeeding\n- Newborn examination\n- Placental histology\n- Guideline updates\n- Review date",
    "BJOG - 2020 - Murphy - Assisted Vaginal Birth.txt": "Assisted Vaginal Birth, preparation, epidural analgesia, positions, delayed pushing, classification system, contraindications, fetal bleeding disorders, fracture predisposition, blood borne viral infections, assessment, expertise, ultrasound, consent, operators, supervision, instrument choice, vacuum, forceps, episiotomy, aftercare, prophylactic antibiotics, thromboprophylaxis, analgesia, psychological support, adverse outcomes, incident report, obstetricians, duty of candour, perinatal outcomes, mediolateral episiotomy, OASI prevention, prophylactic antibiotics, thromboprophylaxis, NSAIDs, urinary retention, incontinence, shared decision making, psychological morbidity, future births, documentation, incident report, training, competency, simulation, high-risk births, neonatal complications, perinatal outcomes, episiotomy, prophylactic antibiotics, hygiene, aseptic techniques, thromboprophylaxis, physiotherapy, individualized care, future pregnancies, obstetricians, adverse event reporting, reviews, maternity units, supportive framework, subdural hemorrhages, Kielland's forceps, maternal and neonatal morbidity, vacuum extraction, sequential instruments, failed vacuum, venous thromboembolism, postpartum care, urinary incontinence, post-traumatic stress disorder, debriefing interventions, duty of candour, instrument placement, antibiotic prophylaxis, postnatal care, emotional distress, pelvic floor muscle training, urinary continence, psychological trauma, OVB proforma, neonatal morbidity, debriefing.",
    "MP045 Pyrexia in Labour & Sepsis.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and category:\n\n### **Core Definitions & Concepts**  \n- **Sepsis** (infection + systemic manifestations)  \n- **Severe sepsis** (organ dysfunction/tissue hypoperfusion)  \n- **Septic shock** (persistent hypoperfusion despite fluids)  \n- **Pyrexia in pregnancy/labour/postpartum**  \n- **Puerperium** (postpartum period)  \n\n### **Risk Factors**  \n- Obesity  \n- Impaired glucose tolerance  \n- Immunocompromised state  \n- Invasive GAS (Group A Streptococcus) infection  \n\n### **Clinical Management**  \n#### **General Principles**  \n- **Maternal observations** (full set required if sepsis suspected)  \n- **Broad-spectrum antibiotics** (early administration)  \n- **IV fluid resuscitation**  \n- **Source control** (identify/treat infection focus)  \n- **DVT prophylaxis**  \n- **Stress ulcer prophylaxis**  \n\n#### **Specific Conditions**  \n- **Mastitis** (potential hospital referral)  \n- **UTI** (urinary tract infection management)  \n- **Pneumonia** (identification & treatment)  \n- **Skin/soft-tissue infections**  \n- **Necrotising fasciitis** (clinical features & urgent treatment)  \n- **Gastroenteritis**  \n- **Pharyngitis**  \n- **Regional anaesthesia-related infections** (rare complications)  \n\n#### **Time-Critical Actions**  \n- **First 6 hours** (tasks for severe sepsis):  \n  - Antibiotics  \n  - Fluid management  \n  - Blood cultures & lactate testing  \n  - Vasopressors if needed  \n\n### **Monitoring & Escalation**  \n- **Fetal monitoring** (if maternal sepsis in labour)  \n- **Neonatal risk** (umbilical exam, paediatric consult if sepsis)  \n- **Community midwife role** (full review, observations, escalate if unwell)  \n- **Hospital referral criteria** (moderate/severe infection signs)  \n\n### **Key Pathogens**  \n- **Group A Streptococcus (GAS)** (high-risk in postpartum)  \n- Other bacterial causes (genital/non-genital sources)  \n\n### **Multidisciplinary Roles**  \n- **Midwives/Obstetricians** (follow protocol)  \n- **Management Team** (ensure protocol updates)  \n",
    "Joint RCOG BSGE Guideline - Suspected Ovarian Masses in Premenopausal Women.txt": "- Ovarian masses\n- Premenopausal women\n- Gynaecological oncologist referral\n- Early diagnosis\n- Conservative management\n- Laparoscopic techniques\n- Serum CA-125 levels\n- Ultrasound findings\n- Risk of Malignancy Index (RMI)\n- USA and Canada guidelines\n- Simple ovarian cysts\n- Surgical intervention\n- Laparoscopic approach\n- Tumor vascularity\n- Adnexal masses\n- Ovarian cancer detection\n- Risk of malignancy index\n- Transvaginal ultrasonography\n- Colour blood flow imaging\n- Logistic regression model\n- Menopausal status\n- Prospective validation\n- Mathematical models\n- Sonographic features\n- Functional ovarian cysts\n- Operative laparoscopy\n- Laparoscopic management\n- Ovarian dermoid cysts\n- Transumbilical port\n- Laparoscopic retrieval",
    "MP006 Antenatal Screening - Infectious Diseases Hepatitis B.txt": "Here are the most clinically significant terms and keywords extracted from the clinical guideline text, which are critical for understanding the guidance:\n\n### **Screening & Testing**  \n- **Antenatal screening for Hepatitis B**  \n- **First antenatal contact**  \n- **Informed choice**  \n- **Testing before 10 weeks**  \n- **Repeat testing (high-risk cases)**  \n- **Declined screening (benefits discussion, follow-up)**  \n- **Confirmatory testing (for positive results)**  \n- **HIV, Hep B, syphilis screening (recommended)**  \n\n### **Key Roles & Personnel**  \n- **Consultant Virologist**  \n- **Antenatal Screening Co-ordinator**  \n- **Neonatal secretary**  \n- **Consultant Neonatologist**  \n- **Specialist Midwife for Reproductive Health and Wellbeing (SMRHW)**  \n- **Midwife/nurse (sample collection)**  \n- **On-call pediatrician**  \n- **Consultant community paediatrician**  \n\n### **Sample Handling & Results**  \n- **Samples taken at booking**  \n- **Brighton Pathology (processing lab)**  \n- **Unacceptable samples (repeat within 10 working days)**  \n- **Results within 5 working days**  \n- **Follow-up within 10 days**  \n- **Negative results (explained, continued caution)**  \n- **Positive results (confirmatory testing, SMRHW coordination)**  \n\n### **Management of HBV-Positive Mothers & Babies**  \n- **Full vaccination course (within first year of life)**  \n- **Hepatitis B immunoglobulin (if indicated by mother\u2019s status)**  \n- **Written information (baby\u2019s injections, full immunization course)**  \n- **Documentation in baby\u2019s notes**  \n- **Notification to SMRHW (birth time, first vaccine administration)**  \n- **Hepatitis B Notification form (sent to SMRHW)**  \n- **Blood test at 1 year (arranged by consultant community paediatrician)**  \n\n### **Audit & Follow-Up Standards**  \n- **Minimum auditable standards (booking, screening uptake, high infectivity, specialist assessment within 10 days, timely vaccinations)**  \n- **Database maintenance (declined screening, HBV-positive women, baby outcomes)**  \n- **Annual audit of women\u2019s notes**  \n- **Incident reporting (trust\u2019s internal system)**  \n- **Antenatal Screening",
    "CG12018 Ectopic Pregnancy Guideline.txt": "Key terms and keywords:\n- Ectopic pregnancy\n- Pregnancy of Unknown Location (PUL)\n- Early Pregnancy Assessment Clinic (EPAC)\n- Gynaecology Day Unit (GDU)\n- Transvaginal Scan (TVS)\n- Full blood count (FBC)\n- Beta-Human Chorionic Gonadotropin (BHCG)\n- Non Steroidal Anti Inflammatory Drugs (NSAIDs)\n- Intravenous (IV)\n- Obstetrics and Gynaecology (O&G)\n- Human Chorionic Gonadotropin (hCG)\n- Laparoscopy\n- Salpingectomy\n- Salpingotomy\n- Ruptured ectopic pregnancy\n- Anti-D rhesus prophylaxis\n- Serum hCG measurements\n- Serum progesterone levels\n- Audit guidelines\n- Maternity services\n- Expectant management\n- ABCDE assessment",
    "MP070 Examination of the Newborn.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance:\n\n### **General Terms:**  \n- **Examination of the Newborn**  \n- **Congenital abnormalities**  \n- **Early health education and advice**  \n- **Within 72 hours of birth**  \n- **Early discharge exceptions**  \n\n### **Process & Elements:**  \n- **First full physical examination**  \n- **Clinical history**  \n- **Observation**  \n- **Detailed physical examination**  \n\n### **Qualified Staff:**  \n- **Consultant Neonatologists**  \n- **Neonatal medical staff**  \n- **Qualified Midwives**  \n\n### **Documentation & Communication:**  \n- **Informed consent**  \n- **Examination outcomes**  \n- **Deviations from normal**  \n- **Discuss procedures with parents**  \n\n### **Referral Criteria:**  \n- **Further medical investigation**  \n- **Abnormalities identified**  \n\n### **Midwives\u2019 Guidelines:**  \n#### **Can Examine:**  \n- **Babies over 37 weeks**  \n- **Normal vaginal birth**  \n- **Uncomplicated instrumental delivery**  \n- **Uncomplicated LSCS (Lower Segment Cesarean Section)**  \n- **Low-risk babies on meconium observations**  \n- **No maternal medical history affecting baby**  \n\n#### **Must Refer:**  \n- **Babies under 37 weeks**  \n- **Complicated/traumatic vaginal or instrumental delivery**  \n- **Complicated/traumatic LSCS**  \n- **Antenatal abnormalities**  \n- **Parental informed consent not obtained**  \n\n#### **Documentation:**  \n- **Referrals in postnatal notes**  \n\nThese terms encapsulate the key clinical, procedural, and decision-making aspects of the guideline.",
    "Joint RCOG and BSGE Guideline- Laparoscopy in Pregnancy.txt": "Keywords and critical terms:\n- Laparoscopic management\n- Non-obstetric abdominal conditions\n- Pregnancy\n- Acute appendicitis\n- Gallbladder disease\n- Benign adnexal tumors\n- Maternal and fetal safety\n- Experienced laparoscopists\n- Open surgery\n- Spontaneous miscarriage\n- First trimester\n- Recovery\n- Hospital stay\n- Wound infection\n- Expertise\n- Gestation\n- Patient preference\n- Maternal risks\n- Anaesthetic risks\n- Obstetric anaesthetist\n- Venous thromboembolism prophylaxis\n- General anaesthesia\n- Multidisciplinary team\n- Urgent surgery\n- Fetal monitoring\n- Insufflation pressures\n- Operating pressures\n- Laparoscope diameter\n- Energy sources\n- Antibiotics\n- Appendicitis\n- Cholecystectomy\n- Ovarian cysts\n- Adnexal masses\n- Adnexal torsion\n- Cystectomy\n- Ovarian fixation\n- Recurrence prevention\n- Iodinated and gadolinium contrast media\n- Systematic review\n- Meta-analysis\n- Ultrasound\n- Cholelithiasis\n- Cardiovascular consequences\n- Biliary disease\n- Pregnancy outcomes",
    "MP050 Caesarean Section.txt": "Here are the most clinically significant terms and keywords extracted from the **Caesarean Section Protocol**, organized by category for clarity:\n\n---\n\n### **1. Protocol & Scope**  \n- **Caesarean Section (LSCS)**  \n- **Protocol MP050**  \n- **Scope**: Women/persons requiring/requesting CS  \n- **Responsibilities**: Midwives, Obstetricians  \n\n### **2. Classification & Urgency**  \n- **Categories 1-4** (urgency-based classification)  \n- **Category 1/2 LSCS** (emergency)  \n\n### **3. Pre-Operative & Surgical Management**  \n- **WHO Surgical Safety Checklist**  \n- **Pre-operative brief**  \n- **Intra-operative cell salvage**  \n- **Blood transfusion**  \n- **Surgical techniques**  \n- **Visceral/parietal peritoneum** (no routine suturing)  \n- **Subcutaneous tissue closure** (only if fat >2cm)  \n- **Skin closure**: Sutures (preferred over staples)  \n- **Superficial wound drains** (not routine)  \n- **Negative pressure wound therapy** (BMI \u226535 kg/m\u00b2)  \n- **Forceps use** (only if difficulty delivering head)  \n\n### **4. Cord Management & Medications**  \n- **Delayed cord clamping** (routine)  \n- **Cord milking** (alternative to delayed clamping)  \n- **Oxytocin 5 units IV** (post-cord clamping)  \n- **Oxytocin 40 units infusion** (not routine)  \n- **Cord blood samples** (required for Category 1/2, Rh-negative, abnormal antibodies)  \n\n### **5. Antenatal & Postnatal Care**  \n- **Antenatal corticosteroids** (elective CS before 38+6 weeks)  \n- **Enhanced Recovery** (for non-complex elective CS)  \n- **Pre-op assessment** (DAU/MAU within 24-48h prior)  \n- **Post-operative analgesia** (mandatory)  \n- **Urinary catheter removal** (after mobility, \u22656h post-epidural)  \n- **Postnatal complications**:  \n  - **Endometritis** (vs. retained products)  \n  - **UTI/urinary retention/stress incontinence**  \n  - **VTE risk assessment & thromboprophylaxis**  \n  - **VB",
    "CG20003 First Trimester Dating USS Protocol.txt": "- First Trimester US Screening\n- Dating Scan\n- Combined Test\n- Declined Combined Test Ultrasound\n- Sonographers\n- Screening Programme\n- CRL (Crown Rump Length)\n- NT (Nuchal Translucency)\n- Twin Pregnancy\n- Dichorionic Twin Pregnancy\n- Monochorionic Twin Pregnancy\n- Quadruple Test\n- Down's Syndrome\n- T21\n- Invasive Diagnostic Testing\n- Selective Reduction\n- Vanished Twin\n- Non-viable Fetus\n- Ultrasound Scan",
    "Guideline No. 452 Diagnosis and Management of Intrahepatic Cholestasis of Pregnancy.txt": "- Intrahepatic cholestasis of pregnancy\n- Itching\n- Elevated bile acids\n- Perinatal risks\n- Preterm birth\n- Neonatal respiratory distress\n- Stillbirth\n- Ursodeoxycholic acid\n- Planned early birth\n- Fetal monitoring\n- Recurrence\n- Pregnant individuals\n- Bile acid testing\n- Monitoring\n- Delivery timing\n- Continuous fetal monitoring\n- Postpartum\n- Family members\n- Liver\n- Genetic susceptibility\n- Risk factors\n- Pruritis\n- Serum bile acids\n- Diagnosis\n- Pre-eclampsia\n- Gestational diabetes\n- Refractory cases\n- Specialist referral\n- Fetal risk\n- Electronic fetal heart rate monitoring\n- Ultrasound\n- Contraception considerations\n- Recurrence risk\n- Metabolic disease\n- World Health Organization\n- Postpartum contraception\n- Adverse pregnancy outcomes\n- Induction of labor\n- Pathophysiology\n- Differential diagnoses\n- AFLP\n- HELLP syndrome\n- Iatrogenic birth\n- Contraceptive eligibility",
    "Joint RCOG BASHH Guideline - Genital Herpes in Pregnancy.txt": "- Genital herpes\n- Pregnancy\n- Neonatal herpes\n- Herpes simplex virus\n- Aciclovir\n- Vaginal delivery\n- Caesarean section\n- Neonatal transmission\n- Recurrent infections\n- Primary infections\n- HSV antibody testing\n- Postnatal transmission\n- HIV-positive women\n- Lumbar puncture\n- PCR testing",
    "UHSx Midwifery Preceptorship Protocol.txt": "Here are the most clinically significant terms and keywords extracted from the clinical guideline text, critical for understanding the guidance:  \n\n### **Key Roles and Responsibilities:**  \n- **Preceptee** (newly registered midwife)  \n- **Preceptor** (mentor/supporting midwife)  \n- **Professional Midwifery Advocate (PMA)**  \n- **Preceptorship Lead**  \n- **Line Manager**  \n- **Chief Nurse**  \n- **Director of Midwifery**  \n- **Head of Midwifery**  \n- **Consultant Midwife**  \n- **Practice Supervisor / Practice Assessor**  \n\n### **Program Components & Processes:**  \n- **A-EQUIP model** (advocacy, education, quality improvement)  \n- **Restorative Supervision** (individual/group)  \n- **Supernumerary status** (minimum 4 weeks)  \n- **Structured learning program** (induction, study days, mandatory training)  \n- **Protected time** (for meetings, training)  \n- **ePortfolio** (documentation of progress)  \n- **Skills Passport**  \n- **Escalation process** (for concerns)  \n- **Final sign-off meeting** (progression to Band 6)  \n- **Capability & Poor Performance Guidance** (if requirements unmet)  \n\n### **Key Activities & Commitments:**  \n- **Reflective practice** (NMC reflective accounts)  \n- **Progress meetings** (3, 6, 9, 12 months)  \n- **Feedback & development planning**  \n- **Quality Improvement Projects (PFIS)**  \n- **Biological Birth Refresher**  \n- **Staff Psychological Support Service**  \n- **Celebrating success**  \n\n### **Support & Wellbeing:**  \n- **Restorative Clinical Supervision**  \n- **HELP service referral** (if needed)  \n- **Wellbeing resources**  \n- **Psychological support**  \n\n### **Documentation & Compliance:**  \n- **Preceptorship Progress Log**  \n- **NMC Code adherence** (Prioritize people, Practice effectively, Preserve safety, Promote professionalism)  \n- **Standardized documentation** (UHSussex framework)  \n- **Annual evaluation** (feedback from preceptees, preceptors, managers)  \n\nThese terms encapsulate the core elements of the preceptorship program, ensuring clarity on roles, processes, and expectations for midwives and",
    "MP073 Pregnancy Loss.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance:\n\n### **General Protocol & Scope**  \n- **Pregnancy loss >14 weeks**  \n- **Fetal loss**  \n- **Termination of pregnancy (TOP)**  \n- **Mid-trimester loss**  \n- **Stillbirth**  \n- **Neonatal death**  \n- **Maternity protocol**  \n- **Professional judgement**  \n\n### **Clinical Management**  \n- **Unexpected intrauterine death**  \n- **Ultrasound scan**  \n- **Mode of delivery**  \n  - Vaginal birth  \n  - Caesarean birth  \n- **Expectant management**  \n- **Induction of labour**  \n- **Mifepristone & misoprostol** (drug regimens for induction)  \n- **Previous caesarean section** (safety considerations)  \n- **Active management (third stage of labour)**  \n- **Regional anesthesia**  \n- **Patient-controlled analgesia (PCA)**  \n- **Manual palpation**  \n\n### **Post-Loss Care & Procedures**  \n- **Post-mortem (PM) examination** (recommended but optional)  \n- **Histology (placenta sent for testing)**  \n- **Genetic testing** (chromosomal/DNA analysis)  \n- **Tissue/organ retention** (for diagnosis, research, or training)  \n- **Consent withdrawal** (for tissue/organ use)  \n- **Funeral arrangements** (options, religious considerations)  \n- **Memory-making** (handprints, photographs, memory boxes)  \n- **SANDS leaflet** (bereavement support)  \n- **Chaplaincy services**  \n\n### **Legal & Administrative Aspects**  \n- **Stillbirth definition (>24 weeks, no signs of life)**  \n- **Certification by doctor/midwife**  \n- **Coroner involvement** (if uncertainty about signs of life)  \n- **Birth registration** (within 42 days for stillbirth)  \n- **MCCD (Medical Certificate of Cause of Death)**  \n- **Datix reporting** (incident review)  \n\n### **Psychosocial & Family Support**  \n- **Grief & mourning**  \n- **Bereavement support**  \n- **Religious/cultural considerations** (Christian, Hindu, Muslim, Jewish, Sikh, etc.)  \n- **Support for fathers & siblings**  \n- **Follow-up care** (",
    "Risk Assessment Obstetric VTE  non-maternity wards.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance:  \n\n### **Key Clinical Terms:**  \n1. **VTE (Venous Thromboembolism) Risk Assessment**  \n2. **Booking Appointment**  \n3. **28 weeks (gestation)**  \n4. **Repeat assessments**  \n5. **Admissions**  \n6. **New risks**  \n7. **Daily risk assessment**  \n8. **Antenatal & Postnatal Risk Assessment**  \n9. **Thromboprophylaxis**  \n10. **Total score (risk scoring system)**  \n11. **Reassess thromboprophylaxis**  \n12. **Haematologist consultation**  \n13. **Bleeding risk**  \n14. **LMWH (Low Molecular Weight Heparin) dose**  \n15. **Weight-based dosing**  \n16. **High prophylactic dose**  \n17. **Enoxaparin (LMWH brand)**  \n18. **Relative contraindications**  \n19. **Consultant Obstetrician discussion**  \n\nThese terms capture the essential clinical actions, timing, decision points, and specialist involvement required for effective VTE risk management in obstetric care.",
    "MP002 Fetal Anomaly Screening Programme SR Sept.txt": "Here are the most clinically significant terms and keywords extracted from the clinical guideline text, critical for understanding the guidance:\n\n### **General Terms**  \n- **Fetal Anomaly Screening Programme (FASP)**  \n- **NHS National Screening Committee (NSC)**  \n- **Protocol**  \n- **Professional judgment**  \n- **Pregnant women and people**  \n- **Midwives & Obstetricians**  \n- **Management Team**  \n- **Service Specification No.16 & No.17**  \n\n### **Screening Conditions**  \n- **Down\u2019s syndrome (T21)**  \n- **Edwards\u2019 syndrome (T18)**  \n- **Patau\u2019s syndrome (T13)**  \n- **Neural Tube Defect (NTD)**  \n\n### **Screening Tests & Procedures**  \n- **Combined screening test**  \n- **Quadruple screening test**  \n- **Nuchal Translucency (NT) scan**  \n- **Non-Invasive Prenatal Test (NIPT)**  \n- **Invasive diagnostic testing (amniocentesis)**  \n- **PCR (Polymerase Chain Reaction)**  \n- **CGH array (Comparative Genomic Hybridization)**  \n- **Karyotype**  \n\n### **Timing & Gestational Age**  \n- **First-trimester screening**  \n- **Second-trimester screening (14+2 to 20+0 weeks)**  \n- **20-20+6 weeks (anomaly scan)**  \n\n### **Key Roles & Responsibilities**  \n- **Sonographer**  \n- **Antenatal Screening Support Worker (ASSW)**  \n- **Laboratory Screening Coordinator**  \n- **Community midwife**  \n- **Fetal Cardiac Unit (Evelina Children\u2019s Hospital)**  \n\n### **Process & Documentation**  \n- **Informed choice**  \n- **Consent**  \n- **Digital notes**  \n- **LifeCycle portal**  \n- **Failsafe checks**  \n- **High chance result (cut-off 1 in 150)**  \n- **Low chance result**  \n\n### **Follow-Up & Referrals**  \n- **Fetal anomaly scan**  \n- **Fetal cardiac scan**  \n- **Referral to fetal medicine consultants**  \n- **Support group (ARC \u2013 Antenatal Results & Choices)**  \n\n### **Patient Communication & Support**  \n- **Pre-test information**  \n- **Interpreter services**  \n- **",
    "UHSussex - MP053 - Obstetric Haemorrhage.txt": "- Obstetric Haemorrhage\n- Protocol\n- Antepartum Hemorrhage\n- Placental Abruption\n- Placenta Praevia\n- Postpartum Hemorrhage\n- Women who decline blood products\n- Professional judgment\n- Midwives\n- Anaesthetists\n- Obstetricians\n- Management\n- Agreed Definitions\n- Minor Antepartum Hemorrhage\n- Major Antepartum Hemorrhage\n- Minor Primary Postpartum Hemorrhage\n- Major Primary Postpartum Hemorrhage\n- Massive Primary Postpartum Hemorrhage\n- Secondary Postpartum Hemorrhage\n- Volume\n- Causes\n- Management\n- Risk assessment\n- Care planning\n- Communication\n- Labor ward coordinator\n- Obstetric Registrar\n- Anaesthetic Registrar\n- Home births\n- Emergency management\n- Resuscitation\n- Hematology department\n- Ultrasound scan\n- Jehovah\u2019s Witness\n- Individual management plan\n- Oxytocic\n- FBC\n- Thromboprophylaxis\n- Debriefing\n- Datix",
    "Reduced Fetal Movements guideline.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance:\n\n### **Core Concepts**  \n- **Reduced fetal movements (RFM)**  \n- **Stillbirth prevention**  \n- **Fetal wellbeing**  \n- **Gestational age**  \n- **Fetal viability**  \n\n### **Risk Factors & Conditions**  \n- **Small for gestational age (SGA)**  \n- **Fetal growth restriction (FGR)**  \n- **Risk factors for stillbirth**  \n\n### **Clinical Assessments & Procedures**  \n- **Computerized CTG (Cardiotocography)**  \n- **Fetal heart rate (FHR) auscultation**  \n- **Growth scans (USS, EFW, AC)**  \n- **Biophysical profile (BPP)**  \n- **Maternity day assessment unit**  \n\n### **Management & Interventions**  \n- **Expediting birth (induction of labor, cesarean birth)**  \n- **Continuous monitoring in labor**  \n- **Referral to fetal medicine consultant**  \n- **Serial growth scans**  \n- **CTG within 2 hours of RFM report**  \n\n### **Timing & Thresholds**  \n- **Before viability gestation**  \n- **24+0 to 25+6 weeks**  \n- **26+0 to 38+6 weeks**  \n- **38+6 to 39+0 weeks (discuss induction/C-section)**  \n- **Recurrent RFM (\u22652 episodes within 3 weeks from 26 weeks)**  \n\n### **Documentation & Decision-Making**  \n- **MIS (Maternity Information System) documentation**  \n- **Senior obstetrician decision for induction**  \n- **Counseling on risks of early birth**  \n\n### **Key Abbreviations**  \n- **CTG (Cardiotocography)**  \n- **FHR (Fetal Heart Rate)**  \n- **EFW (Estimated Fetal Weight)**  \n- **AC (Abdominal Circumference)**  \n- **USS (Ultrasound Scan)**  \n- **BPP (Biophysical Profile)**  \n- **LV (Likely Viable, if contextually relevant)**  \n\nThese terms encapsulate the critical aspects of the guideline, ensuring clinicians can quickly grasp key recommendations for managing reduced fetal movements.",
    "MP066 Neonatal Resuscitation (Term and Pre-term).txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance:\n\n### **Core Concepts & Procedures**  \n- **Neonatal Resuscitation**  \n- **Newborn Life Support (NLS)**  \n- **Meconium-stained liquor**  \n- **Hypoxic-ischaemic encephalopathy (HIE)**  \n- **Therapeutic hypothermia**  \n- **Preterm babies (<32 weeks / <30 weeks)**  \n- **Pre-ductal oxygen saturations**  \n- **Blended oxygen and air**  \n- **Plastic wrap (for preterm infants)**  \n\n### **Key Actions & Interventions**  \n- **Assess breathing, circulation, heart rate, color, tone**  \n- **Effective ventilation**  \n- **Oxygen concentration adjustment**  \n- **Avoid airway suction in vigorous babies (meconium)**  \n- **Dry and wrap non-vigorous babies**  \n- **No tracheal lavage**  \n- **Passive cooling avoidance**  \n- **Maintain warmth during transfer**  \n\n### **Roles & Responsibilities**  \n- **Midwives (homebirth competency)**  \n- **Maternity/Neonatal/A&E staff**  \n- **Advanced Neonatal Resuscitation-trained staff**  \n- **Annual NLS training & skills drills**  \n\n### **Logistics & Environment**  \n- **Preparation & equipment readiness**  \n- **Warm environment**  \n- **Emergency transfer (999 for homebirths)**  \n- **Documentation post-resuscitation**  \n\n### **Protocol-Specific Terms**  \n- **Protocol adherence vs. professional judgment**  \n- **Continual reassessment**  \n- **Trust and National recommendations**  \n\nThese terms encapsulate the critical clinical, procedural, and operational aspects of the guideline. Let me know if you'd like further refinement!",
    "Sussex Regional In utero transfer to RSCH SOP V7 2022.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and category:  \n\n### **General Context**  \n- **Preterm In-Utero Transfer (IUT)**  \n- **Standard Operating Procedure (SOP)**  \n- **Sussex Maternity Units**  \n- **Royal Sussex County Hospital (RSCH)**  \n- **Neonatal Intensive Care Unit (NICU)**  \n- **Local Neonatal Unit (LNU)**  \n- **Special Care Unit (SCU)**  \n- **Operational Delivery Network (ODN)**  \n\n### **Clinical Criteria & Indications**  \n- **Threatened preterm delivery**  \n  - **< 27 weeks gestation (LNUs)**  \n  - **< 28 weeks (multiples)**  \n  - **< 32 weeks (SCUs)**  \n- **Steroids (antenatal corticosteroids)**  \n- **Antibiotics**  \n- **Tocolysis**  \n- **Magnesium sulfate (MgSO\u2084)**  \n- **Rescue cerclage**  \n- **Fibronectin test**  \n- **Preterm rupture of membranes (PROM)**  \n- **Prolonged rupture of membranes (>18/24 hrs)**  \n- **Shortened cervix**  \n- **Placenta praevia**  \n- **Antepartum hemorrhage (APH)**  \n- **Pre-eclampsia (PET)**  \n- **Fetal abnormality**  \n- **IVF pregnancy**  \n\n### **Transfer Process & Management**  \n- **Time-critical transfer**  \n- **Emergency transfer**  \n- **Stabilization before transfer**  \n- **MDT (Multidisciplinary Team) discussion**  \n- **SBAR Communication Tool**  \n- **SECAmb (South East Coast Ambulance Service) Guidance**  \n- **Exception report**  \n- **Refusal of transfer (escalation required)**  \n- **Maternal notes documentation**  \n\n### **Post-Delivery & Learning**  \n- **Birth in the wrong place**  \n- **Maternity clinical incident review**  \n- **Quality & Safety Forum**  \n- **ODN Governance Meeting**  \n- **BadgerNet ID (patient identifier)**  \n- **Outcome of baby (died, transferred, remained on unit)**  \n\nThese terms encapsulate the critical clinical, procedural, and administrative aspects of the guideline, ensuring a clear understanding of preterm in-utero transfer management.",
    "PPH prompt card ED RSCH PRH.txt": "Here are the most clinically significant terms and keywords extracted from the PPH (Postpartum Hemorrhage) PROMPT CARD guideline:\n\n### **Emergency Classification & Response:**  \n- **PPH classification**:  \n  - **Obstetric emergency** (500-1000mls)  \n  - **Major Obstetric Haemorrhage** (1000-2000mls)  \n  - **Massive Obstetric Haemorrhage** (>2000mls)  \n- **2222 call** (emergency response)  \n- **Obstetric emergency team**:  \n  - Obstetric team  \n  - Labour Ward Coordinator  \n  - Anaesthetist on-call  \n  - Theatre team  \n\n### **Immediate Actions:**  \n- **Full observations**  \n- **2 x wide bore cannulas**  \n- **Blood tests**:  \n  - **FBC** (Full Blood Count)  \n  - **Clotting**  \n  - **U&Es** (Urea & Electrolytes)  \n  - **LFT\u2019s** (Liver Function Tests)  \n  - **ROTEM** (viscoelastic haemostatic assay)  \n  - **Cross Match 4 units**  \n- **IV fluids**  \n- **Measure blood loss**  \n\n### **Uterotonics (Medications to Control Bleeding):**  \n- **Oxytocin** (10iu IM / 5iu IV bolus)  \n- **Syntometrine** (1ml IM)  \n- **Ergometrine** (500mcg IM/IV, max 2 doses)  \n- **Oxytocin infusion** (40iu in 500ml NaCL at 125ml/hr)  \n- **Tranexamic Acid** (1g IV)  \n- **Carboprost** (250mcg IM, up to 8 doses at 15min intervals)  \n- **Misoprostol** (1000mcg PR, consultant discussion)  \n\n### **Additional Interventions:**  \n- **Check placenta** (for completeness)  \n- **Check perineum** (for trauma)  \n- **Urometer** (urine output monitoring)  \n- **Transfer to theatre** (if needed)  \n\n### **Documentation & Reporting:**  \n- **Complete Proforma**  \n- **Datix** (incident reporting if >1500mls blood loss)  \n\nThese terms are critical for understanding the",
    "UHSx Maternity Smoking & Smoke Free Pregnancy guideline.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance:  \n\n### **Core Clinical Concepts:**  \n1. **Smoking in pregnancy**  \n2. **Smoke-free pregnancy**  \n3. **Stillbirth**  \n4. **Miscarriage**  \n5. **Sudden infant death (SIDS)**  \n6. **Behavioral support**  \n7. **Nicotine Replacement Therapy (NRT)**  \n8. **CO (Carbon Monoxide) monitoring**  \n9. **Oxygen transport impairment**  \n10. **Opt-Out referral method**  \n11. **Smoking cessation**  \n12. **Electronic cigarettes (ECs)**  \n13. **Secondhand smoke exposure**  \n14. **Smoke-free home**  \n\n### **Key Actions for Healthcare Providers:**  \n1. **Consistent messaging on quitting smoking**  \n2. **CO testing at every antenatal appointment**  \n3. **Referrals for current smokers, ex-smokers, and early quitters**  \n4. **Documentation of smoking status**  \n5. **Interpretation of CO readings**  \n6. **Encouraging partners/household members to quit**  \n7. **Offering NRT for temporary abstinence during hospital stays**  \n\n### **Staff Training & Competencies:**  \n1. **Level 2 training (annual)**  \n2. **Specialist modules (smokefree pregnancy, vaping, smoke-free home)**  \n3. **NCSST competency form (annual completion)**  \n4. **National webinars & knowledge sharing**  \n5. **Behavior change courses / motivational interviewing**  \n\nThese terms encapsulate the essential clinical, procedural, and educational components of the guideline.",
    "CG23001 Support Infant Feeding in CCU.txt": "- Infant feeding\n- Bonding\n- Critical Care Unit (CCU)\n- Postnatal care\n- Mother-baby togetherness\n- Skin-to-skin contact\n- Breastfeeding support\n- SUPC prevention\n- Medication compatibility\n- Infection control\n- Breast pump\n- Sedated patient\n- Collaborative decision\n- Birth partner\n- Maternity staff",
    "MP035 Care of Women in Labour.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and category:\n\n---\n\n### **Protocol & Scope**  \n- **Protocol** (measurable, objective standards)  \n- **Professional judgment**  \n- **Healthy pregnant women/people**  \n- **Term pregnancy (37\u201342 weeks)**  \n- **Labour care settings**  \n\n### **Roles & Responsibilities**  \n- **Midwives & obstetricians** (follow guidance, apply judgment)  \n- **Management** (ensure protocol review, accessibility)  \n\n### **Labour Stages & Definitions**  \n- **1st stage of labour**:  \n  - **Latent phase (early labour)**  \n  - **Established labour**  \n- **2nd stage of labour**:  \n  - **Passive second stage**  \n  - **Active second stage**  \n- **3rd stage of labour** (placenta expulsion)  \n\n### **Key Assessments & Interventions**  \n- **Initial assessment**:  \n  - **BSOTS triage (MP026)**  \n  - **Vaginal examination**  \n  - **Plan of care formulation**  \n- **Pre-labour SROM (Spontaneous Rupture of Membranes)**:  \n  - **Assessment >37 weeks**  \n- **Established labour care**:  \n  - **One-to-one care**  \n  - **Fetal heart monitoring**  \n  - **Partogram use**  \n  - **Observations**:  \n    - **Temperature, pulse, BP**  \n    - **Contractions, bladder care**  \n    - **Liquor assessment**  \n    - **Pain relief options**  \n- **Delay identification**:  \n  - **Cervical dilation**  \n  - **Uterine contractions**  \n  - **Emotional state**  \n\n### **Second Stage Management**  \n- **Full cervical dilatation**  \n- **Maternal positioning**  \n- **Pushing effectiveness**  \n- **Fetal wellbeing monitoring**  \n- **Interventions for delay**:  \n  - **Amniotomy**  \n  - **Bladder emptying**  \n  - **Obstetric referral**  \n\n### **Third Stage & Newborn Care**  \n- **Delayed cord clamping** (iron stores benefit)  \n- **Physiological management** (no routine uterotonics)  \n- **Placenta examination**  \n- **Newborn care**:  \n  - **Apgar score**  \n  - **Skin-to",
    "CG1199 Management of Infectious Diseases.txt": "- Management of Infectious Diseases during Pregnancy\n- sexually transmitted diseases\n- HIV\n- Hepatitis B\n- Hepatitis C\n- Syphilis\n- Genital herpes\n- Chlamydia\n- Gonorrhoea\n- midwives\n- Obstetricians\n- Microbiology staff\n- Sexual Health staff\n- HIV screening\n- multidisciplinary team\n- care plan\n- viral load\n- CS (caesarean section)\n- LSCS (lower segment caesarean section)\n- MTCT (mother-to-child transmission)\n- prenatal diagnosis\n- AZT (zidovudine)\n- antenatal appointment\n- intrapartum care\n- postpartum care\n- infant feeding\n- neonatal care\n- Public Health England\n- liver\n- perinatal transmission\n- antiviral treatment\n- vaccination\n- breastfeeding\n- risk factors\n- IV drug users\n- booking\n- Congenital Syphilis\n- Chlamydia testing\n- Gonorrhoea testing\n- infusion\n- umbilical cord\n- AZT infusion\n- Hep B vaccination\n- Hep B immunoglobulin",
    "MP028 Medical Disorders.txt": "Here are the most clinically significant terms and keywords extracted from the clinical guideline text, organized by topic for clarity:\n\n### **Cardiac Disease in Pregnancy**  \n- Maternal deaths  \n- Acquired heart disease  \n- Physiological changes in pregnancy  \n- Pre-pregnancy assessment  \n- Combined Cardiac Obstetric clinic  \n- Congenital heart disease  \n- Delivery plan by 36 weeks  \n- Labour and delivery considerations  \n- Fluid intake monitoring  \n- Medication adjustments  \n\n### **Seizures & Epilepsy in Pregnancy**  \n- IV benzodiazepines (if seizure >5 min)  \n- IV phenytoin (refractory seizures)  \n- Status epilepticus (life-threatening)  \n- Maternal and fetal monitoring  \n- Post-seizure injury assessment  \n- Transfer to higher care level  \n- Documentation of interventions  \n- Lorazepam/Diazepam (seizures >2 min)  \n- CTG after seizure  \n- **Status Epilepticus Stages:**  \n  - Stage 1: Benzodiazepines  \n  - Stage 2: MET team & emergency AEDs  \n  - Stage 3: Anaesthetist/ITU alert  \n  - Stage 4: ITU transfer  \n\n### **Postnatal Care (Epilepsy)**  \n- Seizure monitoring  \n- Vitamin K for baby  \n- Medication review  \n- Breastfeeding support  \n- Contraception referral  \n\n### **Thyroid Disorders in Pregnancy**  \n#### **Hypothyroidism**  \n- Rapid levothyroxine treatment  \n- Thyroid dysfunction screening  \n#### **Hyperthyroidism**  \n- Medication management  \n- Avoid surgery/radioactive iodine  \n- **Fetal risks:**  \n  - Propylthiouracil (PTU)  \n  - Carbimazole (teratogenicity)  \n- **Complications:**  \n  - Untreated hyperthyroidism risks  \n  - Gestational vs. new-onset hyperthyroidism  \n  - Neonatal thyrotoxicosis (Graves\u2019 disease)  \n  - Post-partum thyroiditis  \n\n### **Inflammatory Bowel Disease (IBD) in Pregnancy**  \n- Pre-pregnancy counseling  \n- Medication safety  \n\n### **Urinary Tract Infections (UTIs) in Pregnancy**  \n- **Treatment:**  \n  - Trimethoprim (avoid 1st trimester)  \n  - Amoxicillin  \n  - Complicated cases \u2192 Microbiologist consult  \n- **Prophylaxis for recurrent UTI:**  \n  - 3+ confirmed UTIs \u2192 Antib",
    "MP072 Newborn Feeding.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and category:\n\n### **General Protocol & Scope**  \n- Protocol  \n- Professional judgement  \n- Brighton & Sussex University Hospitals NHS Trust  \n- Women and Children\u2019s Health  \n- Midwives, Nursery Nurses, Maternity Support Workers, Paediatricians  \n\n### **Breastfeeding & Infant Feeding**  \n- Breastfeeding  \n- Infant formula  \n- Exclusive breastfeeding  \n- Partial breastfeeding  \n- Responsive feeding  \n- Feeding cues  \n- Hand expression  \n- Electric breast pump  \n- Cup feeding  \n- Syringe feeding  \n- Supplementation (medically indicated)  \n- UNICEF UK Baby Friendly Initiative  \n\n### **Clinical Assessments & Monitoring**  \n- Badgernet breastfeeding tool  \n- Wet and dirty nappies  \n- Weight loss (>12%)  \n- Hypoglycemia (jitteriness, lethargy, seizures)  \n- Sodium >150  \n- Reluctant feeding  \n- Neonatal readmission  \n- Tongue tie (frenulotomy)  \n\n### **Feeding Support & Techniques**  \n- Positioning and attachment  \n- Skin-to-skin contact  \n- Non-nutritive sucking  \n- Breast compressions  \n- Expressed breast milk (EBM)  \n- Colostrum  \n- Avoiding dummies/nipple shields  \n- Formula feeding education  \n\n### **High-Risk & Special Cases**  \n- Preterm/ill babies  \n- Birth trauma/sedation  \n- Excessive weight loss management  \n- Bed-sharing guidance  \n- Maternal mental health  \n\n### **Referrals & Emergency Actions**  \n- Refer to Infant Feeding Team  \n- Refer to Neonatal/Paediatric Team  \n- Frenulotomy referral criteria  \n- Post-frenulotomy bleeding management  \n\n### **Documentation & Compliance**  \n- International Code for Breast Milk Substitutes  \n- Training and monitoring compliance  \n- Documentation of feed quality/volumes  \n\nThese terms encapsulate the critical aspects of the guideline, ensuring clarity for healthcare providers in implementing best practices for newborn feeding.",
    "MP010 Anti D Rhesus Negative Women.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and category:  \n\n### **Core Concepts & Key Terms**  \n- **Anti-D immunoglobulin** (critical for prevention)  \n- **Rhesus (Rh) negative** (target population)  \n- **Haemolytic disease of the newborn (HDN)** (condition to prevent)  \n- **Sensitising events** (triggers for anti-D administration)  \n\n### **Timing & Dosage**  \n- **28 weeks gestation** (routine antenatal dose)  \n- **Postnatal administration** (if baby is Rh-positive)  \n- **Dosage variations**:  \n  - **250 IU** (sensitising event <20 weeks)  \n  - **500 IU** (sensitising event >20 weeks, postnatal)  \n  - **1500 IU** (28 weeks, Intraoperative Cell Salvage [ICS])  \n- **Additional anti-D if fetal bleed >4mL** (transfusion consult)  \n\n### **Clinical Events Requiring Anti-D**  \n- **Antenatal sensitising events** (e.g., bleeding, trauma, procedures)  \n- **Delivery** (mandatory if baby Rh-positive)  \n- **Intraoperative Cell Salvage (ICS)** (requires high-dose anti-D)  \n\n### **Testing & Documentation**  \n- **Kleihauer test** (assesses fetomaternal hemorrhage)  \n- **Booking visit** (initial assessment)  \n- **Follow-up procedures** (ensures compliance)  \n\n### **Contraindications & Responsibilities**  \n- **Contraindications for anti-D** (e.g., known hypersensitivity)  \n- **Midwives/obstetricians** (key implementers)  \n- **Management oversight** (ensures protocol accessibility)  \n\nThese terms encapsulate the essential clinical, procedural, and administrative aspects of the guideline.",
    "MP019 Hypertension and Pre-eclampsia in Pregnancy.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by category for clarity:\n\n---\n\n### **1. Conditions & Definitions**  \n- **Hypertension**: Systolic >140 mmHg, Diastolic >90 mmHg (two occasions)  \n- **Pre-existing hypertension**: Present at booking or before 20 weeks  \n- **Gestational hypertension**: New-onset after 20 weeks  \n- **Pre-eclampsia**: BP >140/90 + proteinuria (>20 weeks)  \n- **Eclampsia**: Pre-eclampsia + seizures  \n- **HELLP Syndrome**: Severe pre-eclampsia variant  \n- **Superimposed pre-eclampsia**: New proteinuria/organ dysfunction in pre-existing hypertension  \n\n### **2. Diagnostic Criteria**  \n- **Proteinuria**: Key marker for pre-eclampsia  \n- **Severe features**: BP \u2265160/110, organ dysfunction, seizures  \n- **Fetal growth restriction**: Indication for early birth  \n\n### **3. Management Principles**  \n- **Antiplatelet therapy**: Aspirin (150mg) for high-risk individuals  \n- **Antihypertensives**:  \n  - **First-line**: Labetalol (IV/oral)  \n  - **Second-line**: Nifedipine (oral)  \n  - **Third-line**: Hydralazine (IV)  \n- **Magnesium sulphate**: For eclampsia/severe pre-eclampsia (avoid diazepam/phenytoin)  \n- **Target BP**:  \n  - Chronic hypertension: <140/90 mmHg  \n  - Acute severe hypertension: <135/85 mmHg  \n\n### **4. Timing of Birth**  \n- **Before 37 weeks**: Only if BP \u2265160/110, fetal growth restriction, or other indications  \n- **After 37 weeks**: Shared decision with senior obstetrician  \n\n### **5. Monitoring & Follow-up**  \n- **Antenatal**:  \n  - Fetal ultrasound (growth, Doppler)  \n  - Cardiotocography (if indicated)  \n- **Postnatal**:  \n  - BP monitoring: Daily (first 2 days), then days 3\u20135  \n  - Antihypertensive review: 2 weeks postpartum, 6\u20138 weeks with GP  \n- **Breastfeeding**: Safe antihypertensive options  \n\n### **6. Acute Severe Hypertension Protocol**  \n- **Labetalol IV**:  \n  - **Dosing**: 20mg \u2192 ",
    "NS001 Newborn Hearing Screening Programme.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized for clarity and relevance:\n\n### **Program & Scope**  \n- Newborn Hearing Screening Programme (NHSP)  \n- BSUH (Brighton and Sussex University Hospitals)  \n- RSCH (Royal Sussex County Hospital)  \n- PRH (Princess Royal Hospital)  \n- ESHT (East Sussex Healthcare Trust)  \n\n### **Screening Process**  \n- OAE1 (Otoacoustic Emissions Test 1)  \n- OAE2 (Otoacoustic Emissions Test 2)  \n- AABR (Automated Auditory Brainstem Response)  \n- Bilateral clear responses  \n- Screening before discharge  \n- Minimum 5+ hours between OAE1 and OAE2  \n\n### **Timing & Follow-Up**  \n- Screening completed by **Day 28**  \n- Parent contact for screen **<3 months**  \n- Clinic appointment booked prior to discharge  \n- Targeted follow-up for specific conditions  \n\n### **Referral & Documentation**  \n- Referral to Audiology (Diagnostic Audiology)  \n- Transfer to ESHT NHSP for East Sussex babies  \n- Recording results in **PCHR (Red Book)** or **PCHR insert form**  \n- **Failsafe procedures** for monitoring  \n\n### **Stakeholders & Communication**  \n- Paediatric Audiology  \n- GP (General Practitioner)  \n- HV (Health Visitor)  \n- NHSP Audiology  \n\n### **Key Performance Indicators**  \n- Screening journey up to audiology referral  \n- Excluded babies criteria  \n- Follow-up protocols  \n\nThese terms encapsulate the critical aspects of the newborn hearing screening protocol, ensuring proper clinical understanding and implementation.",
    "CG1126 Multiple Pregnancy and Birth.txt": "- Twin and higher order multiple pregnancies\n- Monochorionic twins\n- Twin-to-twin transfusion syndrome (TTTS)\n- Cord entanglement\n- Diagnosis\n- Antenatal care\n- Planning for birth\n- Monitoring for complications\n- Consultant-led care\n- Birth planning\n- Corticosteroids\n- Fetal growth monitoring\n- Aspirin prophylaxis\n- Postpartum hemorrhage\n- Vaginal birth\n- Caesarean section\n- Continuous CTG monitoring\n- Fetal scalp electrode\n- Bereavement Care Pathway\n- Ultrasound monitoring\n- Preterm labor\n- Mode of birth\n- Placental histology\n- Karyotyping\n- Membrane rupture\n- Presentation\n- Resuscitation\n- Clinical course",
    "MP022 Emergency Maternity Admissions.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by section for clarity:\n\n### **Key Principles & Scope:**  \n- Protocol  \n- Measurable standards  \n- Objective standards  \n- Professional judgement  \n- Pregnant women  \n- People who birth  \n\n### **Responsibilities:**  \n- Midwives  \n- Obstetricians  \n- Management  \n- Protocol review  \n- Trust recommendations  \n- National recommendations  \n\n### **Introduction:**  \n- Pregnant women  \n- Postnatal women  \n- Accident & Emergency (A&E)  \n- Safe and effective care  \n- Medical attention  \n\n### **Women Presenting to A&E:**  \n- High risk grading  \n- Assessment nurse  \n- Acutely ill/collapsed  \n- Early liaison  \n- Emergency services  \n- Maternity services  \n\n### **Women with Obstetric Problems:**  \n- <14 weeks gestation  \n- A&E doctor assessment  \n- Early Pregnancy Unit (EPU)  \n- >24 weeks gestation  \n- Obstetric registrar referral  \n\n### **Women with Postnatal Problems:**  \n- Midwife care  \n- DAU/Triage  \n- GAU (RSCH)  \n- A&E (PRH)  \n\n### **Ectopic Pregnancy:**  \n- Childbearing age  \n- Unexplained abdominal pain  \n- Ectopic pregnancy exclusion  \n\n### **Women with Non-Obstetric Problems:**  \n- Stabilisation (ED team)  \n- Obstetric team involvement  \n\n### **Perimortem Caesarean Section:**  \n- Resuscitation procedure  \n- Cardiac arrest (second half of pregnancy)  \n\n### **Ambulance Service:**  \n- Direct referral to labour ward  \n\n### **Admission to Other Departments:**  \n- Medical conditions  \n- Obstetric team discussion  \n\n### **Monitoring Compliance:**  \n- Auditing  \n- Protocol adherence  \n\n### **Additional Key Questions:**  \n- Labor ward round  \n- Non-Pregnant Female Abdominal Pain Pathway  \n- Known pregnancy status  \n- Non-obstetric problem admission  \n\nThese terms capture the essential clinical and procedural elements necessary for understanding and implementing the guideline.",
    "CG20013 Preterm birth risk pathway.txt": "Keywords and critical terms: preterm birth, pregnant individuals, diagnosis, management, risk factors, Group B Streptococcal colonization, antepartum treatment, urinary tract infection, preterm labor, screening, prevention, high-risk individuals, cervical cerclage, progesterone, pessaries, transvaginal sonography, fetal fibronectin, individualized care, rapid fFN cassette, negative predictive value, management protocols, QUiPP app, emergency cervical cerclage, counseling, corticosteroid prophylaxis, tocolysis, Nifedipine, Magnesium Sulfate, preterm prelabour rupture of membranes, infection identification, admission, monitoring, antenatal corticosteroids, PPROM, fetal monitoring, in utero transfer, obstetric unit, SCBU, singleton pregnancy, Paediatrician, Consultant Obstetrician, Actim PROM test, signs and symptoms of preterm labor, vaginal progesterone, intrauterine transfer, monitoring and observation, Perinatal Management of Extreme Preterm Birth, BAPM Framework for Practice, Suspected Preterm Labour Guidance, CG20013 Preterm Birth Risk Pathway, Antenatal Corticosteroids.",
    "BJOG - 2022 - Stock - Antenatal corticosteroids to reduce neonatal morbidity and mortality.txt": "- Antenatal corticosteroids\n- Preterm birth\n- Neonatal death\n- Respiratory distress syndrome\n- Planned caesarean birth\n- Gestation\n- Twins and triplets\n- Preterm prelabour rupture of membranes\n- Neonatal hypoglycemia\n- Diabetes\n- Fetal growth restriction\n- Antepartum hemorrhage\n- PPROM\n- Dexamethasone phosphate\n- Betamethasone sodium phosphate/acetate\n- Intramuscular administration\n- Cerebroventricular hemorrhage\n- Maternal blood glucose levels\n- Neonatal morbidity\n- Systemic infection\n- Repeat courses\n- Off-target effects\n- Neonatal sepsis\n- Neurocognitive function\n- Low-resource countries\n- Preeclampsia\n- Blood pressure\n- Neurodevelopmental disorders\n- Psychopathology risk\n- Endocrine stress reactivity\n- Functional brain correlates\n- Cognitive monitoring\n- Multifaceted strategy\n- Low-income and middle-income countries",
    "CG15006 Baby Abduction Guidance.txt": "Here are the most clinically significant terms and keywords extracted from the guidance, categorized for clarity:  \n\n### **Core Objectives & Scope**  \n- Baby abduction prevention  \n- Mother-baby togetherness  \n- Suspected/actual abduction response  \n\n### **Staff & Departments Involved**  \n- Maternity staff  \n- Portering staff  \n- Security staff  \n- Switchboard staff  \n- Head of Midwifery/Matron  \n- On-call Midwife Manager  \n- Communications Manager  \n- On-call Hospital Executive  \n- Senior/Lead Midwife  \n\n### **Security Measures**  \n- ID bands (mother & baby)  \n- Staff awareness  \n- CCTV monitoring  \n\n### **Immediate Actions in Abduction**  \n- Raise the alarm  \n- Inform relevant staff  \n- Secure ward entrances  \n\n### **Ongoing Actions**  \n- Support mother  \n- Inform other parents  \n- Cooperate with police  \n\n### **Training & Compliance**  \n- Staff training  \n- Audits  \n- Datix Incident Form  \n\n### **Critical Do\u2019s & Don\u2019ts**  \n- **Do not** remove empty cot  \n- **Do not** touch clothing (preserve evidence)  \n- Direct media to Head of Communications  \n- Inform all when situation normalizes  \n\nThese terms encapsulate the essential clinical, procedural, and security aspects of the guidance.",
    "CG11103 Recovery Post Regional and GA Anaesthesia.txt": "- Recovery following Regional and General Anaesthesia\n- Anaesthetic\n- Caesarean section\n- Obstetric procedures\n- Midwives\n- Obstetricians\n- Anaesthetists\n- Maternity recovery staff\n- Operating department practitioners\n- Maternity assistants\n- Blood pressure monitor\n- Oxygen saturation monitor\n- Thermometer\n- Oxygen\n- Breathing system\n- Suction equipment\n- Infusion devices\n- Vital signs\n- General anaesthesia\n- Regional anaesthesia\n- Intravenous cannulas\n- Medications\n- Discharge criteria\n- Postnatal ward\n- Pressure area care\n- Postnatal care\n- Breastfeeding\n- Complications of anesthesia\n- Obstetric anaesthetist\n- Training\n- Audit/monitoring\n- MEOWS chart documentation",
    "MP042 Epidurals in Labour.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by section for clarity:\n\n### **Key Principles & Scope**  \n- Protocol  \n- Professional judgment  \n- Epidurals in labour  \n- Complications from epidurals  \n\n### **Responsibilities**  \n- Midwives  \n- Anaesthetists  \n- Obstetricians  \n- Management  \n\n### **Indications for Epidural Analgesia**  \n- Maternal/parental request  \n- Obstetric/fetal indications  \n- Regional analgesic block  \n- Medical indications (reduced stress)  \n\n### **Contraindications**  \n- Local/systemic sepsis  \n- Clotting disturbances  \n- Hypovolemia  \n- Allergy to amide local anaesthetics  \n\n### **Midwife & Anaesthetist Responsibilities**  \n- Unbiased information  \n- Platelet count check  \n- Correct equipment  \n- Consent  \n- Epidural procedure  \n- Drug prescription  \n\n### **Equipment**  \n- IV access  \n- Dedicated epidural pump  \n- Oxygen  \n- Resuscitation trolley  \n\n### **Eating & Drinking**  \n- Clear fluids  \n- Light carbohydrate foods  \n- Restrictions (in some cases)  \n\n### **Ongoing Management**  \n- PCEA (Patient-Controlled Epidural Analgesia)  \n- Self-administration  \n- Bolus top-up  \n\n### **Monitoring**  \n- Maternal/parental: Pulse, BP, block distribution, motor function  \n- Fetal: Continuous heart monitoring, contraction palpation  \n- Urinary retention \u2192 catheterisation  \n\n### **Complications & Emergency Management**  \n- Hypotension  \n- Bradycardia  \n- Local anaesthetic toxicity (metallic taste, confusion, respiratory paralysis)  \n- Accidental dural puncture  \n- Intrathecal catheter  \n- Neurological injury  \n- High block (stop epidural, urgent review)  \n- Emergency resuscitation (oxygen, IV fluids, stop infusion)  \n\n### **Post-Procedure & Follow-Up**  \n- Post-dural puncture headache (blood patch)  \n- Post-partum headache (fatigue, dehydration, dural puncture)  \n- GP communication (suspected dural puncture)  \n- Post-natal review (procedure details, blood patch date)  \n- Discharge summary (obstetricians)  \n\nThese terms encapsulate the critical clinical, procedural, and safety aspects of the guideline.",
    "CG1111 Screening for Downs Edwards and Pataus  Syndrome.txt": "- Screening\n- Down's Syndrome\n- Edward's Syndrome\n- Patau's Syndrome\n- Evidence-based\n- Antenatal screening\n- Obstetric consultants\n- Midwifery staff\n- Patient care\n- Screening tests\n- Management\n- Consent\n- Guidelines\n- Abbreviations\n- Informed decision-making\n- Timely results\n- NIPT screening\n- T21\n- T18\n- T13\n- Combined test\n- Quadruple test\n- Prenatal diagnosis\n- Higher chance result\n- Lower chance result\n- Testing timeline\n- IVF\n- Donor egg pregnancies\n- Referral\n- Follow-up procedures\n- Education and training\n- Monitoring\n- Audit process",
    "BHIVA - 2020 - HIV Guideline.txt": "Clinical significant terms and keywords:\n- Antiretroviral therapy\n- Vertical transmission\n- Mode of delivery\n- Psychosocial care\n- Multidisciplinary team\n- Peer support\n- Antenatal and postnatal depression\n- Sexual health screening\n- HIV resistance testing\n- CD4 cell counts\n- HIV viral load tests\n- Nucleoside backbone\n- Integrase inhibitor-based regimen\n- Preterm SROM\n- Zidovudine infusion\n- Pediatric care\n- Infant PEP\n- Co-trimoxazole prophylaxis\n- Immunizations\n- Formula feeding\n- Lactation suppression\n- Breastfeeding\n- Molecular diagnostics\n- Cervical cytology\n- Contraception\n- HBV co-infection\n- HCV co-infection\n- Liver function tests\n- Ribavirin\n- DAAs\n- Thyroid function testing\n- Vertical transmission rates\n- Neonatal PEP\n- Combination PEP\n- Intravenous ART\n- Breastfeeding advice\n- HEU children\n- Postpartum care\n- Mental health assessment\n- Contraceptive needs\n- Cytology\n- Retention in HIV care\n- Postpartum depression\n- PCP prophylaxis",
    "BJOG - 2021 - Navaratnam - Amniocentesis and chorionic villus sampling.txt": "- Amniocentesis\n- Chorionic villus sampling\n- Miscarriage\n- Gestation\n- Multiple pregnancies\n- Blood-borne viruses\n- Infection\n- Fetal injury\n- Maternal Fetal Medicine\n- Advanced Skills Training\n- Severe maternal sepsis\n- Technical challenges\n- Counseling\n- Pregnancy mapping\n- Third-trimester\n- Antiretroviral treatment\n- Mother to child transmission\n- Hepatitis B\n- Hepatitis C\n- HIV\n- HBV DNA\n- Viral load\n- Vertical transmission\n- HCV RNA",
    "CG17004 Newborn Hearing Screening Programme SOP.txt": "- Newborn Hearing Screening\n- Standard Operating Procedure\n- NHS Newborn Hearing Screening Programme\n- Eligible population\n- National screening pathways\n- Well babies\n- NICU babies\n- Referrals\n- Governance structure\n- Training\n- Equipment\n- Quality assurance tests\n- Permanent hearing loss\n- Otoacoustic emission (AOAE)\n- Automated auditory brainstem response (AABR)\n- Consent\n- Audiology\n- Twins/Multiple births\n- KPI reports\n- Incidents reporting\n- Training assessment\n- Equipment maintenance\n- QA checks\n- Rescreening\n- Foster care\n- Child death notifications\n- Decline/Withdrew from Screen\n- Bloodspot/NIPE/NHSP List Failsafe\n- NICU Failsafes\n- High risk of hearing loss\n- Abbreviations",
    "UHSx Protocol for NRT.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance:  \n\n### **Key Entities and Roles:**  \n- **Nicotine Replacement Therapies (NRT)**  \n- **Registered midwives**  \n- **Tobacco dependency advisors**  \n- **University Hospitals Sussex Foundation Trust**  \n\n### **Patient Eligibility:**  \n- **Pregnant patients**  \n- **Over 12 years old**  \n- **Smokers seeking to quit**  \n- **Receiving stop smoking support**  \n\n### **Regulatory & Legal Aspects:**  \n- **General Sales List (GSL) medicines**  \n- **No Patient Group Direction (PGD) or Patient Specific Direction (PSD) required**  \n- **Yearly authorization renewal**  \n\n### **Clinical & Operational Requirements:**  \n- **NCSCT Level 2 training (staff competency)**  \n- **Safe storage and handling of NRT**  \n- **Record-keeping (supply details, patient information)**  \n\n### **NRT Supply Details:**  \n- **Various forms of NRT (e.g., patches, gum, lozenges)**  \n- **Dosage and quantity instructions**  \n- **Exclusions apply (implied but not specified in text)**  \n\nThese terms encapsulate the core clinical, regulatory, and procedural aspects of the guideline.",
    "MP039 Waterbirth.txt": "Here are the most clinically significant terms and keywords extracted from the **Waterbirth Protocol: MP039** that are critical for understanding the guidance:\n\n### **General Protocol Terms:**  \n- Protocol  \n- Objective standards  \n- Professional judgement  \n- Scope  \n- Responsibilities  \n\n### **Patient Eligibility & Risk Assessment:**  \n- Low-risk women  \n- Established labour  \n- Inclusion criteria  \n- Exclusion criteria (multiple births, abnormal CTG/Doppler, breech presentation)  \n- 37 completed weeks gestation  \n- Individual risk assessment  \n\n### **Clinical Management & Procedures:**  \n- Analgesic properties of water  \n- Birth plan  \n- Water temperature (\u226437\u00b0C)  \n- Maternal preference  \n- Movement & positioning in labour  \n- Third stage (physiological vs. actively managed)  \n- Cord cutting  \n- Skin-to-skin contact  \n- Monitoring bleeding (PPH \u2013 postpartum haemorrhage)  \n\n### **Emergency Situations:**  \n- Emergency evacuation  \n- Shoulder dystocia  \n- Maternal collapse  \n- Excessive bleeding (PPH)  \n- Emergency bell  \n- Evacuation net  \n- Hover mattress  \n\n### **Equipment & Hygiene Standards:**  \n- British Standards (pool compliance)  \n- Water thermometer  \n- Delivery pack  \n- Pool cleaning (before each use, every 24 hours)  \n\n### **Documentation & Compliance:**  \n- Documentation of care plan  \n- Datix (incident reporting)  \n- Trust & National recommendations  \n\nThese terms encapsulate the **key clinical, safety, and procedural aspects** of the waterbirth protocol, ensuring safe and effective implementation.",
    "Proforma Shoulder Dystocia UHSx.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, categorized for clarity:  \n\n### **Delivery Assistance Procedures & Maneuvers:**  \n- **McRoberts' maneuver**  \n- **Suprapubic pressure**  \n- **Episiotomy**  \n- **Internal maneuvers**  \n- **Delivery of posterior arm**  \n- **Move baby's shoulders into oblique position**  \n\n### **Escalation & Decision-Making:**  \n- **Inform Consultant Obstetrician & Anaesthetist**  \n- **Alternative maneuvers if shoulders still impacted**  \n\n### **Delivery Documentation & Outcomes:**  \n- **OASI care bundle (Yes/No)**  \n- **Mode of delivery of head (Spontaneous, Ventouse, Forceps)**  \n- **Fetal position during dystocia**  \n- **Birth weight**  \n- **Apgar scores**  \n- **Cord gases**  \n\n### **Post-Delivery Care & Communication:**  \n- **Explanation to parents**  \n- **Baby assessment by pediatrician**  \n- **Baby admitted to NNU (Neonatal Unit)**  \n- **Staff attendance at birth**  \n\nThese terms are critical for understanding the clinical guidance on managing shoulder dystocia and ensuring proper documentation, escalation, and neonatal care.",
    "MP077 Cervical Cerclage (Cervical Sutre).txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance:\n\n### **Key Concepts & Procedures**  \n- **Cervical Cerclage (Cervical Suture)**  \n- **Mid-trimester loss prevention**  \n- **Premature labor prevention**  \n\n### **Types of Cerclage**  \n- **History-indicated cerclage**  \n- **USS (ultrasound)-indicated cerclage**  \n- **Rescue cerclage (salvage method)**  \n\n### **Indications & Contraindications**  \n- **High-risk women**  \n- **Funneling cervix**  \n- **Short cervix \u226425mm**  \n- **Exposed fetal membranes**  \n- **No evidence for multiple pregnancies**  \n- **No evidence for uterine abnormalities**  \n- **Previous radical trachelectomy (individualized decision)**  \n- **Contraindications: Infection, active bleeding, uterine contractions**  \n\n### **Timing & Gestational Age**  \n- **16+0 to 27+6 weeks (rescue cerclage window)**  \n- **Immediate vs. delayed (>48h) insertion (better long-term outcomes if delayed)**  \n- **Prolongs pregnancy by 4-5 weeks**  \n- **Most deliveries around 24 weeks**  \n\n### **Clinical Management**  \n- **Referral to antenatal clinic (assessment & counseling)**  \n- **Pre-operative management**  \n- **Operative considerations**  \n- **Post-suture care**  \n- **Suture removal**  \n- **PPROM (Preterm Premature Rupture of Membranes) management**  \n\n### **Documentation & Consent**  \n- **Informed consent procedures**  \n- **Protocol documentation**  \n\nThese terms encapsulate the critical aspects of the guideline for clinical decision-making and patient management.",
    "BJOG - 2016 - Diagnosis and Management of Ectopic Pregnancy.txt": "Keywords and clinically significant terms extracted from the text:\n\n1. Ectopic pregnancy\n2. Transvaginal ultrasound\n3. Tubal ectopic pregnancy\n4. Serum beta-human chorionic gonadotrophin (b-hCG)\n5. Caesarean scar pregnancy\n6. Diagnostic criteria\n7. Surgical management\n8. Pharmacological management\n9. Conservative treatment\n10. Anti-D immunoglobulin\n11. Long-term fertility prospects\n12. Support and counseling\n13. Training\n14. Methotrexate\n15. Ultrasound-guided needle techniques\n16. RhD-negative women\n17. Laparoscopic removal\n18. Ovarian pregnancy\n19. Heterotopic pregnancy\n20. Expectant management\n21. Success rates\n22. Management options\n23. Transvaginal ultrasound-guided aspiration\n24. Endoscopic approaches\n25. Hysteroscopic resection\n26. Selective UAE\n27. Laparotomy\n28. Follow-up\n29. Methotrexate exposure\n30. Early pregnancy assessment\n31. Cesarean section scar pregnancy\n32. Uterine-preserving emergency surgery\n33. Arterial embolization\n34. Expectant management\n35. Rh immune globulin\n36. Laparoscopic surgery\n37. Outcome measures\n38. Patient satisfaction\n39. Grieving after pregnancy loss\n40. Progressive muscle relaxation training",
    "UHSussex - MP076 - Maternal death.txt": "- Maternal death\n- Protocol\n- Professional judgment\n- Responsibilities\n- Checklist\n- Immediate management\n- Reporting\n- Documentation\n- Clinical trials\n- Referral\n- Medical Examiner\n- Coroner\n- Death certificate\n- Religious/cultural considerations\n- Information to relatives\n- Debriefing\n- Registration information\n- Certifying a death\n- Burial for cultural reasons\n- Referral to Coroner\n- Recognition of reportable deaths\n- Registration of deaths\n- Care after death",
    "Uptodate - 2025 - Prelabor rupture of membranes at term.txt": "- Prelabor rupture of membranes (PROM)\n- Term\n- Regular contractions\n- Inducing labor\n- Oxytocin\n- Maternal infection\n- Newborn infection\n- Vaginal birth\n- Expectant management\n- Hospitalization\n- Antibiotic prophylaxis\n- Group B streptococcus\n- Neonatal infection\n- Positive GBS culture\n- Fetal well-being\n- Signs of infection\n- Monitoring\n- Complications\n- Negative GBS culture\n- Standard risk assessment\n- Fetal monitoring\n- UpToDate\n- Terms of Use",
    "GTG 2010 - Malaria in Pregnancy - Prevention.txt": "- Malaria\n- Pregnancy\n- Prevention\n- Pregnant women\n- Chemoprophylaxis\n- Anopheles mosquito\n- Complications\n- Chloroquine-resistant areas\n- Atovaquone-proguanil\n- Proguanil\n- Mefloquine\n- Doxycycline\n- Primaquine\n- Quinine\n- Clindamycin\n- Standby treatment\n- Emergency treatment\n- Specialist advice\n- Antimalarial drugs\n- Insecticide-treated bednets\n- Sulfadoxine-pyrimethamine\n- Anemia\n- Mosquito bites\n- Herbal remedies\n- Fake artesunate\n- Teratogenic agents\n- Congenital malformations\n- Antifertility effects\n- Plasmodium falciparum\n- Pharmacokinetics\n- Pharmacodynamics\n- Premature infants\n- Tetracycline\n- Breastfeeding\n- Clinical guidelines",
    "UHSussex - Nausea and Vomiting in Pregnancy + Hyperemesis Gravidarum - 2025.txt": "- Nausea and vomiting of pregnancy (NVP)\n- Hyperemesis gravidarum (HG)\n- Antiemetic medications\n- Pyridoxine hydrochloride/doxylamine succinate\n- Cyclizine\n- Thiamine\n- PUQE scoring system\n- Renal function\n- Mental health\n- LMWH (Low Molecular Weight Heparin)\n- Corticosteroids\n- Nutrition\n- Hydration\n- Referral for specialist support\n- Termination of pregnancy\n- Counseling\n- Support groups\n- Future pregnancies\n- Specialist centers\n- RCOG pregnancy sickness patient information leaflet\n- Pregnancy Sickness Support organization\n- UK Teratology Information Service\n- Specialist Pharmacy Service\n- HER Foundation\n- IV thiamine\n- Local policy",
    "ESHRE PIL - Endometriosis.txt": "- Endometriosis\n- Pelvic pain\n- Reduced quality of life\n- Infertility\n- Clinical examination\n- Laparoscopy\n- Medication\n- Hormonal therapy\n- Surgery\n- Fertility\n- Assisted reproduction\n- Doctor\n- Unprotected sexual intercourse\n- IUI\n- ICSI\n- Lesions\n- Menstruation\n- Menorrhagia\n- Natural cycle IVF\n- Ovary\n- Progesterone\n- Ultrasound\n- Symptoms\n- Diagnosis\n- Hormonal treatment\n- Alternative treatment\n- Surgical treatment\n- Ovarian cysts\n- Extragenital endometriosis\n- Menopause\n- Cancer\n- Reimbursement\n- Endometriosis organizations\n- Medical advice",
    "UHSx Perineal Trauma & Repair Guideline.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance:\n\n### **Core Concepts & Interventions**  \n- **OASI care bundle** (Obstetric Anal Sphincter Injury)  \n- **Perineal warming**  \n- **Perineal trauma recognition/classification/repair**  \n- **Wound infection/dehiscence**  \n- **Episiotomy** (mediolateral, 60-degree angle at crowning)  \n- **Manual perineal protection** (bimanual technique)  \n- **Perineal examination** (including rectal exam)  \n- **RCOG guidelines** (for tear classification)  \n\n### **Risk Factors for OASI**  \n- Asian ethnicity  \n- Nulliparity  \n- Birth weight >4kg  \n- Shoulder dystocia  \n- Prolonged second stage of labor  \n\n### **Repair Principles**  \n- **Suture material/technique**  \n- **Analgesia** (regional/general anesthesia for 3rd/4th-degree tears)  \n- **Aftercare** (high-fiber diet, pelvic floor exercises)  \n- **Referral pathways** (obstetric consultant involvement)  \n- **Theatre repair** (for 3rd/4th-degree tears)  \n- **Knot burial** (beneath superficial muscles)  \n- **Rectal/vaginal post-repair exam** (integrity check)  \n\n### **Emergency & Post-Repair Management**  \n- **Immediate suturing** (active bleeding in water births)  \n- **Antibiotics** (prophylactic administration)  \n- **Laxatives** (post-repair)  \n- **Incident reporting** (BadgerNet Maternity documentation)  \n\n### **Documentation & Governance**  \n- **OASI proforma**  \n- **Record keeping** (consent, repair details)  \n- **Audit/monitoring** (OASI recognition/follow-up)  \n\n### **Excluded Terms**  \n- Administrative details (e.g., \"Due for review: March 2027,\" \"SharePoint access\")  \n- Equality assessment (FREDA principles)  \n- Non-clinical appendices (dissemination plans, references to unrelated ophthalmology studies).  \n\nThese terms encapsulate the critical clinical actions, risk factors, and procedural details necessary for adherence to the guideline.",
    "BJOG - 2017 -  External Cephalic Version and Reducing the Incidence of Term Breech Presentation.txt": "- External Cephalic Version (ECV)\n- Breech baby\n- Head-down position\n- Caesarean section\n- Tocolysis\n- Betamimetics\n- Regional analgesia\n- Nulliparous women\n- Spontaneous version\n- Intrapartum\n- Complication rate\n- Trained practitioners\n- Painful procedure\n- Postural management\n- Antenatal detection\n- Success rates\n- Complications\n- Mode of delivery\n- Timing of delivery\n- Contraindications\n- Tocolysis\n- Fetomaternal hemorrhage\n- Patient satisfaction\n- Maternal experience of pain\n- Adverse perinatal outcome\n- Factors associated with adverse outcome",
    "MP027 Female Genital Mutilation (FGM).txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by section for clarity:\n\n### **General Terms**  \n- Female Genital Mutilation (FGM)  \n- Maternity protocol (MP027)  \n- Public health issue  \n- Human rights issue  \n- Safeguarding children  \n\n### **Key Principles & Scope**  \n- Protocol (measurable, objective standards)  \n- Professional judgement  \n- Women/persons with FGM  \n- BSUH FGM policy  \n\n### **Responsibilities**  \n- Midwives & Obstetricians (access, read, follow guidance)  \n- Management (review protocol, ensure accessibility)  \n\n### **Types of FGM**  \n- WHO classification (4 types)  \n\n### **Antenatal Care**  \n- Early recognition of FGM risk  \n- Documentation of FGM status  \n- Mandatory reporting (under 18s)  \n\n### **Antenatal Defibulation**  \n- Early in pregnancy  \n- Advantages & indications  \n\n### **Intrapartum Care**  \n- Privacy & dignity  \n- Hospital birth (recommended)  \n- Home birth (consider if defibulated, low risk)  \n- Unplanned homebirths (midwife care)  \n- Female birth attendants  \n- Individualized birth plan  \n- On-call registrar notification  \n- Full care plan (documented)  \n- Informed consent  \n- Epidural (discussed for defibulation)  \n- Early defibulation (under epidural)  \n- Aseptic technique  \n- Suturing (trained clinician)  \n\n### **Postnatal Care**  \n- Perineum check  \n- Mobilization encouragement  \n- Female infants (at risk, safeguarding)  \n- Discharge summary (include FGM status)  \n- Documentation (discussions, referrals)  \n- Targeted & individualized community visits  \n- Health visitor awareness  \n- Mandatory forms  \n\nThese terms capture the essential clinical, legal, and procedural aspects of the guideline. Let me know if you'd like further refinement.",
    "MP026 BSOTS.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance:\n\n### **Core Protocol Terms**  \n- **Maternity Triage**  \n- **Non-elective admissions**  \n- **Obstetric assessments**  \n- **BSOTS (Birmingham Symptom-specific Obstetric Triage System)**  \n- **Triage Assessment Card**  \n- **MEOWS (Modified Early Obstetric Warning Score)**  \n- **CTG (Cardiotocography)**  \n\n### **Clinical Priorities & Timeframes**  \n- **Initial assessment (15-30 minutes)**  \n- **Urgent obstetric assessment**  \n- **Timely treatment**  \n- **Escalation for delays/breaches**  \n- **Handover & communication**  \n\n### **Patient Assessment Criteria**  \n- **Gestation, gravida, parity**  \n- **Presenting problem/reason for admission**  \n- **Obstetric risk factors**  \n- **Medical history (MH), current problems (CP)**  \n- **Blood/urine results**  \n- **Holistic assessment**  \n\n### **Roles & Responsibilities**  \n- **Midwives (initial triage, MEOWS, CTG)**  \n- **Obstetricians (clinical judgment, escalation)**  \n- **MCA (Maternity Care Assistant) support**  \n- **Translation services (non-English speakers)**  \n\n### **Disposition & Follow-up**  \n- **Admission/Labour Ward/Antenatal Ward transfer**  \n- **Discharge with follow-up**  \n- **Results diary (pending tests actioned)**  \n\n### **Key Guidelines & Systems**  \n- **UH Sussex Maternity Guidelines**  \n- **Standardized care**  \n- **Exclusion criteria (non-obstetric problems)**  \n\nThese terms encapsulate the critical elements for understanding and implementing the triage protocol effectively.",
    "CG20005 Second Trimester Anomaly Screening 18+0 - 20+6 weeks.txt": "- Sonographers\n- Anomaly scan\n- NHS Fetal Anomaly Screening Programme\n- SBLCB v3.1\n- Conditions (Anencephaly, Open spina bifida, Cleft lip, Diaphragmatic hernia, Gastroschisis, Exomphalos, Serious cardiac anomalies, Bilateral renal agenesis, Lethal skeletal dysplasia, Edwards\u2019 syndrome (Trisomy 18), Patau\u2019s syndrome (Trisomy 13))\n- Anatomy examination (Head and neck, Face, Chest, Abdomen, Kidneys, Thorax, Spine, Limbs, Genitalia, Uterine cavity)\n- Fibroids\n- FASP\n- Uterine artery Dopplers\n- Suspected fetal abnormalities\n- Normal variants\n- Fetal growth restriction\n- Placenta assessment (Placental lakes, Placenta praevia, Placenta accreta)\n- Vasa Praevia\n- Placental masses\n- Succenturiate or bi-lobar placentas\n- Neonatal care\n- Fetal Echogenic Bowel\n- Maternity Information System\n- Imaging pathways\n- Clinical protocol review\n- Consultation groups/committees (Trust Wide Governance Group, Medicines Governance Committee, Antimicrobial Stewardship Group, Resuscitation Committee, etc.)",
    "BJOG - 2024 - De\u00c2\u00a0Silva - Outpatient Hysteroscopy.txt": "- outpatient hysteroscopy\n- abnormal uterine bleeding\n- reproductive problems\n- intrauterine devices\n- hysteroscopy service\n- written information\n- benefits and risks\n- pre-operative analgesia\n- anaesthesia\n- vaginoscopy\n- mechanical hysteroscopic tissue removal systems\n- saline\n- conscious sedation\n- informed consent\n- pain and distress\n- safety checklist\n- training\n- NSAIDs\n- TENS\n- opioids\n- antispasmodics\n- cervical preparation\n- hysteroscope size\n- adverse events\n- image quality\n- vasovagal reactions\n- flexible hysteroscopes\n- cervical dilatation\n- local anaesthesia\n- sedation levels\n- antibiotic prophylaxis\n- documentation\n- pain relief\n- feasibility\n- patient experience\n- quality assurance\n- complications\n- uterine perforation\n- medication efficacy\n- hysteroscope type\n- warm saline distension media\n- topical anesthesia\n- paracervical blocks\n- antibiotic use\n- systemic infection\n- polyp treatment\n- endometrial ablation\n- gynecology care",
    "RCOG - 2025 - GTG 76 -Management of Thyroid Disorders in Pregnancy.txt": "- Thyroid Disorders\n- Pregnancy\n- Serum Thyroid Stimulating Hormone (TSH)\n- Free Thyroxine (fT4)\n- Iodine Supplementation\n- Hypothyroidism\n- Levothyroxine\n- TPO Antibodies\n- Fertility\n- Recurrent Miscarriage\n- Multidisciplinary Clinics\n- Thyroid Function Tests\n- Subclinical Hypothyroidism\n- TRAb\n- Hyperthyroidism\n- Antithyroid Drugs\n- Postpartum Thyroiditis\n- Iodine Deficiency\n- Neurodevelopment\n- Fetal Brain Development\n- Thyroid Hormone Action\n- Placenta\n- Thyroid Cancer\n- Thyroid Nodules\n- Pregnancy Outcome\n- Gestational Hypertension\n- Pre-eclampsia\n- Preterm Birth\n- Thyroid Autoimmunity\n- Neonatal Thyroxine\n- Postpartum Depression\n- Selenium Supplementation",
    "MP056 Obstetric High Dependency Care.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance:  \n\n### **Clinical Terms & Keywords:**  \n1. **Obstetric High Dependency Care (HDU)**  \n2. **Intensive Care (ITU)**  \n3. **Life-threatening conditions in pregnancy**  \n4. **Categories of HDU Care (Levels 0-3)**  \n5. **Maternity High Dependency Care**  \n6. **One-to-one nursing**  \n7. **Care documentation**  \n8. **Regular reviews (obstetric & anaesthetic teams)**  \n9. **Critical Care Outreach team**  \n10. **Transfer to HDU/ITU**  \n11. **Discharge from HDU/ITU**  \n12. **Admission to ITU/specialist area**  \n\n### **Key Roles & Responsibilities:**  \n13. **Midwives**  \n14. **Obstetricians**  \n15. **Anaesthetists**  \n16. **HDU/ITU clinicians**  \n17. **Porters & ward clerks**  \n\n### **Clinical & Operational Considerations:**  \n18. **Monitoring and Auditing compliance**  \n19. **Equipment and Resources (HDU bed space)**  \n20. **Criteria for transfer to HDU/ITU**  \n21. **Professional judgement in protocol application**  \n22. **Involvement of specialist clinicians**  \n\nThese terms encapsulate the essential clinical, operational, and decision-making aspects of the guideline.",
    "CG16016 Management of pregnancies with previous Bariatric Surgery.txt": "- Management of pregnant women/people\n- Previous bariatric surgery\n- Complications\n- Optimal care\n- Referral\n- Antenatal care\n- Anaesthetic clinics\n- Supplementation\n- Screening\n- Nutritional deficiencies\n- Stable weight\n- Pregnancy specific multivitamin\n- Retinol form of Vitamin A\n- Teratogenicity risk\n- Multivitamin preparations\n- Calcium/vitamin D/iron/B12 supplements\n- Folate 5mg daily\n- Ultrasound surveillance\n- Gestational weight gain guidelines\n- Referral for anaesthetic assessment\n- Gestational diabetes screening\n- Internal hernia risk\n- Hyperemesis/vomiting considerations\n- Labor, birth, and postnatal care\n- Audit points\n- Supplements\n- Blood tests\n- Growth scans\n- Screening for diabetes",
    "CG1114 Breech guideline.txt": "- Breech management\n- External cephalic version (ECV)\n- Vaginal breech birth\n- Obstetricians\n- Midwives\n- Ultrasonographers\n- Breech presentation\n- ECV procedure\n- Contraindications to ECV\n- Risks of ECV\n- Labor ward\n- Kleihauer test\n- Anti D 1500 units\n- Rhesus negative\n- Fetal back\n- Cephalic presentation\n- Vaginal breech birth\n- Induction and augmentation\n- Fetal heart rate\n- Cord prolapse\n- Medical complications\n- Obstetric complications",
    "GTG 2015 - Chickenpox in Pregnancy.txt": "- Chickenpox\n- Pregnancy\n- Varicella\n- VZV (varicella-zoster virus)\n- VZIG (varicella-zoster immunoglobulin)\n- Aciclovir\n- Fetal varicella syndrome (FVS)\n- Neonatal risks\n- Delivery timing\n- Amniocentesis\n- PCR for VZV DNA\n- Ultrasound abnormalities\n- Breastfeeding\n- Referrals\n- Neonatologists\n- Prophylaxis\n- Screening\n- Treatment\n- Specialist care\n- Hygiene\n- Hospital referral\n- Immunity\n- Prevention strategies\n- Contact with chickenpox\n- Susceptibility\n- Serology\n- Isolation\n- Individualized care\n- Cost-effective\n- Awareness\n- Infectiousness\n- Rash development\n- Risk assessment\n- Follow-up\n- Management\n- Prevention\n- Guidelines\n- Vaccination\n- Blood test\n- Contact tracing\n- Exposure\n- Symptoms\n- Diagnosis\n- Monitoring\n- Support groups\n- Research recommendations\n- Randomized trials\n- Auditable topics\n- Useful links\n- Postpartum immunization\n- Amniotic fluid\n- Sensitivity\n- Specificity\n- Complications\n- Symptomatic treatment\n- Hygiene advice\n- Intravenous aciclovir\n- Severe infection\n- Referral to fetal medicine specialist\n- Potential infectiousness\n- Continuous exposure\n- Antenatal care\n- Reassurance\n- Normal care\n- Tropical/subtropical country\n- Uncertain history\n- Booking sample\n- High risk\n- Complicated chickenpox\n- Potentially susceptible individuals\n- Symptomatic treatment\n- Hygiene advice\n- Delivery delay\n- Prescribed medication\n- Monitoring period\n- Severe cases\n- Infection risks\n- Prevention strategies\n- Management strategies\n- Newborn risks\n- Maternal infection\n- Birth outcomes\n- Delayed delivery\n- Postpartum immunization\n- Referral criteria\n- Information dissemination\n- Clarification of contact significance\n- Initial contact with GP\n- Blood test for VZV IgG\n- No action needed\n- Severe infection management\n- Fetal monitoring\n- Amniocentesis considerations\n- Avoidance of susceptible individuals\n- Prescribed medication\n- Infection timing\n- Abbreviations: FVS, GP, Ig",
    "GAU Proforma JULY 19.txt": "- Acute Gynaecological Proforma\n- Presenting complaint\n- Gynaecological & Obstetric history\n- Menstrual cycle\n- Nature of bleeding\n- Intermenstrual bleeding\n- Last cervical smear\n- Current contraception\n- Deep dyspareunia\n- Previous gynaecological procedures\n- Previous deliveries\n- Early pregnancy losses\n- Medical history\n- Surgical history\n- Sexual history\n- Pregnancy details\n- Pregnancy test\n- Estimated gestation\n- Pregnancy related bleeding & pain\n- Clinical examination\n- General examination\n- Ultrasound findings\n- Ectopic risk factors\n- Investigations requested\n- Investigation results\n- Antibiotic treatment prescribed\n- IV to Oral Switch\n- Nursing review\n- Drug/Fluid prescription & administration",
    "CG1192 Large for Gestational Age.txt": "- Large for Gestational Age\n- Evidence-based guidelines\n- Managing\n- Suspected LGA fetus\n- Medical\n- Midwifery staff\n- Risks\n- Fetal macrosomia\n- Causes\n- Antenatal management\n- Monitoring\n- Fundal height\n- Ultrasound\n- Induction of labor\n- Risks\n- Caesarean birth\n- Informed discussion\n- Expectant management\n- Shoulder dystocia\n- Perineal tears\n- Perinatal death\n- Brachial plexus injuries\n- Emergency caesarean birth\n- Birth experience\n- Decision-making\n- Respect their decision",
    "MD090 Disengaging a Deeply Impacted head at LSCS and use of Fetal Pillow.txt": "- Lower segment Caesarean section (LSCS)\n- \u226537 weeks gestation\n- Cephalic presentation\n- Deeply impacted fetal head\n- Fetal Pillow\n- Second stage LSCS\n- Maternal and neonatal risks\n- Reverse breech extraction\n- First stage LSCS\n- Push technique\n- Decision flowchart\n- Appendix A: How to insert a Fetal Pillow\n- Appendix B: Fetal Pillow Audit Proforma\n- Disposable soft silicone balloon\n- Studies suggest elevation of head by 2-4cm\n- Indications for fetal pillow use\n- Operator training\n- VE findings prior to pillow use\n- Abdominal findings prior to pillow use\n- Difficulties inserting the pillow\n- Grade of doctor delivering\n- Perceived difficulty of delivering head at LSCS\n- Mode of delivery at LSCS\n- Apgar score of baby at delivery\n- Injuries to baby at delivery\n- Cord gases\n- SCBU admission\n- Uterine incision extensions\n- Estimated blood loss (EBL) for procedure\n- Bladder injury\n- ICU/HDU admission of patient",
    "MP020 Multiple Pregnancy and Birth.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and category:  \n\n### **General Key Terms**  \n- **Multiple pregnancy** (twins, triplets, higher-order pregnancies)  \n- **Chorionicity** (DCDA, MCDA, MCMA twins)  \n- **Amnionicity**  \n- **Perinatal morbidity and mortality**  \n- **Maternal risks**  \n- **Monochorionic pregnancies**  \n- **Consultant-led care**  \n- **Fetal medicine team**  \n\n### **Diagnostic & Monitoring Terms**  \n- **Ultrasound examinations** (dating scan, anomaly scan, growth scans)  \n- **Fetal assessment scans**  \n- **Chorionicity determination**  \n- **Continuous cardiotocography (CTG)**  \n- **Fetal scalp electrode**  \n- **Portable ultrasound scan (intrapartum)**  \n\n### **Management & Interventions**  \n- **Active management of third stage (AMTS)** (oxytocin 10 IU IM)  \n- **Physiological management (not recommended in twins/triplets)**  \n- **Additional uterotonics (if PPH risk factors)**  \n- **Antenatal steroids (for fetal lung maturation)**  \n- **External cephalic version (ECV)**  \n- **Internal podalic version**  \n- **Augmentation of labour (oxytocin)**  \n- **Elective LSCS (caesarean section)**  \n- **Induction of labour (IOL)**  \n- **Epidural use**  \n\n### **Intrapartum & Delivery Terms**  \n- **Continuous CTG monitoring (>26 weeks)**  \n- **Twin delivery protocols**  \n- **Delivery room preparation** (resuscitaires, ultrasound, oxytocin infusion)  \n- **Optimum cord clamping**  \n- **Interval between twin deliveries (<45 minutes recommended)**  \n- **Vaginal birth vs. caesarean section**  \n- **Senior obstetrician presence**  \n- **Neonatal support at delivery**  \n\n### **Risk Factors & Complications**  \n- **Preterm labour**  \n- **Postpartum haemorrhage (PPH)**  \n- **Twin-twin transfusion syndrome (TTTS)**  \n- **Cord entanglement (MCMA twins)**  \n- **Fetal compromise (suspicious/pathological CTG)**  \n- **Gestational diabetes screening**  \n-",
    "UHSussex - MD090 - Disengaging a Deeply Impacted head at LSCS and use of Fetal Pillow.txt": "- Lower segment Caesarean section (LSCS)\n- Fetal Pillow\n- Deeply impacted fetal head\n- Cephalic presentation\n- Reverse breech extraction technique\n- Insertion\n- Professional judgment\n- Pre-term cases\n- Obstetrician's decision-making\n- Disposable soft silicone balloon\n- Elevate the fetal head\n- Indications\n- Operator training\n- Assessments\n- Difficulty delivering the head\n- Mode of delivery\n- Apgar score\n- Injuries to the baby\n- Cord gases\n- SCBU admission\n- Uterine incision extensions\n- Estimated blood loss\n- Bladder injury\n- ICU/HDU admission",
    "UHSx Homebirth & Freebirth guideline.txt": "Here are the most clinically significant terms and keywords extracted from the clinical guideline text, organized by relevance and category:\n\n### **Core Concepts & Guidance**  \n- **Homebirth**  \n- **Freebirth**  \n- **Evidence-based care**  \n- **Midwives' responsibilities**  \n- **NMC The Code**  \n- **Safety prioritization**  \n- **Risk assessment**  \n- **Professional judgment**  \n- **Informed decision-making**  \n- **Consultant midwife referral**  \n- **Obstetric unit birth (for high-risk cases)**  \n- **Emergency transfer**  \n- **Thromboprophylaxis**  \n- **Intrapartum care**  \n- **Postnatal care**  \n- **Newborn check (within 24 hours)**  \n\n### **Risk Factors & Indications for Hospital Transfer**  \n- **Pre-existing medical conditions**  \n- **Previous complicated births**  \n- **High-risk pregnancy**  \n- **Delay in first/second stage of labour**  \n- **Intrapartum haemorrhage**  \n- **Abnormal fetal heart rate (<110 or >160 bpm)**  \n- **Fetal decelerations (unless birth imminent)**  \n- **Need for continuous electronic fetal monitoring**  \n- **Hypertonic uterus**  \n- **Abnormal presentation (e.g., cord presentation)**  \n- **Meconium-stained liquor**  \n- **Anhydramnios/Polyhydramnios**  \n- **Chorioamnionitis**  \n- **Retained placenta**  \n- **Postpartum haemorrhage (PPH)**  \n- **Third/fourth-degree tear**  \n- **Neonatal resuscitation**  \n- **Suspected infection/trauma/congenital abnormalities**  \n- **Jaundice at birth**  \n\n### **Operational & Safety Considerations**  \n- **Second midwife attendance (mandatory)**  \n- **Lone worker safety checklist**  \n- **Midwife fatigue (>12 hours without break)**  \n- **Service suspension (extreme circumstances)**  \n- **Staffing arrangements (minimum 2 midwives per site)**  \n- **Geographical/travel time considerations**  \n- **Community midwife backup (4-hour limit when called in)**  \n- **Birth Centre as alternative transfer option**  \n\n### **Legal & Ethical Considerations**  \n- **Illegal for non-professionals to assume midwife/doctor roles**  \n- **Respect",
    "MP003 Antenatal Screening - Sickle Cell and Thalassaemia.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance:\n\n### **Core Concepts & Conditions**  \n- **Antenatal screening**  \n- **Sickle Cell Disease (SCD)**  \n- **Thalassemia**  \n- **Haemoglobin disorders**  \n- **Autosomal recessive conditions**  \n\n### **Screening Process & Timing**  \n- **Offered before 10 weeks of pregnancy**  \n- **Family Origin Questionnaire (limitations noted)**  \n- **Booking appointment (initial prenatal visit)**  \n- **Sample collection & laboratory processing (within 1 working day)**  \n- **Results timeframe (3 working days, rare disorders may take longer)**  \n- **Failsafe check (within 10 days of sample collection)**  \n\n### **Screening Results Categories**  \n1. **Non-carrier**  \n2. **Inconclusive**  \n3. **Clinically significant disorder**  \n4. **Genetic carrier**  \n\n### **Follow-Up & Referrals**  \n- **At-risk couples**  \n- **Prenatal diagnosis referral**  \n- **Specialized counseling (for unusual hemoglobin types)**  \n- **Postnatal testing (for babies of high-risk couples)**  \n- **Neonatal team involvement (blood specimen after birth)**  \n\n### **Paternal Involvement**  \n- **Baby\u2019s father/second biological parent testing (if indicated)**  \n- **Paternal blood results interpretation**  \n  - **Nothing abnormal detected (low risk, but 50% chance baby inherits mother\u2019s carrier status)**  \n  - **Father is a carrier (referral for prenatal diagnosis counseling)**  \n\n### **Patient Rights & Documentation**  \n- **Right to decline screening (with documentation of reason)**  \n- **Option for later screening (via community midwife)**  \n\n### **Logistics & Systems**  \n- **Unacceptable samples (notified to screening midwives)**  \n- **Shared database of carrier women (for failsafe follow-up)**  \n- **NHS Sickle Cell & Thalassaemia Screening Programme (established 2001, England)**  \n\n### **Key Contacts & Resources**  \n- **Antenatal screening midwives**  \n- **Prenatal diagnostic laboratory (consultation required for complex cases)**  \n- **BSUH designated programme leads (for maternity services)**  \n- **External support resources**  \n\nThese terms encapsulate the critical clinical, procedural, and ethical aspects of the guideline",
    "Carbetocin to prevent PPH at CS UHS-CG-0009-2023.txt": "Keywords and critical terms:\n- Carbetocin\n- Postpartum haemorrhage\n- Caesarean birth\n- Oxytocin\n- Anaesthetist\n- Obstetrician\n- Midwife\n- Administration\n- Dose\n- Contraindications\n- Cautions\n- Adverse effects\n- Training\n- Monitoring\n- BNF\n- SPC Carbetocin\n- Medusa NHS Injectable Medicines Guide",
    "UHSx Bladder Care guideline.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, categorized for clarity:\n\n### **General Concepts**  \n- Bladder care and management  \n- Evidence-based guidance  \n- Labour and postnatal period  \n- Bladder health optimization  \n- Overdistension prevention  \n- Infection risk reduction  \n- Urethral damage prevention  \n- Voiding dysfunction  \n- Management plans  \n\n### **Clinical Recommendations**  \n- Fluid intake monitoring  \n- Regular voiding encouragement  \n- Timely catheterization  \n- Postnatal voiding assistance  \n- Voiding volume documentation  \n- Bladder scan  \n- Physiotherapy referral  \n- Urinary catheter removal (when clinically indicated)  \n- Catheter care instructions  \n- Trial without catheter (TWOC)  \n- Close monitoring and prompt intervention  \n\n### **Bladder Scan Management (Post-Scanning Volumes)**  \n- **<200 mL**: Hydration advice, TWOC process, fluid balance review  \n- **200-500 mL**: In-out catheter, restart TWOC  \n- **500-1000 mL**: Indwelling catheter (IDC) for 24h, urine dip/CSU, repeat TWOC  \n- **>1000 mL / second failed TWOC**:  \n  - Urine dip, CSU  \n  - Datix (incident reporting)  \n  - Obstetrician review  \n  - IDC for 7 days (bladder rest)  \n  - Community Continence Nurse Referral (home TWOC)  \n\n### **Second Unsuccessful TWOC Management**  \n- Document 2 voided volumes post-IDC removal  \n- Post-void residual (PVR) check within 30 min  \n- **Discharge criteria**:  \n  - Voided volume >200 mL & PVR <150 mL  \n- **Persistent dysfunction**:  \n  - Reinsert IDC for 7 days (free-drainage bag)  \n\n### **Indications for Indwelling Catheter (IDC)**  \n- Post-LSCS (caesarean) or operative birth  \n- Spinal/epidural analgesia  \n- Distended bladder in labour  \n- Persistent retention/voiding dysfunction  \n- Retained placenta  \n- Postpartum hemorrhage (PPH)  \n- 3rd/4th degree tear  \n- Extensive perineal trauma (periurethral tear, labial swelling, hematoma)  \n\n### **Key Abbreviations & Procedures**  \n- **TWOC** (Trial Without Catheter)  \n- **",
    "CG1151 Uterine Rupture.txt": "- Uterine rupture\n- Diagnosis\n- Management\n- Pregnancy\n- Labor\n- Patient safety\n- Optimal outcomes\n- Evidence-based\n- Full thickness separation\n- Hemorrhage\n- Fetal distress\n- Rare occurrence\n- Risk factors\n- Cesarean birth\n- High parity\n- Pregnancy complications\n- Intrapartum care\n- Continuous fetal monitoring\n- Signs of rupture\n- Surgical delivery\n- Warning signs\n- Tonic contractions\n- Poor progress in labor\n- Scar pain\n- Pyrexia\n- Tachycardia\n- Dehydration\n- Compromise\n- Maternal shock\n- Morbidity\n- Mortality\n- Surgery\n- Recovery\n- Critical care\n- Elective caesarean\n- Monitoring\n- Auditing\n- Quality improvement",
    "UHSx Maternity Vaping Protocol.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance:  \n\n### **Core Concepts & Recommendations**  \n- **Maternity Vaping Protocol**  \n- **Smoking cessation aid during pregnancy**  \n- **Nicotine vape products**  \n- **Less harmful than smoking**  \n- **Behavioral support**  \n- **Regulated vape starter kit**  \n- **Not recommended for non-smokers or under 18**  \n- **Harm reduction (vs. tobacco smoke toxicity)**  \n- **Inclusion/exclusion criteria**  \n- **Medical conditions (cautions)**  \n\n### **Clinical Interventions & Support**  \n- **Personalized nicotine reduction plan**  \n- **12-week program**  \n- **NRT (Nicotine Replacement Therapy) patches**  \n- **Voucher scheme (e-liquids, atomizer heads)**  \n- **Follow-up appointments**  \n- **Relapse management (stop vaping if relapse occurs)**  \n- **Midwife/practitioner training**  \n- **Oxygen therapy (avoid vaping during)**  \n\n### **Service Delivery & Logistics**  \n- **Vape voucher system**  \n- **Totally Wicked (voucher provider)**  \n- **Service account for ordering**  \n- **Financial costs (charged to Maternity Department)**  \n- **Disposal/recycling of faulty devices**  \n- **Internal management system (MIS updates)**  \n\n### **Approval & Governance**  \n- **Trust-wide protocol**  \n- **Approved by (Caroline Thomas, Cara Henwood, Juliette Golding)**  \n- **Review date (May 2027)**  \n- **Protocol owners (Sebastian Adamson & Francis Usifo)**  \n\nThese terms capture the essential clinical, operational, and governance aspects of the guideline. Let me know if you need further refinement!",
    "UHSussex - MP055 - Perinatal Collapse in Pregnancy & Puerperium.txt": "- Perinatal Collapse\n- Maternity Protocol\n- Responsibilities\n- Maternal Collapse\n- Resuscitation\n- Modified Early Obstetric Warning System (MEOWS)\n- Roles and Responsibilities\n- Specialist Clinicians\n- Major Obstetric Hemorrhage\n- Cardiac Disease\n- Thromboembolism\n- Amniotic Fluid Embolism\n- Sepsis\n- Drug Toxicity\n- Eclampsia\n- Intracranial Hemorrhage\n- Anaphylaxis\n- Aortocaval Compression\n- Resuscitation Council (UK) guidelines\n- Perimortem Cesarean Section\n- Clinical Incident Form\n- Debriefing\n- Post-Traumatic Stress Disorder\n- Postnatal Depression\n- Tocophobia\n- Mental Health\n- Audit\n- Incident Reporting\n- Training\n- Support Groups",
    "MP018 Diabetes in Pregnancy SR.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance:  \n\n### **Core Clinical Terms**  \n- **Diabetes in pregnancy** (pre-existing, gestational)  \n- **Glycaemic control** (blood glucose levels, targets)  \n- **Insulin therapy** (insulin pump, hypoglycemia, glucagon)  \n- **Diabetic ketoacidosis (DKA)** (emergency management)  \n- **MODY (Maturity-Onset Diabetes of the Young)** (genetic testing)  \n- **Metformin** (alternative to insulin)  \n- **VRIII (Variable Rate Intravenous Insulin Infusion)** (stopped at delivery)  \n\n### **Monitoring & Targets**  \n- **Blood glucose monitoring** (fasting, postprandial)  \n- **HbA1c testing** (postnatal, annual screening)  \n- **Continuous glucose monitoring (CGM)** (during labor)  \n- **Targets**:  \n  - **Fasting**: \u22646.0 mmol/L  \n  - **Postprandial (2h)**: \u22647.8 mmol/L  \n\n### **Antenatal & Postnatal Care**  \n- **Pre-pregnancy planning** (for pre-existing diabetes)  \n- **Multidisciplinary team (MDT) involvement** (obstetrician, diabetic team)  \n- **20-week antenatal ultrasound**  \n- **Individualized management plan**  \n- **Postpartum insulin adjustment** (return to pre-pregnancy levels)  \n- **Neonatal hypoglycemia monitoring**  \n\n### **Lifestyle & Prevention**  \n- **Healthy diet & weight management**  \n- **Lifestyle advice** (postnatal, future pregnancies)  \n- **Screening for diabetes** (future pregnancies)  \n\n### **Documentation & Protocols**  \n- **Accurate documentation** (insulin in \"units\")  \n- **MDT evidence in records**  \n- **Timetable of antenatal appointments**  \n\nThese terms encapsulate the critical clinical, diagnostic, and management aspects of the guideline.",
    "CG1195 ANTI D guideline.txt": "- Fetal testing\n- D group\n- Anti-D administration\n- RhD negative\n- sensitisation\n- Haemolytic Disease of the Fetus and Newborn (HDFN)\n- anti-D antibodies\n- Cell-free DNA fetal D testing\n- Midwives Exemptions\n- G&S sample\n- ANC\n- EDD\n- viability\n- Kleihauer samples\n- potentially sensitizing events\n- FMH\n- DATIX\n- SHOT\n- Antenatal Screening Team\n- Transfusion Practitioner\n- Trust Patient Identification Policy\n- Universal precautions\n- transfusion paperwork\n- monitoring\n- audit",
    "BJOG - 2022 - Girling - Intrahepatic cholestasis of pregnancy.txt": "Key terms and keywords:\n- Intrahepatic cholestasis of pregnancy (ICP)\n- Itching\n- Bile acid concentration\n- Stillbirth\n- Twin pregnancies\n- Ultrasound\n- CTG (cardiotocography)\n- Liver function tests\n- Ursodeoxycholic acid\n- Planned birth timing\n- Pre-eclampsia\n- Gestational diabetes\n- Hepatobiliary diseases\n- Immune-mediated diseases\n- Preterm birth\n- Neonatal care\n- Active management\n- Fetal movements\n- Vitamin K\n- Dietary fat absorption\n- Maternal itch\n- Prognostic tools\n- Gestational diabetes testing\n- Continuous fetal monitoring\n- Baseline liver function tests\n- Recurrence in subsequent pregnancies\n- Audit topics\n- Support groups\n- Conflict of interests\n- Funding information",
    "CG19002 Accidentally dropped babies in hospital.txt": "- Assessment\n- Management\n- Babies\n- Accidentally dropped\n- Hospital\n- Maternity units\n- Special Care Baby Units\n- Prevention\n- Actions\n- Evidence-based\n- National Institute for Health and Care Excellence\n- Head injury\n- Falls\n- Predictive factors\n- Stability\n- Observations\n- Neonatal team\n- Safeguarding midwife\n- Skull injury\n- SCBU\n- Pediatric ward\n- Administration\n- Medical notes\n- Observation charts\n- DATIX form\n- Baby falls proforma\n- Body map\n- Documentation\n- Audit\n- New baby falls NEWTT chart\n- SCBU admission\n- Head/C-Spine imaging\n- Radiation risks\n- Audit\n- Flowchart\n- Parental information\n- Symptoms\n- Signs\n- Medical attention",
    "P19011 Referral for low platelets in pregnancy protocol.txt": "Here are the most clinically significant terms and keywords extracted from the guideline text, critical for understanding the guidance:  \n\n### **Key Clinical Terms:**  \n1. **Low platelets (thrombocytopenia)**  \n2. **Pregnancy (pregnant women/people)**  \n3. **Referral pathway/protocol**  \n4. **New onset thrombocytopenia**  \n5. **Platelet count levels**  \n6. **Severe complications**  \n7. **Midwives & obstetricians**  \n8. **Joint Haematology and Obstetric Clinic**  \n9. **Urgent referral (platelets <50)**  \n10. **ANC (Antenatal Clinic) & labor ward**  \n11. **Hematologist consultation**  \n12. **Medical background & previous investigations**  \n\n### **Critical Action Points:**  \n- **Referral based on platelet count**  \n- **Urgent review for platelets <50**  \n- **Liaise with hematologist if needed**  \n- **Include medical history in referral**  \n\nThese terms and actions encapsulate the essential clinical and procedural aspects of the guideline.",
    "CG1109 Diabetes in Pregnancy guideline.txt": "- Diabetes in Pregnancy\n- Pregnant women/people\n- Pre-existing diabetes\n- Gestational diabetes\n- Antenatal care\n- Screening\n- Blood glucose monitoring\n- Medications\n- Complications\n- OGTT (Oral Glucose Tolerance Test)\n- GTT (Glucose Tolerance Test)\n- Fasting plasma glucose\n- Corticosteroids\n- Insulin\n- IV fluids\n- Hyperemesis\n- VRIII (Variable Rate Intravenous Insulin Infusion)\n- Breastfeeding\n- Diabetic emergencies\n- Ultrasound scanning\n- Fetal heart examination\n- Antenatal corticosteroid risks\n- COVID-19 vaccination\n- JCVI guidance\n- Gestational Diabetes\n- Vaccination\n- Increased risk",
    "MP053 Obstetric Haemorrhage.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance:\n\n### **Core Conditions & Definitions**  \n- **Obstetric Hemorrhage**  \n- **Antepartum Hemorrhage (APH)** (Minor: <50ml, Major: >50ml)  \n- **Postpartum Hemorrhage (PPH)** (Minor: 500-1000ml, Major: >1000ml, Massive: \u22652000ml)  \n- **Placental Abruption**  \n- **Placenta Praevia** (grading, elective C-section)  \n- **Vasa Praevia**  \n- **Women declining blood products** (e.g., Jehovah\u2019s Witnesses)  \n\n### **Management & Interventions**  \n- **Resuscitation** (massive hemorrhage protocol)  \n- **Oxytocin administration** (post-delivery)  \n- **Blood product transfusion** (urgent request, alternatives for refusers)  \n- **Thromboprophylaxis** (after bleeding control)  \n- **FBC (Full Blood Count)** (pre-discharge)  \n- **Coagulation monitoring** (hemoglobin, clotting parameters)  \n- **Consultant Obstetrician involvement** (high-risk cases, placenta praevia)  \n- **Neonatology support** (emergency delivery)  \n- **Debriefing** (post-hemorrhage)  \n\n### **Risk Assessment & Documentation**  \n- **Individualized care plans** (for blood product refusal, high-risk PPH)  \n- **Antenatal counseling** (risks, blood refusal)  \n- **Ultrasound placental localization**  \n- **Datix reporting** (>1500ml blood loss)  \n\n### **Key Responsibilities**  \n- **Midwives/Obstetricians/Anaesthetists** (protocol adherence, professional judgment)  \n- **Labor ward coordinator** (team communication)  \n- **Management** (protocol accessibility, review compliance)  \n\n### **Critical Actions**  \n- **Maternal observations** (vital signs, vaginal loss assessment)  \n- **Fetal heart auscultation** (APH cases)  \n- **Elective cesarean** (asymptomatic placenta praevia)  \n- **Emergency delivery protocols** (Consultant-led, oxytocin, neonatology)  \n\nThese terms encapsulate the clinical urgency, diagnostic criteria, and management steps essential for adhering",
    "CG18005 Newborn BCG Immunisation guideline.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance:\n\n### **General Guideline & Program**  \n- **BCG Immunisation Programme**  \n- **Newborn babies**  \n- **Selective neonatal BCG immunization**  \n- **TB (Tuberculosis) exposure**  \n- **Infection reduction**  \n- **Transmission prevention**  \n- **NHS England monitoring**  \n- **High-risk groups**  \n- **High TB incidence areas**  \n- **Family members from high TB incidence countries**  \n\n### **Key Responsibilities & Processes**  \n- **Midwives, pediatricians, management roles**  \n- **BCG referral & administration**  \n- **Timely vaccination**  \n- **Accurate documentation**  \n- **Monitoring outcomes**  \n- **NIPE (Newborn and Infant Physical Examination) reports**  \n- **SCID (Severe Combined Immunodeficiency) screening**  \n- **Medway spreadsheet tracking**  \n- **Public Health England (PHE) reporting**  \n\n### **Eligibility & Contraindications**  \n- **Infants at increased TB risk**  \n- **Exclusions for BCG vaccination:**  \n  - High fever  \n  - Cancer/immunosuppressive treatment  \n  - HIV-positive status  \n  - Generalized skin condition  \n  - Passive antibodies received  \n  - Steroid treatment  \n  - No NBBS (Newborn Blood Spot Screening) result  \n  - SCID detected  \n  - Immunosuppression exposure in pregnancy/breastfeeding  \n- **HIV-unexposed infants (low-risk)**  \n\n### **Vaccine Administration Details**  \n- **BCG vaccine dose:**  \n  - **Under 12 months:** 0.05ml (intradermal)  \n  - **Over 12 months:** 0.1ml (intradermal)  \n- **Injection site:** Lateral aspect of left upper arm (deltoid insertion)  \n- **Intradermal injection (strictly)**  \n- **Concurrent vaccination with inactivated/live vaccines allowed**  \n- **No other vaccinations in same arm for 3 months (risk of lymphadenitis)**  \n\n### **Post-Vaccination Care & Monitoring**  \n- **Expected reactions:** Sore area, fluid/blood leakage, lump formation  \n- **No creams/lotions on injection site**  \n- **TB Nursing Team contact for concerns**  \n- **Parent/c",
    "UHSx Baby Abduction & Security guideline.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance:\n\n### **Core Concepts & Security Measures:**  \n- **Baby abduction**  \n- **Newborn security**  \n- **Hospital security**  \n- **Identification bands** (mothers, babies, staff)  \n- **CCTV**  \n- **Security measures**  \n- **Early attachment** (mother-baby bonding)  \n\n### **Roles & Responsibilities:**  \n- **Maternity staff**  \n- **Portering staff**  \n- **Security staff**  \n- **Switchboard staff**  \n- **Management oversight**  \n- **Service user compliance** (visiting hours, restrictions)  \n\n### **Action Plan for Abduction:**  \n- **Confirm abduction**  \n- **Raise alarm**  \n- **Notify authorities** (police, hospital security)  \n- **Secure ward area**  \n- **Support families**  \n- **Multidisciplinary case review**  \n- **Media inquiries**  \n\n### **Monitoring & Compliance:**  \n- **Incident monitoring**  \n- **Staff education & training**  \n- **Guideline review & updates**  \n- **Dissemination plan** (SharePoint, Safety Huddles)  \n- **Version control** (removal of outdated guidelines)  \n\n### **Legal & Ethical Considerations:**  \n- **Human Rights FREDA principles** (Fairness, Respect, Equality, Dignity, Autonomy)  \n- **Due Regard Assessment** (equality impact)  \n\nThese terms encapsulate the critical aspects of the guideline, ensuring clarity on prevention, response, and compliance in newborn security protocols.",
    "MP064 Hyponatraemia in Labour.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and category:\n\n### **Core Definitions & Diagnostic Criteria**  \n- **Hyponatraemia** (serum sodium < **130mmol/L**)  \n- **Severe hyponatraemia** (sodium < **125mmol/L** + **symptoms**)  \n- **Symptoms**: headache, lethargy, confusion  \n\n### **Risk Factors & Prevention**  \n- **Pregnant individuals** (higher risk)  \n- **Fluid intake/output monitoring**  \n- **Avoid excess water intake**  \n- **Bladder care**  \n\n### **Emergency Management (Severe Cases)**  \n- **Medical emergency**  \n- **Urgent senior obstetric & anaesthetic review**  \n- **ITU/Critical Care Outreach team involvement**  \n- **Transfer to Level 2 care (ITU if possible)**  \n\n### **Treatment Principles**  \n- **Goal**: Improve symptoms (not normalize sodium)  \n- **Strict fluid restriction** (**30mls/hr**)  \n- **Accurate fluid balance monitoring**  \n- **Hourly sodium checks**  \n\n### **Specific Interventions**  \n- **1.8% Sodium Chloride** (ITU-supplied)  \n  - **150ml bolus** (only under ITU instruction/supervision)  \n  - **2nd bolus (150ml)** if no improvement  \n- **Sodium correction limit**: \u2264 **10mmol/L in 24 hours**  \n\n### **Monitoring & Follow-up**  \n- **Continue fluid restriction until asymptomatic**  \n- **Repeat sodium levels hourly**  \n\nThese terms encapsulate the critical clinical actions, thresholds, and precautions necessary for managing hyponatraemia in labour, particularly in severe cases.",
    "GP021 The Management of Foreign Body in Female Genital Tract (RSCH PRH).txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance:  \n\n### **General Protocol Terms:**  \n- Protocol  \n- Objective standards  \n- Professional judgement  \n- Scope  \n- Responsibilities  \n- Compliance monitoring  \n- Audit  \n\n### **Patient Population & Indications:**  \n- Women  \n- Foreign body in genital tract  \n- Suspected foreign body  \n\n### **Causes & Risk Factors:**  \n- Accidental insertion  \n- Self-insertion (habitual)  \n- Child insertion  \n- Sexual abuse  \n- Mental health issues  \n\n### **Clinical Roles & Responsibilities:**  \n- Nurses  \n- Gynaecologists  \n- Management (ensuring protocol accessibility & review)  \n\n### **Assessment & Diagnosis:**  \n- Patient assessment  \n- History taking  \n- Physical examination  \n- Nature of foreign body  \n- Duration of insertion  \n- Investigations (infection/complications)  \n\n### **Referral & Urgency:**  \n- Urgent symptoms \u2192 Immediate referral  \n- Less urgent symptoms \u2192 Daytime assessment  \n\n### **Treatment & Management:**  \n- Urgent removal (sharp objects, severe bleeding)  \n- Symptom-based treatment  \n\n### **Aftercare & Follow-up:**  \n- Same-day discharge  \n- Mental health support (habitual insertion cases)  \n\nThese terms encapsulate the core clinical and procedural elements necessary for understanding and implementing the guideline.",
    "UHSussex - MP050 - Caesarean Section.txt": "Clinical significant terms and keywords from the clinical guideline text:\n\n- Caesarean section\n- Protocol\n- Midwives\n- Obstetricians\n- Emergency\n- Urgent\n- Scheduled\n- Elective\n- Documentation\n- WHO Safety Surgical Checklist\n- Intra-operative cell salvage\n- Blood transfusion\n- PPI/Sodium Citrate\n- Antibiotics\n- Surgical techniques\n- Delayed cord clamping\n- Cord milking\n- Oxytocin\n- Resuscitation\n- Skin-to-skin contact\n- Breast/chest feeding\n- Negative pressure wound therapy\n- BMI\n- Wound infections\n- Endometritis\n- VTE risk assessment\n- Thromboprophylaxis\n- VBAC\n- Postnatal depression\n- Uterine rupture\n- Neonatal mortality\n- Childhood obesity\n- Urinary incontinence\n- Faecal incontinence\n- OASIS\n- Pain\n- Major obstetric haemorrhage\n- Infection\n- Postnatal depression\n- Persistent verbal delay\n- Infant mortality\n- Stillbirth\n- Neonatal respiratory morbidity\n- Cerebral palsy\n- Autism spectrum condition\n- Type 1 diabetes\n- Anaesthetic clinics\n- ITU admission\n- Obstetric Anaesthetist\n- Bleep number",
    "MP057 Communication and Handover of Care betweeen Professionals.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance:\n\n### **Core Concepts:**  \n1. **Handover of care**  \n2. **Professional responsibility and accountability**  \n3. **Patient safety**  \n4. **Clinical incidents**  \n5. **Effective communication**  \n6. **Documentation**  \n\n### **Key Processes & Tools:**  \n7. **SBAR format** (Situation, Background, Assessment, Recommendation)  \n8. **Structured handover tool**  \n9. **Shift change handover**  \n10. **Personal handover**  \n11. **Verbal handover**  \n12. **Transfer between care settings**  \n\n### **Clinical Settings & Roles:**  \n13. **Midwives**  \n14. **Medical staff**  \n15. **ITU/HDU (Intensive Therapy Unit/High Dependency Unit)**  \n16. **Ward transfer**  \n\n### **Critical Actions:**  \n17. **Joint decision-making**  \n18. **Full verbal handover**  \n19. **Document discussions, decisions, and care plans**  \n20. **Continuity of care**  \n\nThese terms encapsulate the essential elements of the guideline, ensuring clarity in communication, documentation, and patient safety during care transitions.",
    "MP030 Latent Phase of Labour.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance:  \n\n### **General Protocol & Context**  \n- **Latent Phase of Labour**  \n- **Brighton & Sussex University Hospitals**  \n- **Protocol MP030**  \n- **Midwives & Obstetricians**  \n- **Women\u2019s wishes & decision-making**  \n\n### **Clinical Care & Monitoring**  \n- **Early assessment**  \n- **Telephone advice**  \n- **Encouraging normal activities**  \n- **Monitoring fetal movements**  \n- **Fetal heart monitoring**  \n- **Prolonged latent phase** (may require interventions)  \n\n### **Analgesia & Pain Management**  \n- **Morphine sulfate (Oramorph) 10mg/5mL** (preferred option)  \n- **Contraindications for morphine sulfate**:  \n  - **Opiate/Morphine allergies or sensitivities**  \n  - **Intra-uterine growth restriction (IUGR)**  \n- **Side effects of opiates**  \n\n### **Key Actions & Considerations**  \n- **Consult obstetrician as needed**  \n- **Administering analgesia with caution**  \n\nThese terms capture the essential clinical, pharmacological, and procedural aspects of the guideline. Let me know if you'd like further refinement!",
    "Clinical Consensus No. 455 Fetal Sex Determination and Disclosure.txt": "- Fetal sex determination\n- Obstetric ultrasound examinations\n- Parental wishes\n- Disclosure of fetal sex\n- Prenatal diagnosis\n- Fetal genital anomalies\n- Ultrasound reports\n- Fetal perineum\n- Health care providers\n- Fetal development\n- Genitalia assessment\n- Second-trimester ultrasound\n- Referral\n- Re-examination\n- Direct communication\n- Diagnostic ultrasound\n- Knowledge of fetal sex",
    "GTG 2011 - Pregnancy and Breast Cancer.txt": "- Pregnancy\n- Breast cancer\n- Diagnosis\n- Treatment\n- Contraceptive choices\n- Prognosis\n- Survival\n- Hormonal contraception\n- BRCA gene mutations\n- Tamoxifen treatment\n- Fertility\n- Chemotherapy-induced gonadotoxicity\n- Fertility preservation\n- Assisted conception\n- Assisted reproduction\n- Ovarian reserve\n- Hormone replacement therapy\n- Reproductive concerns\n- GnRH agonist\n- Cryopreservation\n- Amenorrhea",
    "Shoulder Dystocia prompt card  ED RSCH PRH.txt": "Here are the most clinically significant terms and keywords extracted from the **Shoulder Dystocia PROMPT Card** guideline, critical for understanding the guidance:  \n\n### **Key Clinical Terms & Keywords:**  \n1. **Shoulder dystocia** (primary condition)  \n2. **Call for help** (senior MW, Registrar, paediatrician)  \n3. **Neonatal resuscitation** (preparation required)  \n4. **McRoberts maneuver** (first-line intervention)  \n   - Lie flat, elevate legs  \n5. **Suprapubic pressure** (first-line intervention)  \n   - 30 seconds continuous **OR** 30 seconds rocking pressure  \n6. **Attempt to deliver baby** (after each maneuver)  \n7. **Evaluate for episiotomy** (if needed)  \n8. **Posterior shoulder pressure techniques** (3-step approach):  \n   - Pressure on **posterior aspect of anterior shoulder**  \n   - Pressure on **posterior aspect of anterior shoulder & anterior aspect of posterior shoulder**  \n   - Pressure on **posterior aspect of posterior shoulder**  \n9. **Adduct shoulders & push baby into oblique** (alternative maneuver)  \n10. **Rotate 180\u00ba** (in both directions if needed)  \n11. **Remove posterior arm** (advanced maneuver)  \n12. **Roll onto all fours** (change maternal position)  \n13. **If unsuccessful:**  \n    - **Repeat all maneuvers**  \n    - **Cleidotomy** (fracture clavicle)  \n    - **Zavanelli maneuver** (cephalic replacement)  \n    - **Symphysiotomy** (last resort)  \n14. **Consultant obstetrician** (must be contacted)  \n15. **Critical Warnings:**  \n    - **Never apply excessive traction or flexion to fetal head**  \n    - **Order of maneuvers depends on clinical judgment**  \n\n### **Most Critical Takeaways:**  \n- **First-line:** McRoberts + Suprapubic pressure  \n- **Escalation steps** if unsuccessful  \n- **Avoid harmful traction**  \n- **Consultant involvement mandatory** for advanced interventions  \n\nThese terms encapsulate the essential actions, warnings, and decision points in managing shoulder dystocia.",
    "FIGO - 2015 - Intrapartum Fetal Monitoring - Cardiotocography.txt": "- CTG monitoring\n- Fetal hypoxia/acidosis\n- Continuous monitoring\n- Intermittent fetal auscultation\n- Cesarean delivery\n- Maternal heart rate\n- Baseline\n- Variability\n- Accelerations\n- Decelerations\n- Contractions\n- Tachycardia\n- Bradycardia\n- Oxygen administration\n- Intravenous fluids\n- Sinusoidal patterns\n- Fetal anemia\n- Clinical judgment\n- Prompt action\n- Limitations\n- Observer disagreement\n- Training",
    "UHS Anaemia in pregnancy guideline.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and category:\n\n### **General & Diagnostic Terms**  \n- **Anaemia during pregnancy**  \n- **Haemoglobin (Hb) concentration**  \n- **Iron deficiency**  \n- **Vitamin B12 deficiency**  \n- **Folate deficiency**  \n- **Inflammatory disorders**  \n- **Haemoglobinopathy**  \n- **Serum ferritin**  \n- **MCV (Mean Corpuscular Volume)**  \n- **MCH (Mean Corpuscular Haemoglobin)**  \n- **MCHC (Mean Corpuscular Haemoglobin Concentration)**  \n\n### **Clinical Presentation & Risks**  \n- **Fatigue (most common symptom)**  \n- **Perinatal mortality**  \n- **Neonatal mortality**  \n- **Low birth weight**  \n- **Pre-term birth**  \n- **Multiparity**  \n- **Twin pregnancy**  \n- **Poor diet**  \n- **Recent significant bleeding**  \n\n### **Screening & Diagnosis**  \n- **Screening at booking & 28 weeks**  \n- **Ferritin <30 (diagnostic of iron deficiency)**  \n- **Non-anaemic individuals at risk**  \n- **Prophylactic iron**  \n\n### **Management & Treatment**  \n- **Dietary advice (iron-rich foods)**  \n- **Recommended daily iron intake (27 mg)**  \n- **Oral iron replacement therapy**  \n- **Intravenous (IV) iron therapy**  \n  - **Indications:**  \n    - Non-compliance  \n    - Intolerance of oral iron  \n    - Malabsorption  \n    - GI diseases  \n    - Poor response to oral iron  \n  - **Contraindications:**  \n    - Anaphylaxis history  \n    - Hypersensitivity reactions  \n    - First trimester of pregnancy  \n    - Acute/chronic bacteraemia  \n    - Liver disease  \n  - **Preparation:** Ferric Derisomaltose (Pharmacosmos)  \n  - **Infusion precautions:**  \n    - Avoid out-of-hours administration  \n    - Minimize iron staining risk  \n    - Monitor for adverse effects  \n  - **Delayed reactions:**  \n    - Arthralgia  \n    - Myalgia  \n    - Fever (resolves in 2\u20134 days)  \n  - **Hypersensitivity management:**  \n    - Stop infusion  \n    - Call medical assistance  \n    - Follow **Resuscitation Council UK An",
    "CG1119 IOL & Augmentation of Labour & Use of Oxytocin.txt": "Keywords and clinically significant terms:\n- Induction of labor\n- Augmentation of labor\n- Oxytocin\n- Stillbirth\n- Gestational age\n- Minority ethnic backgrounds\n- Deprived areas\n- Membrane sweep\n- Cervical balloon catheter\n- Dinoprostone\n- Artificial rupture of membranes\n- Bishop Score\n- BMI\n- CTG monitoring\n- Terbutaline\n- IV oxytocin infusion\n- Fetal compromise\n- Preterm labor\n- Intrauterine fetal death\n- Fetal abnormality\n- Previous cesarean section\n- Diabetes\n- Obesity\n- Maternal request\n- Pre-labor rupture of membranes\n- GBS (Group B Streptococcus)\n- Uterine hyperstimulation\n- Tocolysis\n- Uterine rupture\n- Cesarean birth\n- Audit and monitoring\n- Lithotomy position\n- Dawes Redman criteria\n- VE (Vaginal Examination)\n- ARM (Artificial Rupture of Membranes)\n- CRB audit monitoring\n- Postpartum hemorrhage\n- Syringe driver",
    "BJOG - 2016 -  - Management of Bladder Pain Syndrome.txt": "- Bladder Pain Syndrome\n- Initial clinical assessment\n- Differential diagnoses\n- Severity classification\n- Dietary modifications\n- Stress management\n- Analgesia\n- Intravesical treatments\n- Lidocaine\n- Hyaluronic acid\n- Botulinum toxin A\n- Dimethyl sulfoxide\n- Referral to secondary care\n- Physiotherapy\n- Psychological support\n- Pelvic pain\n- Physical examination\n- Sexual abuse history\n- Baseline investigations\n- Multimodal therapy\n- Intravesical treatments\n- Conservative treatments\n- Oral amitriptyline\n- Cimetidine\n- Pain clinic referral\n- Neuromodulation\n- Major surgery\n- Physiotherapist referral\n- Clinical psychologist referral\n- Pregnancy effects on BPS\n- Oral amitriptyline in pregnancy\n- Intravesical heparin in pregnancy\n- DMSO in pregnancy\n- Genetic predisposition\n- Research recommendations\n- Support groups\n- Interstitial cystitis\n- Gynecological disorders\n- Effect of amitriptyline\n- Alkalinized lidocaine",
    "GP018 Management of Miscarriage under local Anaesthetic MVA.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by category for clarity:  \n\n### **Procedure & Indications**  \n- **Manual Vacuum Aspiration (MVA)**  \n- **Pregnancy loss <12/40**  \n- **Retained products of conception**  \n- **Failed medical/surgical management of miscarriage**  \n- **Early embryonic demise**  \n- **Incomplete miscarriage (<10 weeks)**  \n- **Mean sac diameter <4cm**  \n\n### **Clinical Personnel & Requirements**  \n- **Trained Gynaecologists**  \n- **Registrar-grade doctors (signed off for procedure)**  \n- **Informed consent**  \n- **Patient counseling & education**  \n\n### **Exclusions & Contraindications**  \n- **Allergy to local anaesthetic**  \n- **Allergy to misoprostol**  \n- **History of panic attacks**  \n- **Certain medical conditions (unspecified)**  \n\n### **Procedure Details**  \n- **Local anaesthetic (injection into cervix)**  \n- **Tissue removal**  \n- **Duration: 10-15 minutes**  \n- **Recovery time: 60 minutes**  \n- **Nitrous oxide (pain relief option)**  \n- **Post-procedure pain medication offered**  \n\n### **Post-Procedure Care & Monitoring**  \n- **Tissue examination**  \n- **Monitoring for 2 hours post-procedure**  \n- **Urine pregnancy test at 3 weeks**  \n- **Contact EPAU if pregnancy test still positive**  \n- **Report persistent bleeding/pain to EPAU**  \n\n### **Risks & Complications**  \n- **Incomplete tissue removal**  \n- **Bleeding**  \n- **Infection**  \n- **Fainting**  \n- **Perforation of the womb**  \n\n### **Alternatives to MVA**  \n- **Conservative management**  \n- **Medical management**  \n- **Surgical management**  \n\n### **Patient Support & Follow-Up**  \n- **Encouragement for decision-making time**  \n- **Post-procedure contact information for concerns**  \n\nThese terms encapsulate the critical clinical, procedural, and patient-care aspects of the guideline. Let me know if you'd like any refinements!",
    "Gynae CEPOD pathway.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by category for clarity:  \n\n### **Clinical Assessment & Criteria**  \n- **SIRS Assessment** (Systemic Inflammatory Response Syndrome)  \n  - Temperature **<36\u00b0C or >38\u00b0C**  \n  - Heart rate **>90 bpm**  \n  - Respiratory rate **>20/min**  \n  - **Admission to Level 11** (if \u22652 SIRS criteria met)  \n\n### **Working Diagnoses (Gynaecological Conditions)**  \n- **Bartholin\u2019s Cyst/Abscess**  \n- **Vulva Abscess/Haematoma**  \n- **Retained Products of Conception (RPOC)**  \n- **Ectopic Pregnancy**  \n\n### **Planned Procedures**  \n- **Marsupialisation**  \n- **Incision & Drainage (I&D)**  \n- **Evacuation of Retained Products of Conception (ERPC)**  \n- **Diagnostic Laparoscopy**  \n\n### **Checklist & Administrative Steps**  \n- **Acute Gynaecological Proforma**  \n- **Consent form**  \n- **Cremation form** (if applicable)  \n- **CEPOD booking form** (CEPOD = **Emergency Operating Pathway**)  \n- **CEPOD Coordinator** (Bleep **8061**)  \n- **Fast-track CEPOD days**: **Tuesday, Wednesday, Friday PM**  \n- **Nurse-led discharge permission** (Yes/No)  \n\n### **Post-Procedure/Admission Steps**  \n- **Patient information leaflet**  \n- **GAU nurse** (Ext. **4013/4022**)  \n- **Day Surgery Unit admission** (Ext. **7242**)  \n\nThese terms are critical for clinicians to understand the **assessment criteria, diagnoses, procedures, and administrative workflow** in this gynaecological emergency pathway.",
    "NICE Guidance - 2024 - Endometriosis.txt": "Clinical significant terms and keywords from the guideline text include:\n- Endometriosis\n- Diagnosis\n- Management\n- Referral\n- Symptoms\n- Signs\n- Diagnosing\n- Staging\n- Monitoring\n- Pharmacological pain management\n- Non-pharmacological management\n- Surgical management\n- Fertility\n- Deep endometriosis\n- Pelvic MRI\n- Laparoscopy\n- Ultrasound\n- Gynaecologist\n- Biopsy\n- Outpatient follow-up\n- Analgesics\n- Hormonal treatment\n- Excision\n- Ablation\n- Adhesiolysis\n- Ovarian cystectomy\n- Managed clinical networks\n- Chronic pelvic pain\n- Paediatric and adolescent gynaecology service\n- Specialist lifestyle interventions\n- Quality of life\n- Information and support interventions\n- Hormonal treatments\n- Fertility outcomes",
    "CG1130 Assisted Vaginal Birth Guideline.txt": "Assisted Vaginal Birth, Forceps, Vacuum Extraction, Rotational, Non-Rotational, Instrument Use, Procedure Abandonment, Indications, Contraindications, Timing Considerations, Operators, Successful Birth, Benefits, Risks, Cephalohematoma, Retinal Hemorrhage, Maternal Trauma, Fetal Head Position, Ultrasound Assessment, Antibiotics, Complications, Postnatal Planning, Referral, Traumatic Birth, Psychological Interventions, Maternity Units, Duty of Candour, Clinical Incident Reporting, Auditable Standards, RCOG Guideline.",
    "MP033 Induction of labour.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by category for clarity:\n\n### **General Protocol Terms**  \n- Induction of Labour (IOL)  \n- Protocol  \n- Professional judgement  \n- Scope (pregnant women)  \n- Responsibilities (Midwives, Obstetricians, Management)  \n\n### **Key Clinical Concepts**  \n- Prolonged pregnancy (>42 weeks)  \n- Low-lying placenta (check before membrane sweeping)  \n- Membrane sweeping (recommended adjunct)  \n- Bishop Score (assessment before induction)  \n- Vaginal PGE2 (preferred pharmacological method)  \n- Amniotomy (avoid as primary method unless contraindications)  \n- Oxytocin (secondary method)  \n- Uterine hyperstimulation (risk with PGE2)  \n- Continuous electronic fetal monitoring (required)  \n\n### **Specific Indications & Contraindications**  \n- **41+0 to 42+0 weeks** (recommended induction window)  \n- **Preterm pre-labour rupture of membranes (PPROM)**  \n- **Term pre-labour rupture of membranes (PROM)**  \n- **VBAC (Vaginal Birth After Caesarean)** (refer to MP034)  \n- **Maternal request** (not routinely offered)  \n- **Breech presentation** (not recommended unless failed ECV)  \n- **Fetal growth restriction (severe with compromise)** (not recommended)  \n- **History of precipitate labour** (not routinely offered)  \n- **Intrauterine fetal death (IUFD)** (support & tailored induction)  \n- **Suspected fetal macrosomia** (not sole reason for induction)  \n- **Diabetes & hypertension** (refer to specific protocols)  \n\n### **Methods NOT Recommended**  \n- Herbal supplements  \n- Acupuncture  \n- Homeopathy  \n- Castor oil  \n- Hot baths  \n- Enemas  \n- Sexual intercourse  \n- Balloon catheters (mechanical methods)  \n- Laminaria tents  \n\n### **Monitoring & Safety**  \n- Outpatient induction (only if safety protocols in place)  \n- Inpatient induction (preferred for PGE2)  \n- Continuous fetal heart rate monitoring  \n- Uterine contraction monitoring  \n- Pain management (informed about increased pain)  \n- Cord prolapse (precautions)  \n- Uterine rupture (emergency C-section if suspected)  \n- Failed induction (management options discussed)",
    "Uptodate - Pregnancy Loss Ultrasound Diagnosis.txt": "Keywords and clinically significant terms:\n- Pregnancy loss\n- Miscarriage\n- Nonviable intrauterine pregnancy\n- Early pregnancy loss\n- Transvaginal ultrasound evaluation\n- Intrauterine gestation\n- Ectopic pregnancy\n- Pelvic ultrasound\n- Embryonic cardiac activity\n- Gestational sac diameter\n- Cardiac activity\n- Diagnostic certainty\n- Patient preferences\n- Clinical context\n- Gestational sac\n- Yolk sac\n- Embryo\n- CRL (Crown-rump length)\n- Nonviable early pregnancy\n- Discrepancy in gestational duration\n- Multiple gestations\n- Pregnancy of unknown location\n- Amnion\n- Subchorionic hematoma\n- Chorionic bump\n- Live pregnancy\n- Transvaginal ultrasonographic diagnosis\n- Pregnancy failure\n- False-positive rate (FPR)",
    "MP023 Maternal and In Utero Transfers.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and category:\n\n### **General Protocol & Scope**  \n- Protocol  \n- Measurable standards  \n- Objective standards  \n- Antenatal  \n- Intrapartum  \n- Postpartum  \n- Midwives  \n- Obstetricians  \n- Management  \n- Trust recommendations  \n- National recommendations  \n\n### **Maternal Transfer Processes**  \n- Maternal transfer  \n- Ambulance transfer  \n- Multidisciplinary arrangements  \n- Safe transfer  \n- Antenatal transfer  \n- Intrapartum transfer  \n- Postnatal transfer  \n- Clinical assessment  \n- Indications for transfer  \n- Pre-term labor  \n- Risk factors  \n\n### **Inter-Site & Off-Site Transfers**  \n- Transfer site to site  \n- Communication between sites  \n- Documentation in maternal notes  \n- Transfer off-site  \n- Accepting units  \n- Maternity notes  \n\n### **Emergency & Urgent Transfer Procedures**  \n- 999 (emergency call)  \n- Immediate emergency treatment  \n- Urgent treatment  \n- Labour ward transfer  \n- Emergency transfer  \n- Delayed labor progress  \n- Fetal compromise  \n- Maternal collapse  \n- Medical conditions  \n\n### **Critical Care & Postnatal Transfers**  \n- Transfer to ITU (Intensive Therapy Unit)  \n- Transfer to HDU (High Dependency Unit)  \n- Obstetric Consultant  \n- Anaesthetic Consultant  \n- SBAR tool (Situation-Background-Assessment-Recommendation)  \n- Handover of care  \n- Postnatal transfer  \n- Unwell women  \n- Delivery suite  \n\n### **Documentation & Legal/Procedural Requirements**  \n- Consent for transfer  \n- Neonatal unit coordination  \n- Completion of paperwork  \n- Documentation of care  \n- Referrals  \n- Staff preparation  \n\nThese terms encapsulate the critical aspects of maternal and in utero transfers, ensuring compliance with clinical guidelines and patient safety.",
    "UHSussex - MP064 - Hyponatraemia in Labour.txt": "- Hyponatraemia\n- Labour\n- Measurable standards\n- Prevention\n- Oral intake\n- Fluid balance\n- Low-risk care\n- High-risk care\n- Oxytocin use\n- Management flowchart\n- Sodium levels\n- Treatment\n- Severe hyponatraemia\n- Medical emergency\n- Senior obstetric and anaesthetic review\n- ITU/Critical Care Outreach team\n- Level 2 care\n- Fluid restriction\n- Sodium Chloride bags\n- Bolus\n- Improvement\n- 10mmol/L in 24 hours",
    "Shoulder Dystocia Guideline UHSx.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance on **shoulder dystocia (SD)**:\n\n### **Core Definitions & Key Concepts**  \n- **Shoulder dystocia (SD)**  \n- **Vaginal cephalic birth**  \n- **Additional obstetric manoeuvres**  \n- **Gentle downward traction (unsuccessful)**  \n\n### **Epidemiology & Risks**  \n- **Incidence (~0.6% of vaginal births)**  \n- **Perinatal mortality & morbidity**  \n- **Maternal morbidity**  \n  - **Postpartum haemorrhage (PPH)**  \n  - **Maternal trauma**  \n\n### **Risk Factors**  \n- **Fetal macrosomia**  \n- **Diabetes mellitus (maternal)**  \n- **Maternal obesity**  \n- **Previous shoulder dystocia (recurrence risk)**  \n\n### **Clinical Management**  \n#### **Antenatal**  \n- **Risk assessment**  \n- **Recurrence prevention planning**  \n\n#### **Intrapartum**  \n- **Prompt recognition**  \n- **Systematic care**  \n  - **Hypoxic acidosis prevention**  \n  - **Minimizing fetal trauma**  \n- **Emergency management**  \n  - **Experienced obstetrician involvement**  \n  - **Systematic techniques (e.g., PROMPT)**  \n\n#### **Post-birth**  \n- **Maternal monitoring** (haemorrhage, perineal tears)  \n- **Paediatric management** (if **brachial plexus injury** suspected)  \n- **Follow-up care & counselling**  \n\n### **Training & Documentation**  \n- **Training for birth attendants**  \n- **Record keeping & reporting**  \n\n### **Appendices (Key Supporting Tools)**  \n- **PROMPT management** (Appendix 1)  \n- **Shoulder Dystocia Proforma** (Appendix 2)  \n\nThese terms encapsulate the critical clinical, management, and risk-related aspects of shoulder dystocia as outlined in the guideline.",
    "GTG 2015 - FGM.txt": "Keywords and clinically significant terms: Female Genital Mutilation (FGM), complications, Female Genital Mutilation Act, re-infibulation, UK law, mandatory reporting, training, multidisciplinary services, clinical signs, examination findings, referral pathways, psychological assessment, de-infibulation, clitoral reconstruction, antenatal visits, hepatitis C screening, intrapartum care, postnatal care, legal processes, global epidemiology, medicalisation, data collection, clitoridectomy, defibulation, short-term complications, long-term complications, haemorrhage, urinary retention, infection, scarring, dyspareunia, bacterial vaginosis, infertility, HIV, hepatitis B, obstetric complications, HSCIC FGM Enhanced Dataset, designated consultants, midwives, sensitve care, stillbirth rates, auditable topics, healthcare worker training, referrals, obstetrician, specialist midwife, individual risk assessment, screening, high obstetric risk, child protection, caesarean section.",
    "UHSussex - MP046 - Management of Breech and ECV.txt": "- Breech presentation\n- External cephalic version (ECV)\n- Frank breech\n- Complete breech\n- Footling breech\n- Kneeling breech\n- Perinatal mortality\n- Perinatal morbidity\n- Absolute contraindications\n- Planned caesarean section\n- Vaginal breech birth\n- Antenatal assessment\n- Multidisciplinary team\n- Continuous CTG monitoring\n- Upright position in labor\n- Pain relief options\n- Informed consent\n- Progress in labor\n- Assisted vaginal breech maneuvers\n- Semirecumbent position\n- Cord compression\n- Selective episiotomy\n- Lack of tone or color\n- Lovset's manoeuvre\n- Mauriceau-Smellie-Veit manoeuvre\n- Physiological breech birth\n- Preterm breech presentation\n- Twin pregnancy\n- Skills and drills training\n- Emergency caesarean\n- Individual risk assessment\n- Maternal factors\n- Fetal compromise",
    "CG1103 Antenatal Care & Patient Info.txt": "- Antenatal care\n- Pregnant women\n- Birthing people\n- Booking appointments\n- Antenatal risk assessments\n- Midwives\n- Obstetricians\n- Health professionals\n- Individualized care\n- Informed choices\n- Antenatal screening\n- Blood tests\n- Urine tests\n- Chlamydia & Gonorrhea Screening\n- Blood and blood products consent\n- Maternity records\n- Screening programs\n- Baby development\n- Preterm birth\n- Urinalysis\n- Proteinuria\n- UTIs\n- Consultant-led care\n- Specialist referrals\n- Safeguarding concerns\n- Mental health services\n- Domestic abuse support\n- FGM\n- Smoking cessation\n- Alcohol consumption\n- Weight management\n- Fetal growth monitoring\n- Common pregnancy problems\n- Vaginal bleeding\n- EPAC\n- Labour ward\n- Minority ethnic backgrounds\n- Migrant pregnant women\n- Language support\n- Unbiased information\n- Continuity of carer\n- Complex medical problems\n- Antenatal Clinic\n- MBRRACE-UK\n- Asymptomatic bacteriuria\n- UK National Screening Committee",
    "UHSx Maternal Death Protocol.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance:\n\n### **Immediate Actions**  \n- **Unanticipated death**  \n- **Key personnel notification**  \n- **Clear documentation (notes of actions/events)**  \n- **Avoid speculation on cause of death**  \n- **Family support & notification**  \n- **Next of kin verification**  \n- **Removal of tubes/lines (unless implicated in death)**  \n- **Coroner/procurator fiscal referral**  \n- **MNSI (Maternal and Newborn Safety Investigations) investigation**  \n- **Medical staff & authorities notification**  \n\n### **Within 24 Hours**  \n- **Key family contacts nomination**  \n- **Coroner discussion**  \n- **National Confidential Enquiry into Maternal Deaths (CEMD) reporting**  \n\n### **Within First Week**  \n- **Case review coordination**  \n- **MBRRACE-UK reporting**  \n\n### **Special Circumstances**  \n- **Death outside maternity/gynaecology department \u2192 Head of Midwifery contact**  \n- **Anticipated death \u2192 Legal guardianship for baby, care pathway review**  \n\n### **Postmortem & Death Certification**  \n- **Postmortem discussion with family**  \n- **Ockenden requirements \u2192 Specialist pathologist postmortem**  \n- **Death registration (local office for certificate issuance)**  \n\n### **Additional Critical Considerations**  \n- **Coroner involvement (body release & certification)**  \n- **Funeral arrangements support**  \n- **Neonatal team notification (if baby survives)**  \n- **Legal parental responsibility establishment**  \n- **Bereavement care (family & staff)**  \n- **Organ donation consideration**  \n- **Media management (trust communications team)**  \n- **Staff support & counseling access**  \n- **Reflection & shared learning for future care improvement**  \n- **Local & national investigations (monitoring/audit)**  \n\n### **Follow-Up & Communication**  \n- **Partner/family follow-up visits**  \n- **Ongoing information updates (cause of death, local review, inquest)**  \n\nThese terms encapsulate the essential clinical, legal, and supportive actions required in the event of a maternal or birthing parent death.",
    "SP22006 In-Patient Maternity Observations SOP.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance:  \n\n### **General Terms & Scope:**  \n- **In-Patient Maternity Observations and Monitoring SOP**  \n- **UH Sussex (University Hospitals Sussex)**  \n- **Pregnant/postpartum women/people**  \n- **Midwives, obstetricians, maternity staff**  \n- **MEOWS chart (Modified Early Obstetric Warning System)**  \n- **Maternal Observation Bundle**  \n\n### **Roles & Responsibilities:**  \n- **Registered staff accountability**  \n- **Maternity care assistants**  \n- **Medical staff & management duties**  \n- **Student midwives (mentor-assessed)**  \n- **University link tutor (feedback for deficiencies)**  \n\n### **Clinical Monitoring & Procedures:**  \n- **Baseline vital signs (on admission)**  \n- **MEOWS score calculation**  \n- **MEOWS Escalation table**  \n- **Frequency of observations (individualized & flowchart-based)**  \n- **Obstetric plan adherence**  \n\n### **Emergency & Assessment Criteria:**  \n- **Carotid pulse (if radial absent)**  \n- **ACVPU (consciousness assessment)**  \n- **Temperature measurement methods**  \n- **Emergency Team criteria:**  \n  - **Airway, Breathing, Circulation (ABC)**  \n  - **Disability, Exposure (DE)**  \n  - **Urine output & other concerns**  \n\n### **Training & Compliance:**  \n- **Staff training requirements (equipment use)**  \n- **Local processes for Maternal Observation Bundle**  \n- **Deficiency reporting & documentation**  \n\nThese terms encapsulate the core clinical, procedural, and administrative aspects of the guideline.",
    "UHSx Midwives Exemption.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance:  \n\n### **Key Terms & Keywords:**  \n1. **Midwives**  \n2. **Administration of medicines**  \n3. **Dosage**  \n4. **Legal requirements**  \n5. **Supply medicines without prescription**  \n6. **Appropriate training**  \n7. **Documentation**  \n8. **Patient safety**  \n9. **Approved medicines list**  \n10. **Safe and appropriate use**  \n11. **Settings:**  \n   - Inpatient  \n   - Home birth  \n   - Outpatient  \n   - Community  \n12. **Registered midwives (accountability)**  \n13. **Up-to-date medication knowledge**  \n14. **Student midwives (under supervision)**  \n15. **Midwife exemption**  \n16. **Key checks before administration:**  \n   - Knowledgeable about medication  \n   - Patient known to midwife  \n   - Medication appropriateness  \n   - No allergies  \n   - No contraindications  \n   - Correct dosage  \n   - Patient informed  \n17. **Authorized prescriber (if issues arise)**  \n18. **Medication documentation (trust policy)**  \n19. **Prescription Only Medicines (POM)**  \n20. **Training implications:**  \n   - Policy familiarity  \n   - Necessary training  \n   - Trust policy compliance  \n\nThese terms encapsulate the core clinical and procedural aspects of the guideline, ensuring clarity and adherence to best practices.",
    "GTG 2008 - Prevention of Entry-Related Laparoscopic Injuries.txt": "- Laparoscopic surgery\n- Complications\n- Bowel damage\n- Trocar insertion\n- Veress needle\n- Open (Hasson) approach\n- Surgeon training\n- Risks and complications\n- Intra-abdominal pressure\n- Alternative entry techniques\n- Palmer's point\n- Adhesion formation\n- Secondary ports\n- Obesity\n- Thin women\n- Nulliparous women\n- Audit standards\n- Evidence levels\n- Clinical guidelines\n- Best practice",
    "GTG 2016 - Epilepsy in Pregnancy.txt": "- Epilepsy\n- Pregnancy\n- Neurologist\n- Seizures\n- AEDs\n- Folic acid\n- Antenatal care\n- Labour\n- Postnatal care\n- Contraception\n- Disability legislation\n- WWE (Women with epilepsy)\n- Teratogenicity\n- AED polytherapy\n- Seizure deterioration\n- Eclampsia\n- Congenital malformations\n- Fetal abnormalities\n- AED exposure\n- Sodium valproate\n- Levetiracetam\n- Carbamazepine\n- Breastfeeding\n- Vitamin K\n- Postpartum hemorrhage\n- Neonates\n- Cognitive outcomes\n- Depression\n- Equality legislation\n- Multidisciplinary care\n- Neurodevelopmental effects",
    "Uptodate - Approach to the patient with pregnancy of unknown location.txt": "- Pregnancy of unknown location (PUL)\n- Transvaginal ultrasound (TVUS)\n- Intrauterine pregnancy (IUP)\n- Ectopic pregnancy\n- Differential diagnosis\n- Human chorionic gonadotropin (hCG)\n- Hemodynamic stability\n- Expectant management\n- Serial hCG measurements\n- Clinical judgment\n- Final diagnosis\n- Hemodynamically unstable\n- Proactive intervention\n- Persistent hCG elevations\n- Nonpregnancy-related causes",
    "CG18007 Newborn screening failsafes.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and category:\n\n### **Core Screening Programs & Procedures**  \n- **Newborn Bloodspot Screening (NBS)**  \n- **Newborn & Infant Physical Examination (NIPE)**  \n- **Newborn Hearing Screening Programme (NHSP)**  \n- **Failsafe procedures**  \n- **KPI (Key Performance Indicator)**  \n- **Eligible population (NHS numbers/GP registration)**  \n\n### **Critical Timeframes**  \n- **Up to 72 hours of age (NIPE KPI)**  \n- **Up to 6 weeks old (general screening window)**  \n- **Day 1, Day 5, Day 10 visits (screening checkpoints)**  \n\n### **Databases & Systems**  \n- **S4N (Screening for Newborns database)**  \n- **S4H (Hospital-based screening system)**  \n- **NIPE, NBS, NHSP databases (web-based)**  \n- **Red (Breached) baby spreadsheet (NICU tracking)**  \n- **NIPE referral follow-up spreadsheet**  \n\n### **Key Clinical Actions**  \n- **Daily checks (transfers, discharges, screenings)**  \n- **Referral/outcome export (from S4N, twice weekly)**  \n- **NICU protocol babies (tracking missed screens)**  \n- **Systmone report (NHSP, CHIS-run)**  \n- **Duplicate record merging**  \n- **Discharge emails (copied to screening administrator)**  \n- **Home births documentation**  \n- **Independent midwives (postnatal care notation)**  \n- **Repeat bloodspot notifications (Community Team Leads)**  \n- **QA (Quality Assurance) checks**  \n\n### **Conditions Screened**  \n- **Sickle cell disease**  \n- **Cystic fibrosis**  \n- **Congenital hypothyroidism**  \n- **Permanent hearing loss (NHSP)**  \n- **Eyes, heart, hips, testes abnormalities (NIPE)**  \n\n### **Consent & Ethical Considerations**  \n- **Confidentiality & data sharing**  \n- **Anonymized data for monitoring**  \n- **Parental right to decline screening**  \n- **Surrogacy and consent documentation**  \n\n### **Abbreviations & Roles**  \n- **NICU (Neonatal Intensive Care Unit)**  \n- **CHIS (Child Health Information System)**  \n",
    "UHSussex - MP048 - Shoulder Dystocia.txt": "- Shoulder Dystocia\n- Obstetric manoeuvres\n- Risk factors\n- Macrosomia\n- Maternal diabetes\n- Maternal BMI\n- Induction of labor\n- Prolonged labor\n- Prolonged second stage\n- Oxytocin augmentation\n- Assisted vaginal delivery\n- Prevention\n- Elective caesarean\n- Gestational diabetes\n- Diagnosis\n- McRoberts' manoeuvre\n- Suprapubic pressure\n- Postpartum hemorrhage\n- Vaginal tears\n- Training\n- Skills\n- Complications",
    "UHSx Conflict of Clinical Opinion UHS-CG-0004-2023.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance:\n\n### **Core Concepts & Scope**  \n- **Conflict of clinical opinion**  \n- **Patient safety**  \n- **Healthcare professionals (maternity)**  \n- **Clinical care**  \n\n### **Causes of Conflict**  \n- **Guidelines not followed**  \n- **Concerns not acknowledged**  \n- **Disagreement on diagnosis/management**  \n- **Interventions deemed necessary**  \n\n### **Essential Principles**  \n- **Timely response**  \n- **MDT (Multidisciplinary Team) approach**  \n- **Objectivity**  \n- **Patient involvement**  \n- **Effective communication**  \n- **Documentation**  \n- **Incident reporting**  \n\n### **Supportive Tools & Techniques**  \n- **MEOWS (Modified Early Obstetric Warning System)**  \n- **NEWTT (National Early Warning Trigger Tool)**  \n- **CTG (Cardiotocography) stickers**  \n- **SBAR (Situation-Background-Assessment-Recommendation)**  \n- **PAUSES (communication tool)**  \n\n### **Escalation & Resolution Process**  \n- **Senior staff involvement**  \n- **MDT discussion**  \n- **Best outcome for patient**  \n- **Incident reports (monitoring)**  \n\n### **Key Skills for Resolution**  \n- **Facilitating respectful discussions**  \n- **Refocusing on patient outcomes**  \n- **Mutual respect**  \n\n### **Safety & Accountability**  \n- **Respectful conversations**  \n- **Freedom to raise concerns**  \n- **Support from multiple sources**  \n- **On-call consultant (clinical & legal accountability)**  \n\nThese terms encapsulate the critical aspects of managing conflicts of clinical opinion while prioritizing patient safety and structured resolution processes.",
    "MP025 Day Assessment Unit (DAU).txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and clinical importance:  \n\n### **General Protocol & Scope**  \n- **Day Assessment Unit (DAU)**  \n- **Maternity Protocol (MP025)**  \n- **University Hospital Sussex NHS Trust (East)**  \n- **Midwives & Obstetricians**  \n- **Management Team**  \n- **Early Pregnancy Unit (EPU)**  \n- **Delivery Suite**  \n- **Referrals & Documentation**  \n- **BadgerNet (electronic documentation system)**  \n\n### **Clinical Assessments & Procedures**  \n- **Ultrasound Scans (USS)**  \n  - **Urgent scans**  \n  - **Indications for scans**  \n- **Fetal Assessment**  \n  - **Abdominal palpation**  \n  - **Symphysis-Fundal Height (SFH)**  \n  - **Fetal movements**  \n  - **Cardiotocography (CTG) (if \u226526 weeks)**  \n- **Maternal Observations**  \n  - **Blood Pressure (BP)**  \n  - **Pulse**  \n  - **Temperature**  \n  - **Urinalysis**  \n\n### **High-Risk Pregnancy Conditions & Management**  \n- **Vaginal Bleeding in Pregnancy**  \n- **Clinically Small for Dates**  \n  - **Umbilical Artery (UA) Doppler**  \n  - **Middle Cerebral Artery (MCA) Doppler**  \n  - **Amniotic Fluid Index (AFI)**  \n  - **Reverse or Absent End-Diastolic Flow (EDF)**  \n  - **Steroids (if preterm delivery likely)**  \n  - **Cesarean Section (C/S) if viable**  \n  - **Fetal Medicine referral**  \n- **Suspected Large for Dates (LGA)**  \n  - **Polyhydramnios**  \n  - **Glucose Tolerance Test (GTT)**  \n  - **Glycosuria**  \n  - **Consultant Antenatal Clinic (ANC) referral**  \n- **Indications for Growth Scans**  \n\n### **Labor & Delivery-Related Terms**  \n- **Induction of Labour (IOL)**  \n  - **Propess (for IOL in low-risk pregnancies)**  \n  - **Maternity Assessment Unit (MAU) for urgent IOL (<72 hours)**  \n- **Women Declining IOL at 42 weeks**",
    "GP014 Management of Patients Admitted for Major Vaginal Surgery for Pelvic Organ Prolapse (POP).txt": "Here are the most clinically significant terms and keywords extracted from the guideline, which are critical for understanding the guidance:  \n\n### **General Context:**  \n- **Brighton & Sussex University Hospitals NHS Trust**  \n- **Urogynaecology Protocol**  \n- **GP014** (Protocol identifier)  \n- **Management of Patients Admitted for Major Vaginal Surgery for Pelvic Organ Prolapse (POP)**  \n- **Review Date: 31st October 2017**  \n\n### **Key Clinical & Procedural Terms:**  \n1. **Pelvic Organ Prolapse (POP)** \u2013 Primary condition being addressed.  \n2. **Major Vaginal Surgery** \u2013 Core intervention discussed.  \n3. **Herniation of Bladder, Rectum, or Uterus** \u2013 Anatomical defects in POP.  \n4. **Failure of Support** \u2013 Underlying cause of POP.  \n5. **Vaginal Hysterectomy** \u2013 A specific surgical procedure.  \n6. **Vaginal Mesh** \u2013 A surgical intervention (note: now highly regulated due to complications).  \n7. **Pre-operative Management** \u2013 Key phase before surgery.  \n8. **Post-operative Bladder Care** \u2013 Critical recovery aspect.  \n9. **Prescription Guidelines** \u2013 Medication-related protocols.  \n10. **Follow-up Guidelines** \u2013 Post-surgical monitoring.  \n\n### **Operational & Compliance Terms:**  \n- **Protocol** (Objective standards for care)  \n- **Professional Judgement** (Allows flexibility in application)  \n- **Scope** (Applies to women undergoing major vaginal surgery for POP)  \n- **Responsibilities** (Nursing staff, Gynaecologists, Management)  \n- **Monitoring Compliance** (Ensuring adherence to guidelines)  \n\nThese terms encapsulate the essential clinical, procedural, and administrative aspects of the guideline. Would you like any further refinement or categorization?",
    "UHSx Surrogacy protocol.txt": "Here are the most clinically significant terms and keywords extracted from the clinical guideline text, critical for understanding the guidance:  \n\n### **Core Concepts and Definitions**  \n- **Surrogacy**  \n- **Straight Surrogacy**  \n- **Full Surrogacy**  \n- **Surrogate mother / surrogate**  \n- **Commissioning parents / intended parents**  \n- **Parental order**  \n- **Adoption**  \n- **Legal mother (surrogate until parental order)**  \n- **Same-sex couples**  \n- **Foreign commissioning parents**  \n\n### **Legal and Policy Framework**  \n- **Surrogacy Arrangements Act 1985**  \n- **Human Fertilisation and Embryology Bill 2007**  \n- **Parental responsibility**  \n- **Equality Act 2010**  \n- **Protected characteristics (pregnancy & maternity)**  \n- **Cafcass (Child and Family Court Advisory and Support Service)**  \n\n### **Clinical and Care Pathway**  \n- **Antenatal planning**  \n- **Labour and postnatal period**  \n- **Non-judgmental and supportive care**  \n- **Accurate record-keeping**  \n- **Handover of the baby**  \n- **Postnatal care for surrogate**  \n- **Breastfeeding (commissioning mother with medication)**  \n- **Risk assessment (biological parents)**  \n- **Mental capacity assessment (if needed)**  \n- **Termination rights (surrogate\u2019s decision)**  \n- **Discharge and transfer procedures**  \n- **Newborn screening consent**  \n- **Reporting welfare concerns**  \n\n### **Inclusive Language and Communication**  \n- **Surrogacy-inclusive language**  \n- **\"The baby\" (instead of \"your baby\" for surrogate)**  \n- **\"Your baby\" (for intended parents)**  \n- **Biological father/mother (if applicable)**  \n- **Commissioning parent (if no biological link)**  \n\n### **Data and Compliance**  \n- **Annual audit of surrogacy cases**  \n- **Parental order tracking (Cafcass data)**  \n- **Domestic vs. international surrogacy trends**  \n\nThese terms encapsulate the key medical, legal, ethical, and procedural aspects of surrogacy care as outlined in the guideline.",
    "CG12004 APH & Intrapartum Haemorrhage.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and category:\n\n### **1. Core Conditions & Definitions**  \n- **Antepartum haemorrhage (APH)**  \n- **Intrapartum haemorrhage**  \n- **Placenta praevia**  \n- **Placenta accreta (PAS)**  \n- **Placental abruption**  \n- **Vasa praevia**  \n- **Uterine rupture**  \n\n### **2. Key Risk Factors**  \n- Previous **Caesarean section (CS)**  \n- Multiple pregnancy  \n- Smoking  \n- Termination of pregnancy  \n- **Morbidly adherent placenta** (risk: placenta praevia + prior CS)  \n\n### **3. Diagnostic & Screening Terms**  \n- **Transvaginal scan (TVS)**  \n- **Ultrasound scan (USS)**  \n- **CTG (cardiotocography)**  \n- **Speculum examination** (to exclude cervical cancer)  \n- **Anomaly ultrasound** (routine screening)  \n\n### **4. Management & Interventions**  \n- **Corticosteroid therapy** (for preterm risk)  \n- **Resuscitation** (early anaesthetist involvement)  \n- **Emergency management** (acute APH/IPH)  \n- **Outpatient vs. inpatient management** (placenta praevia)  \n- **Timely delivery** (vasa praevia)  \n\n### **5. Complications & Adverse Outcomes**  \n- **Maternal:**  \n  - Anaemia  \n  - Infection  \n  - Shock  \n  - **DIC (disseminated intravascular coagulation)**  \n  - **HELLP syndrome**  \n- **Fetal:**  \n  - Death  \n  - Preterm birth  \n\n### **6. Monitoring & Follow-up**  \n- **Rescan at 32 weeks** (asymptomatic low-lying placenta)  \n- **Consultant attendance** (mandatory for CS in placenta praevia)  \n- **Documented management plans** (placenta praevia/accreta)  \n- **MEOWS (Modified Early Obstetric Warning System)**  \n\n### **7. Abbreviations (Clinically Critical)**  \n- **APH** (Antepartum haemorrhage)  \n- **PPH** (Postpartum haemorrhage)  \n- **IR** (Interventional radiology)  \n- **BP",
    "CG21010 Care of the Late Preterm Newborn Guideline.txt": "Here are the most clinically significant terms and keywords extracted from the clinical guideline text, organized by category for clarity:\n\n### **General Care for Late Preterm Infants**  \n- Late preterm infants (35-36+6 weeks gestation)  \n- Transitional care  \n- Skin-to-skin contact (uninterrupted)  \n- Vital signs stabilization  \n- Parental involvement in care  \n- Thermal care  \n- Observations (NEWTT guidelines)  \n- Neonatal Transitional Care (NTC)  \n- Red Hats (identification for NTC babies)  \n\n### **Feeding & Nutrition**  \n- Breastfeeding within first hour  \n- Hand expression of colostrum  \n- Minimum 3-hourly feeds  \n- Latch, suck, swallow assessment  \n- Breast compressions  \n- Switch feeding  \n- Paced bottle feeding  \n- Triple feeding regimen (breastfeeding, expressing, supplementing)  \n- Expressed breast milk supplementation  \n- Inefficient feeding (sleepy/reluctant to feed)  \n- Insufficient milk intake (weight loss, reduced output)  \n- Pre-feed blood glucose (BG) monitoring  \n\n### **Monitoring & Complications**  \n- Blood glucose monitoring (hypoglycemia pathway)  \n  - BG \u2265 2.6 mmol/L (3-hourly feeds)  \n  - BG 1.4\u20132.6 mmol/L (2-hourly feeds)  \n  - BG < 1.4 mmol/L (urgent pediatric review, possible NNU admission)  \n- Jaundice checks  \n- Weight monitoring (72 hours, Day 5, discharge)  \n- Weight loss \u22657% (urgent evaluation)  \n- Urine/stool output deviations  \n\n### **Admission & Discharge Criteria**  \n- Admission to TANGMERE/BRAMBER Ward (feeding/weight loss concerns)  \n- Admission to Howard/Bluefin Ward (if unwell)  \n- Immediate NNU referral (jaundice <24 hrs, severe symptoms)  \n- Discharge criteria:  \n  - Successful feeding  \n  - Temperature stability  \n  - Weight gain  \n  - Parent education (preterm care, safer sleeping, illness signs)  \n- Avoid discharge before 72 hours (increased readmission risk)  \n\n### **Emergency & Referral Pathways**  \n- Call 999 if unwell (floppy, unresponsive, hypothermic, respiratory distress)  \n- Pediatrician notification for readmission  \n- Neonatal outreach care",
    "UHSussex - Obstetric VTE - 2025.txt": "- Venous Thromboembolism (VTE)\n- Pregnancy\n- Postnatal period\n- Thrombosis\n- Antenatal\n- Thromboprophylaxis\n- Deep Vein Thrombosis (DVT)\n- Pulmonary Embolism (PE)\n- LMWH (Low Molecular Weight Heparin)\n- Joint Obstetric Haematology Clinic (JOHC)\n- Risk assessment\n- Thrombophilia\n- Antithrombin\n- Protein C\n- Protein S\n- Factor V Leiden\n- Thromboprophylaxis\n- Hyperemesis Gravidarum\n- Contraindications\n- Danaparoid\n- Fondaparinux\n- Aspirin\n- Warfarin\n- DOACs\n- Anti-embolism stockings\n- Maternal death\n- Diagnosis\n- Treatment\n- Multidisciplinary team\n- Medication\n- Enoxaparin",
    "GTG 2010 - Malaria in Pregnancy - Treatment.txt": "Keywords: malaria, pregnancy, diagnosis, treatment, evidence-based, antimalarials, intravenous artesunate, severe falciparum malaria, hospitalization, infectious diseases specialists, blood films, oral quinine, Riamet, chloroquine, primaquine, relapse, fetal distress, obstetric management, vertical transmission, thrombocytopenia, congenital malaria, compliance, safety, quinine poisoning, pharmacokinetics, toxicity, artemisinin-based combination therapy, atovaquone-proguanil, artemether-lumefantrine, chloroquine-resistant, Plasmodium falciparum, quinidine, clindamycin, placenta, sequestration, peripheral blood parasitemia, local parasitemia.",
    "GP001 - Management of Pregnancy of Unknown Location.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance on **Management of Pregnancy of Unknown Location (PUL)**:\n\n### **Key Clinical Terms & Keywords:**  \n1. **Pregnancy of Unknown Location (PUL)** \u2013 Primary diagnosis (positive pregnancy test, no ultrasound confirmation).  \n2. **Ectopic pregnancy** \u2013 Must be ruled out until location is confirmed.  \n3. **hCG levels** (human chorionic gonadotropin) \u2013 Key biomarker for monitoring and decision-making.  \n4. **Progesterone levels** \u2013 Used alongside hCG for risk stratification.  \n5. **Conservative management** \u2013 Based on symptoms and hCG trends.  \n6. **Methotrexate contraindication** \u2013 Not to be used for PUL.  \n7. **Emergency care** \u2013 Advised for severe pain or feeling unwell.  \n8. **Ultrasound** \u2013 Primary imaging tool (failure to visualize pregnancy defines PUL).  \n9. **Laparoscopy** \u2013 Potential intervention if ectopic pregnancy is suspected.  \n10. **Written information** \u2013 Must be provided to patients (emergency protocols).  \n11. **Individualized management** \u2013 Based on clinical signs/symptoms (may include repeat scans or surgery).  \n12. **Travel restrictions** \u2013 Avoid areas without immediate medical access.  \n\n### **Key Stakeholders:**  \n- **Clinicians** (Gynaecologists, Obstetricians, Midwives, Nurses) \u2013 Responsible for applying guidance.  \n- **Management Team** \u2013 Ensures protocol accessibility and updates.  \n\nThese terms encapsulate the core clinical, diagnostic, and management principles for PUL.",
    "Appendix 7 PCEA Labour Chart V2 July 2020 FINAL.txt": "- Consent\n- Anaesthetist\n- Hypotension\n- Headache\n- Multiple Attempts\n- Failure\n- Patchy Block\n- Effect on Labour\n- Mobility\n- Urinary Catheter\n- Neurological damage\n- Levobupivacaine\n- Fentanyl\n- PCEA\n- Epidural\n- Labour Analgesia\n- Entonox\n- Parenteral Opioid\n- TENS\n- Interspace\n- Tuohy\n- Paraethesia\n- LOR\n- Chl.hex\n- Initial setup\n- Extra Bolus\n- Cassette & connection check\n- IV infusion\n- Hartmann's\n- Observation Chart\n- Duration of PCEA\n- NIBP\n- Total volume infused\n- Boluses delivered\n- Boluses demanded\n- Pressure area assessment\n- Mobilisation\n- Hydration",
    "MP032 Pre Labour Rupture of Membranes Term & Pre-term.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and category:\n\n### **General Terms**  \n- **Pre-Labour Rupture of Membranes (PROM)**  \n- **Pre-term Pre-Labour Rupture of Membranes (PPROM)**  \n- **Gestational age (term vs. pre-term)**  \n- **Induction of Labour (IOL)**  \n- **Bishop score**  \n- **MDT (Multidisciplinary Team) review**  \n\n### **Assessment & Diagnosis**  \n- **Telephone/verbal risk assessment**  \n- **Clinical assessment (history, physical exam, testing)**  \n- **Sterile speculum examination**  \n- **Amnisure\u00ae test**  \n- **CTG monitoring (>26 weeks)**  \n- **BSOTS MP026 (assessment tool)**  \n\n### **Management & Interventions**  \n- **Conservative management**  \n- **Antibiotics (for PPROM)**  \n- **Antenatal corticosteroids (23-34+6 weeks)**  \n- **Magnesium sulphate (MgSO\u2084) (if delivery within 24 hours)**  \n- **Dexamethasone**  \n- **Fetal wellbeing monitoring**  \n- **Liquor volume assessment**  \n- **Timing of delivery discussions**  \n\n### **Gestational Age-Specific Considerations**  \n- **<22 weeks (maternal wellbeing prioritized, poor neonatal outcomes)**  \n- **22-24+6 weeks (neonatal team discussion, active management)**  \n- **24+6\u201333+6 weeks (EFW/presentation, steroids, MgSO\u2084)**  \n- **34\u201336+6 weeks (2-weekly scans, EFW/presentation)**  \n- **>37 weeks (term PROM, IOL considerations)**  \n\n### **Monitoring & Follow-Up**  \n- **4-weekly scans (unless concerns for fetal movements)**  \n- **2-weekly scans (34 weeks until delivery)**  \n- **Intrapartum monitoring & resuscitation planning**  \n\n### **Guidelines & References**  \n- **NICE guidelines**  \n- **RCOG Green Top Guideline**  \n\nThese terms encapsulate the critical clinical, diagnostic, and management aspects of both **term PROM** and **PPROM**, ensuring a structured understanding of the guidance.",
    "GTG 2014 - Endometrial Hyperplasia.txt": "- Endometrial hyperplasia\n- Risk factors\n- WHO classification\n- Diagnosis\n- Surveillance\n- Endometrial sampling\n- Hysteroscopy\n- Progestogens\n- LNG-IUS\n- Surgical management\n- Atypical hyperplasia\n- Total hysterectomy\n- Fertility preservation\n- HRT\n- Breast cancer\n- Endometrial polyp\n- Disease regression\n- PCOS\n- Tamoxifen\n- Endometrial ablation\n- Biomarkers\n- Weight loss\n- Follow-up biopsies\n- Endometrial destruction\n- Tissue regeneration\n- Endometrial thickness\n- Transvaginal ultrasound\n- Ovulation\n- Regression rate\n- Adverse effects\n- Endometrial surveillance\n- Laparoscopic hysterectomy\n- Endometrial ablation\n- Annual endometrial biopsies\n- Fertility-sparing therapy\n- Assisted reproduction\n- Referral to fertility specialist\n- Bariatric surgery\n- Ovarian cysts\n- Inhibin\n- Granulosa cell tumor\n- Venous thromboembolism\n- Levonorgestrel\n- Heavy menstrual bleeding\n- Efficacy\n- Prediction of regression and relapse\n- Mortality\n- Fertility-sparing therapy\n- American College of Obstetricians and Gynecologists\n- Practice Bulletin\n- NICE clinical guideline\n- IVF-ET outcomes\n- Hormone replacement therapy",
    "CG22005 Management of Weight Loss in Neonates.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance:\n\n### **Core Clinical Concepts**  \n- **Weight loss in neonates**  \n- **Postnatal weight management**  \n- **Feeding plans**  \n- **Breastfeeding assessment**  \n- **Top-up feeds**  \n- **Supplementation**  \n- **Weight loss percentage calculation**  \n- **Glucose monitoring**  \n- **Septic screen (if concerns)**  \n- **EBM (expressed breast milk) as first-line top-up**  \n\n### **Key Measurements & Calculations**  \n- **Birth weight**  \n- **Weight loss (%)** (formula: *Birth weight \u2013 current weight / Birth weight \u00d7 100*)  \n- **Weight gain target (>20g/day)**  \n- **Volumes required per kg (24-hour intake)**  \n- **Intake amounts per feed (first 96 hours)**  \n\n### **Clinical Monitoring & Interventions**  \n- **Regular weighing (birth, subsequent weights, pre-discharge)**  \n- **Infant Feeding Team support**  \n- **Feeding chart documentation**  \n- **Follow-up in community**  \n- **Audit process for weight loss management**  \n\n### **Risk Factors & Special Considerations**  \n- **Mothers/birthing parents needing additional support**  \n- **Factors impacting feeding & weight loss**  \n- **Jaundice (NICE guidelines)**  \n- **Faltering growth (NICE guidelines)**  \n- **Blood profile normalization**  \n\n### **Stakeholders & Compliance**  \n- **Midwives, neonatal nurses, paediatricians, obstetricians**  \n- **NICE guidelines (jaundice, postnatal care, faltering growth)**  \n- **Maternity notes audit (re-admissions for weight loss/feeding issues)**  \n\nThese terms encapsulate the essential clinical, procedural, and monitoring aspects of neonatal weight loss management as per the guideline.",
    "CG17003 NIPE guideline.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and category:  \n\n### **1. Screening Program & Timing**  \n- **Newborn Infant Physical Examination (NIPE)**  \n- **Congenital abnormalities** (eyes, heart, hips, testes)  \n- **72 hours of birth** (initial screening)  \n- **6 to 8 weeks of age** (follow-up screening)  \n- **NIPE-trained midwife/paediatric doctor**  \n- **SCBU (Special Care Baby Unit)**  \n- **Postnatal Ward**  \n\n### **2. Key Responsibilities & Procedures**  \n- **Verbal consent** (from mother/birthing parent)  \n- **Professional judgment**  \n- **Record keeping** (S4N, Personal Child Health Record)  \n- **Referral pathways**  \n- **False positives vs. missed screening**  \n- **Parental presence & explanation**  \n\n### **3. Physical Examination Components**  \n#### **Hips (Developmental Hip Dysplasia - DDH)**  \n- **Ortolani and Barlow maneuvers**  \n- **Hip ultrasound** (if positive screening)  \n- **Risk factors** (breech, family history, multiple pregnancies)  \n- **Leg length symmetry, knee levels, hip abduction**  \n\n#### **Heart (Congenital Heart Disease - CHD)**  \n- **Critical Congenital Heart Disease (CCHD)**  \n- **Duct-dependent conditions**  \n- **Auscultation areas** (pulmonary, aortic, tricuspid, mitral, coarctation)  \n- **Murmurs, extra heart sounds**  \n- **Tachypnoea, cyanosis, weak femoral pulses**  \n- **Pulse oximetry (<95%, >2% arm-leg difference)**  \n- **12-lead ECG** (if murmur present)  \n\n#### **Nervous System & Reflexes**  \n- **Moro reflex** (abnormal = CNS concern)  \n- **Limb tone & movements**  \n\n#### **Spinal Abnormalities**  \n- **Spina bifida (myelocoele/meningomyelocoele)**  \n- **Sacral sinuses, spinal hemangiomas**  \n- **Spinal X-ray & ultrasound**  \n\n#### **Other Key Findings**  \n- **Talipes (fixed vs. non-fixed)**  \n- **Ambiguous genitalia** (urg",
    "MP009 Management of HIV in pregnancy and Postpartum Period.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by section for clarity:\n\n### **General Terms**  \n- HIV in pregnancy  \n- Neonatal period  \n- Vertical transmission (mother-to-child transmission)  \n- Antiretroviral therapy (ART)  \n- Viral load (VL)  \n- CD4 count  \n\n### **Preconception Management**  \n- Lifestyle factors  \n- Folic acid supplementation  \n- Vitamin D supplementation  \n- Undetectable viral load before conception  \n\n### **Conception in Serodifferent Couples**  \n- Zero risk of transmission (U=U: Undetectable = Untransmittable)  \n- Adherence to treatment  \n\n### **Screening & Monitoring**  \n- Mental health screening  \n- Sexually transmitted infections (STIs)  \n- Bacterial vaginosis  \n- Routine ultrasound  \n- Invasive prenatal diagnostic testing (deferred until HIV status known)  \n\n### **Antiretroviral Therapy (ART) in Pregnancy**  \n- Combination ART (cART)  \n- Elite controllers (still require ART)  \n- Resistance testing before starting ART  \n- Switch from D4T/DDI to other ARVs  \n- Zidovudine monotherapy (not recommended)  \n- Short-term ART (not recommended)  \n- Transplacental fetal loading  \n\n### **Intrapartum Management**  \n- Emergency ART initiation  \n- Mode of delivery (vaginal vs. caesarean section based on VL)  \n- Spontaneous rupture of membranes (SROM)  \n- Delivery within 24 hours if term pre-labour SROM  \n- Peri-operative antibiotics for CS  \n- Intrapartum pyrexia (antibiotics if present)  \n\n### **Neonatal Management**  \n- Neonatal post-exposure prophylaxis (PEP)  \n- PEP within 4 hours of delivery  \n- PEP regimen based on maternal VL and ART duration  \n- Formula feeding (recommended in high-income countries)  \n- Breastfeeding (allowed if undetectable VL + strict monitoring)  \n- Infant HIV testing (serial testing based on risk)  \n\n### **Postpartum & Long-term Care**  \n- Lifelong ART continuation  \n- Postnatal depression screening  \n- Future contraception planning  \n- Annual cervical screening  \n\n### **Co-infections & Additional Considerations**  \n- Hepatitis B (HBV) neonatal PEP  \n- Hepatitis C (HCV) (treatment not recommended in pregnancy)  \n- Partner and child testing (if newly diagnosed in pregnancy",
    "UHS Anaemia in pregancy UHS-CG-0008-2023 (3).txt": "- Anaemia\n- Pregnancy\n- Iron deficiency\n- Hemoglobin levels\n- Symptoms\n- Consequences\n- Screening\n- Serum ferritin\n- Red cell indices\n- Dietary advice\n- Iron-rich foods\n- Oral iron supplementation\n- Oral iron replacement therapy\n- Elemental iron dose\n- Side effects\n- Monitoring\n- Intravenous iron therapy\n- Contraindications\n- Ferric Derisomaltose\n- Iron staining\n- Hypersensitivity reactions\n- Postpartum complications\n- Blood transfusion\n- Consent",
    "CG12029 PPH guideline.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by category for clarity:\n\n### **Core Concepts**  \n- Postpartum haemorrhage (PPH)  \n- Primary PPH  \n- Secondary PPH  \n- Massive obstetric haemorrhage (MOH)  \n- Blood loss volume definitions  \n\n### **Prevention Strategies**  \n- Risk factor identification  \n- Prophylactic uterotonics  \n- Tranexamic acid (TXA)  \n- Carbetocin (long-acting oxytocin derivative)  \n\n### **Management Principles**  \n- Early intervention  \n- Multidisciplinary team approach  \n- Emergency calls for PPH/MOH  \n- Assessment and resuscitation  \n- Shock recognition (late sign)  \n\n### **Pharmacological Interventions**  \n- Oxytocin  \n- Carbetocin (vs. oxytocin comparison)  \n- Tranexamic acid (role in active bleeding vs. prevention)  \n- Fresh frozen plasma (FFP)  \n- Platelet transfusion  \n- Factor VIIa (avoidance in acute management)  \n\n### **Mechanical & Surgical Interventions**  \n- Examination under anaesthesia (EUA)  \n- Intrauterine balloon tamponade  \n- Haemostatic brace suturing  \n- Aortic compression  \n- Stepwise uterine devascularization  \n- Internal iliac (hypogastric) artery ligation  \n- Selective arterial embolization  \n- Hysterectomy  \n\n### **Monitoring & Resuscitation**  \n- Serum lactate measurement  \n- Base deficit monitoring  \n- Hematocrit and hemoglobin (Hb) levels  \n- Blood transfusion protocols  \n- Intraoperative cell salvage  \n\n### **Causes & Risk Factors (The Four T\u2019s)**  \n1. **Tone**  \n   - Uterine atony  \n   - Overdistention of the uterus  \n   - Intra-amniotic infection  \n   - Uterine distortion  \n\n2. **Tissue**  \n   - Retained products of conception  \n   - Retained placenta (cotyledon/succenturiate lobe)  \n   - Placenta accreta/percreta  \n\n3. **Trauma**  \n   - Genital tract lacerations (cervix, vagina, perineum)  \n   - Uterine rupture  \n   - Uterine inversion  \n\n4. **Thrombin**  \n   - Coagulation disorders (pre-existing or acquired)  \n\n### **Communication & Aftercare**  \n- Patient and birthing partner communication  \n- Documentation accuracy  \n-",
    "MP044 Failed intubation in the Obstetric patient SR.txt": "Here are the most clinically significant terms and keywords extracted from the guideline text, which are critical for understanding the guidance:  \n\n### **General Terms:**  \n- **Failed intubation**  \n- **Obstetric patient**  \n- **General anesthesia**  \n- **Peri-partum period**  \n- **Protocol**  \n- **Professional judgment**  \n\n### **Key Physiological & Clinical Considerations:**  \n- **Rapid oxygen desaturation**  \n- **Increased aspiration risk**  \n- **Difficult airway**  \n- **Maternal and fetal status**  \n- **Physiological changes in pregnancy**  \n\n### **Guidelines & Algorithms:**  \n- **OAA/DAS Guidelines (2015)**  \n- **Algorithmic approach**  \n- **Unanticipated difficult airway**  \n\n### **Responsible Personnel:**  \n- **Anaesthetists**  \n- **Midwives**  \n- **Obstetricians**  \n- **Management Team**  \n\n### **Protocol & Governance:**  \n- **Trust and National recommendations**  \n- **Review and accessibility**  \n\nThese terms encapsulate the critical aspects of managing failed intubation in obstetric patients, including physiological risks, clinical responsibilities, and guideline adherence.",
    "UAE BSUH guidelines September 2016.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance on **Uterine Artery Embolisation (UAE)**:\n\n### **Indications for UAE:**  \n- **Symptomatic fibroids**  \n- **Lifestyle-altering symptoms**  \n- **Heavy menstrual bleeding**  \n- **Severe dysmenorrhoea**  \n- **Anaemia**  \n- **Fibroid-related pain**  \n- **Mass effect (bladder/bowel compression)**  \n\n### **Contraindications:**  \n- **Viable pregnancy**  \n- **Gynaecological malignancy**  \n- **Active uterine infection**  \n\n### **Pre-Procedure Requirements:**  \n- **Gynaecological review**  \n- **Diagnosis confirmation**  \n- **Discussion of alternative treatments**  \n\n### **Procedure Details:**  \n- **Embolisation of uterine arteries**  \n- **Arterial closure devices**  \n\n### **Post-Procedure Care:**  \n- **Complication monitoring**  \n- **Pain management**  \n- **Follow-up MRI**  \n- **Prompt addressing of concerns**  \n\n### **Outcomes:**  \n- **High technical success rate**  \n- **Satisfactory clinical outcomes**  \n\nThese terms encapsulate the essential clinical, procedural, and management aspects of UAE for fibroids.",
    "CG1134 Postnatal Care.txt": "- postnatal women\n- newborn babies\n- postnatal care\n- maternal care\n- birthing parent care\n- discharge\n- physical well-being\n- emotional well-being\n- potential complications\n- support\n- education\n- perineal healing\n- lochia\n- inpatient care\n- community care\n- postnatal visiting\n- baby care\n- Lullabytrust\n- 'red flags'\n- jaundice\n- Neonatal Jaundice\n- assessments\n- Transfer of Care form\n- health visitor\n- complex needs\n- language support\n- follow-up appointments\n- readmissions\n- audit\n- healthcare professionals\n- out of area discharge\n- checklist",
    "UHSussex - Cord Prolapse Protocol.txt": "- Cord prolapse\n- Umbilical cord\n- Ruptured membranes\n- Breech presentation\n- Risk factors\n- Long cord\n- Artificial rupture of membranes\n- Immediate action\n- Bladder filling\n- Cord compression\n- Category 1 caesarean birth\n- Fetal heart rate patterns\n- Labor ward\n- Maternity care staff\n- Clinical incident forms\n- Audits\n- Postnatal debriefing\n- Post-traumatic stress disorder\n- Protocol version control\n- Approval groups\n- Guideline group\n- Governance group\n- Medicines committee\n- Clinical document approval group",
    "GP015  Management of Patients Admitted for Vaginal Wall Repair.txt": "Here are the most clinically significant terms and keywords extracted from the guideline text, critical for understanding the guidance:\n\n### **General Terms:**  \n- **Brighton & Sussex University Hospitals NHS Trust**  \n- **Urogynaecology Protocol**  \n- **GP015**  \n- **Vaginal Wall Repair**  \n\n### **Key Sections & Principles:**  \n- **Key Principles**  \n- **Scope**  \n- **Responsibilities**  \n- **Objective Standards**  \n\n### **Clinical Focus Areas:**  \n1. **Vaginal wall prolapse**  \n   - **Pre-operative management**  \n   - **Post-operative bladder care**  \n   - **Post-operative prescription**  \n   - **Follow-up**  \n\n### **Compliance & Monitoring:**  \n- **Monitoring compliance**  \n\nThese terms encapsulate the core aspects of the guideline, including the clinical condition (vaginal wall prolapse), procedural phases (pre-operative, post-operative), key care components (bladder care, prescriptions), and governance (compliance monitoring).",
    "NICE Guidance - 2023 - Ectopic.txt": "- Ectopic pregnancy\n- Miscarriage\n- Early pregnancy\n- Diagnosis\n- Management\n- Healthcare professionals\n- Pregnancy test\n- Ultrasound scans\n- Serum hCG measurements\n- Antenatal care\n- Methotrexate\n- Surgical treatment\n- Laparoscopic surgery\n- Salpingectomy\n- Anti-D immunoglobulin prophylaxis\n- Outpatient care\n- Medical management\n- Psychological impact\n- Emotional impact\n- Counseling\n- Quality of life\n- Maternal mortality\n- Substandard care\n- Early pregnancy loss\n- Adverse effects\n- Psychological morbidity\n- Deaths\n- Women's perspective\n- Emotional recovery\n- Expectant management\n- Cost savings\n- Standardizing practices\n- Progestogens\n- NHS\n- Admissions\n- Adnexal mass\n- Rh-negative women\n- Emergency care\n- Clinical review\n- Intrauterine pregnancy\n- Viable pregnancy\n- Support services\n- Referral\n- Risk factors\n- Complications\n- Symptoms\n- Signs\n- Recommendations\n- Guideline",
    "SP21003 Process for checking daily safety standards SOP.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance:\n\n### **Core Concepts & Scope**  \n- **Standard Operating Procedure (SOP)**  \n- **Maternity staff** (Midwives, Maternity assistants, Maternity managers)  \n- **Safety standards**  \n- **Daily checks**  \n- **UH Sussex West (University Hospitals Sussex West)**  \n\n### **Key Responsibilities**  \n- **Midwives**: Follow SOP, apply professional judgment  \n- **Management**: Ensure SOP review, accessibility  \n\n### **Safety Standards to Check**  \n- **Equipment checks**  \n- **Fire safety checks**  \n- **Cleaning checks**  \n- **Drug & treatment room checks**  \n- **Other checks**  \n\n### **Documentation & Compliance**  \n- **Documented compliance**  \n- **Laminate/electronic handover board**  \n\n### **Action for Non-Compliance**  \n- **Rectify lapses**  \n- **Escalate to matron** (if no immediate solution)  \n- **Midwife in charge** (initial escalation point)  \n\nThese terms encapsulate the essential clinical, procedural, and accountability aspects of the guideline.",
    "CG1145 Fetal Abnormality Guideline (including fetal echo referral criteria).txt": "- Fetal Abnormality Guideline\n- Effective communication\n- Referral\n- Fetal abnormalities\n- Optimal care\n- Antenatal women\n- Management\n- Inconclusive scan\n- Abnormal scan\n- Fetal medicine referral criteria\n- Continuing care\n- Designated midwife care\n- Labor ward staff\n- Pediatric team\n- Obstetric team\n- Postnatal care\n- Birth outcomes\n- Follow-up appointments\n- Confirmed fetal anomalies\n- Departmental meetings\n- National Congenital Anomaly and Rare Disease Registration Service\n- Fetal echo\n- Cardiac abnormalities\n- Maternal anti-Ro/La antibodies\n- Diabetes\n- Routine anomaly scan\n- Fetal medicine early anomaly scan\n- Teratogenic drugs\n- KPI data\n- Public Health England",
    "MP001 Provision and Schedules of Antenatal Care.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by category for clarity:\n\n---\n\n### **General Principles & Scope**  \n- Antenatal care  \n- Professional judgment  \n- Childbearing service users  \n- Midwives & Obstetricians  \n\n### **Key Processes & Timelines**  \n- Booking visit (by 10 weeks)  \n- Late bookers (>20 weeks)  \n- Concealed pregnancy (immediate referral to Children's Social Care)  \n- Migrant service users (urgent GP referral)  \n\n### **Risk Assessment & Referrals**  \n- Pre-eclampsia risk (high/moderate/low)  \n- Neonatal risk factors (Neonatal Consultant referral)  \n- VTE (venous thromboembolism) risk  \n- BMI calculation  \n- Safeguarding referrals  \n- Anaesthetic Clinic referrals (e.g., airway problems, drug allergies)  \n- Placenta praevia  \n- Raised BMI (>50)  \n\n### **Screening & Diagnostics**  \n- Badgernet app & pre-booking questionnaire  \n- GTT (glucose tolerance test) for high-risk  \n- MSU (midstream urine)  \n- Chlamydia screening (<25 years)  \n- Downs syndrome/Edwards/Patau screening  \n- 20-week anomaly scan  \n- Hb (<11: iron investigation)  \n- Rh-negative (Anti-D implications)  \n- Carbon monoxide screening  \n- Symphysis-Fundal Height (SFH) measurement  \n- Growth scans (30/34 weeks, polyhydramnios)  \n\n### **Clinical Monitoring**  \n- BP & proteinuria checks  \n- Fetal movements (FM) monitoring  \n- Malpresentation palpation  \n- Membrane sweep (post-term)  \n- IOL (induction of labour)  \n\n### **Patient Education & Support**  \n- Perineal care (3rd/4th degree tears)  \n- Interpreter services  \n- Home birth/water birth/parentcraft classes  \n- Breastfeeding/newborn care/vitamin K  \n- Postnatal depression awareness  \n\n### **Special Populations & Conditions**  \n- IVDU/ex-IVDU (One Stop referral)  \n- Hepatitis C contact  \n- Sex workers/ex-prisoners  \n- Sexual assault  \n- Multiple pregnancies  \n- Prolonged pregnancy management  \n\n### **Documentation & Systems**  \n- BadgerNet records  \n- Previous pregnancy notes retrieval  \n- Named Midwife continuity  \n\n---\n\nThese terms encapsulate the",
    "MP055 Perinatal Collapse in Pregnancy & Puerperium.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance:\n\n### **General Protocol & Scope**  \n- Perinatal collapse  \n- Pregnancy & puerperium  \n- Maternal collapse  \n- Life-threatening event  \n- Prompt resuscitation  \n- Modified Early Obstetric Warning System (MEOWS)  \n- Multidisciplinary team  \n\n### **Immediate Management & Resuscitation**  \n- Basic life support (BLS)  \n- Advanced life support (ALS)  \n- ABCDE approach  \n- Oxygen administration  \n- Venous access  \n- Fluid resuscitation  \n- Chest compressions  \n- Intubation (cuffed endotracheal tube)  \n- Left uterine displacement (aortocaval compression)  \n- Delivery of fetus & placenta (within 5 minutes if cardiac arrest)  \n\n### **Causes of Maternal Collapse**  \n- Major obstetric haemorrhage  \n  - Postpartum haemorrhage (PPH)  \n  - Placenta praevia  \n  - Placental abruption  \n  - Uterine rupture  \n  - Ectopic pregnancy  \n- Cardiovascular events  \n- Thromboembolism  \n- Amniotic fluid embolism  \n- Sepsis/infection  \n- Drug toxicity  \n- Eclampsia  \n- Intracranial haemorrhage  \n- Anaphylaxis (1\u20133.5 per 100,000)  \n- Hypoglycaemia  \n- Hyponatraemia  \n- Metabolic/electrolyte disturbances  \n\n### **Key Clinical Roles & Responsibilities**  \n- Midwives  \n- Obstetricians  \n- Anaesthetists  \n- Haematologists (blood disorders)  \n- Microbiologists (sepsis/antibiotics)  \n- ITU consultants  \n- Specialist clinicians (when needed)  \n\n### **Monitoring & Early Recognition**  \n- MEOWS chart (antenatal/postnatal)  \n- Regular observations  \n- Clinical deterioration  \n- Fast bleep Obstetric Registrar  \n\n### **Treatment & Interventions**  \n- Adrenaline (anaphylaxis)  \n- Chlorphenamine (anaphylaxis)  \n- Hydrocortisone (anaphylaxis)  \n- High-flow oxygen  \n- Manual uterine displacement (>20 weeks)  \n\n### **Post-Collapse Care & Follow-Up**  \n- Debriefing (woman, family, staff)  \n- Post-traumatic stress disorder (PTSD)  \n- Postnatal depression  \n- Tocophobia (fear of childbirth)  \n- Incident reporting  \n- Annual multidisciplinary training (ABLS,",
    "CG14004 Miscarriage Guideline.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance:\n\n### **1. Core Clinical Concepts**  \n- **Miscarriage** / **Early pregnancy loss**  \n- **Pain and/or bleeding in early pregnancy** (up to 18 weeks)  \n- **Threatened miscarriage**  \n- **Incomplete miscarriage**  \n- **Complete miscarriage**  \n- **Retained products of conception (RPOC)**  \n- **Expectant management**  \n- **Medical management** (Misoprostol, Mifepristone)  \n- **Surgical management** (if required)  \n- **Ultrasound scan (USS)** (6-12 weeks gestation)  \n- **Transvaginal scan**  \n- **Crown Rump Length (CRL)**  \n- **Gestational sac diameter (GSD)**  \n- **Yolk sac presence/absence**  \n- **Fetal heart movement**  \n- **Haematoma (size/location)**  \n- **Free fluid (measurement)**  \n- **Adnexal masses/tenderness**  \n- **Corpus luteum**  \n\n### **2. Key Clinical Assessments & Actions**  \n- **Confirm intrauterine pregnancy**  \n- **Diagnosis and classification of miscarriage on USS**  \n- **Assess for signs of shock/severe bleeding**  \n- **Seek advice if findings are equivocal**  \n- **Provide clear conclusions in scan reports**  \n- **Offer outpatient medical management (\u22649 weeks)**  \n- **Repeat misoprostol dose if needed (48-72 hrs)**  \n- **Urine pregnancy test post-treatment (3-4 weeks)**  \n- **Contraindications to medical management**  \n- **Risks: infection, hemorrhage, retained products**  \n\n### **3. Patient Management & Communication**  \n- **Verbal and written information**  \n- **Sensitive disposal of fetal remains**  \n- **Support at home during medical management**  \n- **Return with passed products for disposal**  \n- **Follow-up if pregnancy test remains positive**  \n\n### **4. Roles & Referral Processes**  \n- **Early Pregnancy Assessment Unit (EPAC)**  \n- **Referral pathways (email, phone)**  \n- **Triage by EPAC nurse**  \n- **Do not promise same-day scan/review**  \n- **Required referral details (LMP, DOB, symptoms)**  \n\n### **5. Append",
    "PP14002 Newborn Blood Spot Screening.txt": "Here are the most clinically significant terms and keywords extracted from the Newborn Blood Spot Screening SOP, critical for understanding the guidance:  \n\n### **Core Clinical Terms & Keywords**  \n1. **Newborn Blood Spot Screening (NBS)**  \n2. **Eligible Population** (NHS number, GP registration, babies born abroad)  \n3. **Antenatal Notification** (family history of metabolic conditions)  \n4. **Screening Pathway** (Well baby, Premature Neonate)  \n5. **Results Pathway** (CHIS notification, normal/abnormal results, clinician notification)  \n6. **Governance & Reporting** (KPIs, screening incidents, root cause analysis)  \n7. **Movers in/out of area** (blood spot tracking, transfer procedures)  \n8. **Training & Avoidable Repeats** (staff competency, retraining)  \n9. **Newborn Outcome Solutions** (SCT database, lead consultants)  \n10. **Parental Declines** (individual vs. group IMD declines, documentation)  \n11. **Transfused Neonate** (pre-transfusion sampling)  \n12. **Repeat Blood Spots** (clinical vs. avoidable repeats, 28-day spot)  \n13. **Quality Assurance** (good quality samples, accurate results)  \n14. **Referral Pathways** (specialist referrals based on condition)  \n15. **NICU Procedures** (NBS FS record transfers, Badgernet checks)  \n16. **Data Management** (NBS FS updates, record deletion, manual corrections)  \n17. **KPI Monitoring** (proportion of conclusive results, avoidable repeats)  \n18. **Screening Incidents** (Datix reporting, SIAF escalation)  \n19. **Multilingual Support** (information in preferred language)  \n20. **CHT Screening** (suspicion-based pathways)  \n\n### **Key Abbreviations & Systems**  \n- **NHS Newborn Blood Spot (NBS) Programme**  \n- **CHIS** (Child Health Information System)  \n- **NBS FS** (Newborn Blood Spot Failsafe System)  \n- **IMDs** (Inherited Metabolic Diseases)  \n- **CHT** (Congenital Hypothyroidism)  \n- **SCT** (Sickle Cell & Thalassaemia)  \n- **KPIs** (Key Performance Indicators)  \n- **",
    "Consultant Midwife SOP.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance:\n\n### **Key Clinical Concepts & Guidance**  \n1. **Consultant Midwife Clinic** \u2013 Central support for non-standard care.  \n2. **Non-standard care** \u2013 Includes **twin births**, **VBAC (Vaginal Birth After Cesarean)**, and deviations from guidelines.  \n3. **Referral criteria** \u2013  \n   - **Routine referrals** (before **36 weeks**)  \n   - **Late referrals** (postdates, unexpected complications)  \n   - **Urgent referrals** (postdates declining induction, undiagnosed breech, labor complications)  \n4. **Postdates pregnancy** \u2013 Key trigger for urgent referral if induction declined.  \n5. **Unexpected complications** \u2013 Includes **undiagnosed breech presentation** in labor.  \n\n### **Risk Assessment & Care Planning**  \n6. **Risk assessment** \u2013 Begins at **booking visit**, reassessed at every contact.  \n7. **Antenatal, intrapartum, postnatal periods** \u2013 Continuous monitoring for deviations.  \n8. **\"Amber\" and \"Red\" level clients** \u2013 Require dual referral to **Consultant Midwife & Consultant Obstetrician**.  \n9. **Birth preferences** \u2013 Personalized care discussions if inconsistent with recommendations.  \n\n### **Referral Process & Documentation**  \n10. **Urgent referral pathway** \u2013 Direct contact via **telephone** if Consultant Midwife unavailable (escalate to **labor ward lead/coordinator**).  \n11. **Documentation systems** \u2013  \n   - **Badgernet** (Brighton/Hayward Heath)  \n   - **Handheld notes** / **Hospital maternity notes** / **MIS** (Worthing/Chichester)  \n12. **Referral form steps** \u2013 Mandatory fields:  \n   - **\"Reason for Referral\"** (select \"Consultant Midwife input needed\")  \n   - **\"Additional notes\"** (detailed free text)  \n   - **Digital signature** (Badgernet login)  \n\n### **Professional Practice & Escalation**  \n13. **Scope of practice uncertainty** \u2013 Midwives must escalate to **Consultant Midwife/Obstetrician**.  \n14. **Multidisciplinary team (MDT)** \u2013 Essential for communication in complex cases.  \n15. **Triage timeline** \u2013",
    "UHSussex - MP059 - Baby Abduction Policy.txt": "- Baby abduction policy\n- Brighton and Sussex NHS Trust\n- Safe environment\n- Baby and infant safety\n- Prevent abduction\n- Suspected or actual abduction\n- Maternity staff\n- Portering staff\n- Security staff\n- Switchboard staff\n- Professional judgement\n- Immediate action\n- Informing security\n- Contacting police\n- Coordinating response\n- Private area\n- Identification bands\n- Reassure mothers\n- Media inquiries\n- Training\n- Monitoring\n- Audited\n- Human Rights FREDA principles",
    "Penthrox (use of) in ambulatory gynaecology guideline.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance:\n\n### **Clinical Guidance & Use of Penthrox**  \n- **Penthrox (methoxyflurane)**  \n- **Pain relief in adults**  \n- **Ambulatory gynaecology**  \n- **Gynaecological procedures**  \n- **Contraindications**  \n- **Side effects**  \n- **Warnings**  \n- **Dosage information**  \n- **Staff training**  \n- **Prescribing guidelines**  \n- **Administration guidelines**  \n- **Storage & disposal procedures**  \n- **Monitoring effectiveness**  \n- **Pain scores**  \n- **Procedure rates**  \n\n### **Dissemination & Implementation**  \n- **Outpatient hysteroscopy**  \n- **Colposcopy**  \n- **GOPD (Gynaecology Outpatient Department)**  \n- **USC clinics (Unscheduled Care?)**  \n- **Clinical governance**  \n- **Interactive teaching session**  \n- **CPD (Continuous Professional Development)**  \n- **Gynaecology matron oversight**  \n- **Specialist nurses**  \n- **SCPs (Specialist Care Practitioners)**  \n- **AHPs (Allied Health Professionals)**  \n- **OneDrive / Intranet access**  \n- **Guideline version control**  \n- **CDAG (Clinical Documents Approval Group)**  \n\nThese terms capture the essential clinical, procedural, and administrative aspects of the guideline. Let me know if you need further refinement.",
    "GP013 Management of patients admitted for urinary incontinence surgery N.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by section for clarity:\n\n### **Key Principles & Scope:**  \n- Protocol  \n- Measurable standards  \n- Professional judgement  \n- Women  \n- Urinary incontinence surgery  \n\n### **Urinary Incontinence (Epidemiology & Impact):**  \n- 15-30% of women over 65  \n- Up to 50% of nursing home residents  \n- Adverse effects on quality of life  \n\n### **Pre-Operative Management:**  \n- Fasting from midnight  \n- Routine observation  \n- Enhanced recovery programme  \n\n### **Post-Operative Bladder Care:**  \n- Catheter (not usually required)  \n- Pack insertion (not usually required)  \n- Pass urine before discharge  \n- Monitor for retention symptoms  \n\n### **Management of PVR/TWOC:**  \n- Post-void residual (PVR)  \n- Assess within 4 hours post-surgery  \n- High residuals \u2192 catheterization  \n- TWOC (Trial Without Catheter, implied)  \n\n### **Post-Operative Prescription & Follow-Up:**  \n- Eat and drink once conscious  \n- Discharge criteria: passing urine, feeling well  \n- Follow-up in Urogynecology clinic  \n\nThese terms capture the essential clinical actions, patient criteria, and procedural steps necessary for adhering to the guideline. Let me know if you'd like any refinements!",
    "MP069 Care of the Newborn.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by category for clarity:\n\n### **General Newborn Care**  \n- Warmth  \n- Heat loss prevention  \n- Skin-to-skin contact  \n- Postnatal care  \n- General wellbeing monitoring  \n- Feeding  \n- Development  \n- Examinations & screenings  \n- Bathing  \n- Umbilical stump care  \n- Bonding  \n- Recognizing illness  \n- Safer sleeping  \n- Smoke-free environment  \n- Vitamin D supplements  \n- Immunizations  \n\n### **Immediate Post-Birth Actions**  \n- Meconium-stained liquor  \n- Neonatologist  \n- Advanced neonatal nurse practitioner  \n- Well babies  \n- Significant meconium staining  \n- Hypothermia  \n\n### **Jaundice Management**  \n- Visual inspection for jaundice  \n- Bilirubin levels  \n- Phototherapy  \n- Exchange transfusion  \n- Treatment threshold graphs  \n- Supine position  \n- Temperature monitoring  \n- Hydration support  \n- Lactation support  \n\n### **Hypoglycaemia**  \n- Low blood glucose  \n- Irritability  \n- Poor feeding  \n- Seizures  \n- Glucose gel administration  \n\n### **Neonatal Infections & Sepsis**  \n- Early/late neonatal infections  \n- Risk factors  \n- Antibiotic treatment  \n- Cefotaxime  \n- Blood culture  \n- GBS (Group B Streptococcus)  \n- Meningitis (GBS/Gram-negative)  \n- Microbiology Consultant  \n\n### **Risk Factors for Early Onset Neonatal Sepsis (EONS)**  \n- **Maternal risk factors:**  \n  - Sepsis  \n  - Chorioamnionitis  \n  - Previous baby with invasive GBS  \n  - GBS colonization  \n  - Bacteriuria  \n  - Rupture of membranes >24h (PROM)  \n  - Fever before/during birth  \n  - Prematurity (<35 weeks)  \n  - Low birth weight (<2500g)  \n  - Meconium liquor  \n\n- **Baby risk factors:**  \n  - Apgar <5 at 5 mins  \n  - Siblings on IV antibiotics  \n  - Temperature instability  \n  - Respiratory distress  \n  - Bradycardia/tachycardia  \n  - Poor feeding/vomiting  \n  - Abdominal pathology signs  \n  - Hypo/hyperglycemia  \n  - Bleeding disorder signs  \n  - Jaundice  \n  - Abnormal muscle tone  \n  - Mild encephalopathy signs  \n  - Irritability",
    "CG1118 Neonatal hypothermia.txt": "Neonatal hypothermia, detection, management, staff, newborn babies, midwives, healthcare assistants, pediatricians, guidelines, professional judgment, at-risk groups, neonatal observations, skin-to-skin contact, feeding, low temperatures, hot cot, heart rate, temperature, monitoring, warm environment, risk factors, dry, stabilize, correct use, switched on, gradually reduce temperature, continuing care, focus on feeding, patient information, parents, monitoring, audit, Maternity Audit Document.",
    "GP010 Termination of Pregnancy.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and category:\n\n### **General Protocol & Eligibility**  \n- Termination of Pregnancy (TOP)  \n- Under 14 weeks  \n- Medical and Anesthetic risks  \n- Fetal Abnormality  \n- Nurses, Midwives, Obstetricians, Gynaecologists  \n- ASA PS physical classification criteria  \n- Exclusion criteria (second-trimester surgical termination)  \n- Organ systems affecting eligibility (respiratory, cardiovascular, endocrine, renal, liver, neurological, haematological)  \n\n### **Clinical Management & Medications**  \n- **Pain Management:**  \n  - Codydramol (2 tablets, 4-6 hourly PRN, max 8/day for 4 days)  \n  - Ibuprofen (400mg TDS, caution in asthmatic patients, OTC purchase)  \n- **Medical Termination Regimen:**  \n  - Mifepristone (200mg PO)  \n  - Misoprostol (800mcg vaginal)  \n  - High efficacy, low failure rates, patient acceptability  \n- **Follow-Up & Monitoring:**  \n  - Home pregnancy test at 3 weeks  \n  - Positive test \u2192 contact EPU  \n  - Transvaginal ultrasound if still positive at 3 weeks  \n  - No formal EPU follow-up required (high success rate)  \n- **Alternative Management:**  \n  - Medical evacuation (safe, patient-preferred alternative to surgery)  \n  - ERPC (estimated low need post-medical management)  \n\n### **Documentation & Administrative Procedures**  \n- **Forms & Reporting:**  \n  - Form HSA 4 (Yellow Booklet)  \n  - Completed post-TOP, sent to Gynae Secretary (Denise Hemsley)  \n  - Forwarded to Chief Medical Officer (Department of Health)  \n- **Discharge & Referral Protocols:**  \n  - Electronic discharge summary required  \n  - Fax to BPAS within 24 hours (01273 562337)  \n  - TOP Dentrite Database entry mandatory  \n- **Patient Communication:**  \n  - Written and verbal discharge instructions  \n  - No hospital follow-up required  \n  - BPAS provides counselling & contraception advice pre-TOP  \n\n### **Key Principles & Takeaways**  \n- Measurable standards & professional judgement  \n- Patient choice in management (medical vs. surgical)  \n- Streamlined follow-up (home testing, selective EPU contact)  \n",
    "ESHRE RPL Guideline_27112017_FINAL_v2.txt": "- Recurrent Pregnancy Loss (RPL)\n- Investigation\n- Treatment\n- Psychosocial needs\n- Risk factors\n- Health behavior modifications\n- Age\n- Stress\n- Smoking\n- Obesity\n- Alcohol consumption\n- Lifestyle factors\n- Diagnostic investigations\n- Medical history\n- Family history\n- Genetic analysis\n- Thrombophilia screening\n- Thyroid screening\n- Thyroid stimulating hormone (TSH)\n- Thyroid peroxidase (TPO)-antibody\n- Polycystic ovary syndrome (PCOS)\n- Prolactin testing\n- Ovarian reserve testing\n- Luteal phase insufficiency testing\n- Androgen testing\n- Luteinizing Hormone (LH) testing\n- Homocysteine plasma levels\n- Uterine anatomy\n- Transvaginal 3D ultrasound\n- Sonohysterography (SHG)\n- Hysterosalpingography (HSG)\n- Lifestyle factors in male partner\n- Sperm DNA fragmentation\n- Prognosis\n- Genetic counseling\n- Thrombophilia\n- Antiphospholipid syndrome (APS)\n- Antithrombotic prophylaxis\n- Thyroid dysfunction\n- Thyroid autoimmunity\n- Subclinical hypothyroidism\n- Uterine malformations\n- Male factors\n- Sperm quality\n- Lifestyle habits\n- Oxidative stress\n- Smoking\n- Obesity\n- Antioxidants\n- Multi-vitamin supplements\n- Chinese herbal medicines\n- Combined medicines\n- GRADE approach\n- ESHRE guideline development\n- Strong recommendations\n- Conditional recommendations\n- Implementation strategies\n- Revision\n- New evidence\n- Methodology\n- ESHRE guidelines",
    "UHSx Local Requirements PMRT SOP.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance:  \n\n### **Clinical Process & Review Terms:**  \n- **Perinatal Mortality Review Tool (PMRT)**  \n- **Stillbirth**  \n- **Neonatal death**  \n- **Post-neonatal death**  \n- **Late fetal loss**  \n- **Systematic multidisciplinary review**  \n- **Serious incident review process**  \n- **MBRRACE-UK reporting**  \n- **Duty of candor**  \n- **HSIB (Healthcare Safety Investigation Branch) investigations**  \n- **MDT (Multidisciplinary Team) review**  \n- **External panel reviewers**  \n- **Initial review within 72 hours**  \n- **Quarterly audit (NHS Resolution Safety Action 10)**  \n\n### **Communication & Support Terms:**  \n- **British Sign Language (BSL) interpreters**  \n- **Textphone/SMS for hearing/speech difficulties**  \n- **Overseas language interpreters**  \n- **ReciteMe & CardMedic Services**  \n- **Trust Communication team (for translation)**  \n- **Bereavement support**  \n- **Group debriefs (case-by-case basis)**  \n- **Coroner statements**  \n- **Patient Advice and Liaison Service (PALS)**  \n- **Feedback form for parents**  \n\n### **Parental Involvement & Care Review:**  \n- **Obstetricians**  \n- **Neonatologists**  \n- **Midwives & nurses**  \n- **Post-mortem results (if consented)**  \n- **Parental feedback on care (pregnancy, birth, postnatal)**  \n- **Key contact for parents**  \n- **Review report shared face-to-face**  \n- **Sands (parent charity involved in PMRT development)**  \n\n### **Documentation & Compliance:**  \n- **Medical records scanned & securely saved**  \n- **Delays communicated to parents**  \n- **Translation of letters for non-English-speaking families**  \n\nThese terms encapsulate the core clinical, procedural, and communication aspects of the PMRT process, ensuring clarity and adherence to best practices in perinatal mortality review.",
    "GTG 2015 - Birth After Previous CS.txt": "Keywords and clinically significant terms:\n1. Birth after previous Caesarean birth\n2. VBAC (Vaginal Birth After Cesarean)\n3. ERCS (Elective Repeat Cesarean Section)\n4. Uterine rupture\n5. Antenatal care\n6. Labour\n7. Success rates\n8. Complications\n9. Induction of labor\n10. Maternal morbidity\n11. Fetal outcomes\n12. Perinatal mortality\n13. Decision-making\n14. Risk factors\n15. Patient preferences\n16. Mode of delivery\n17. Gestation\n18. Thromboprophylaxis\n19. Antepartum stillbirth\n20. Neonatal respiratory distress\n21. Uterine dehiscence\n22. Perioperative care\n23. Prediction models\n24. Maternal infection\n25. Epidural analgesia\n26. Cervical ripening\n27. Broad-spectrum antibiotics\n28. Venous thromboembolism\n29. Neonatal morbidity\n30. Fetal macrosomia\n31. Uterine scar\n32. Uptake of VBAC\n33. Adverse outcomes\n34. Expertise\n35. Multivariate analysis\n36. Patient information leaflet\n37. Decision aids\n38. Clinical guidelines\n39. Pregnancy outcomes\n40. Personalized decision-making.",
    "P19005 LocSOP for Obstetric Procedural Counts.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance:  \n\n### **Core Concepts & Procedures:**  \n- **Swab, needle, and instrument counts**  \n- **Invasive procedures (obstetric/gynaecological)**  \n- **Retention prevention**  \n- **Two-person counting**  \n- **Pre-procedure and post-procedure counts**  \n- **Count discrepancies**  \n- **Missing item investigation**  \n- **Sharps safety standards**  \n- **Audible counting**  \n- **Reconciliation of counts**  \n- **Clinical incident classification**  \n\n### **Key Actions & Responsibilities:**  \n- **Count recording and signing**  \n- **Disposal of sharps**  \n- **X-ray for missing items (urgent imaging)**  \n- **Documentation (notes, transfer letters)**  \n- **Communication with theatre team**  \n- **Emergency vaginal packing documentation**  \n\n### **Specific Scenarios:**  \n- **Non-reconciled counts (confirmed missing item, removal plan, x-ray if not found)**  \n- **Unreconciled counts at homebirths (hospital x-ray required)**  \n- **Transfer to theatre (counts completed before transfer)**  \n\n### **Audit & Compliance:**  \n- **Pre-procedure checklist**  \n- **Procedural checks/counts**  \n- **End-of-procedure count verification**  \n- **Actions for missing items**  \n\nThese terms encapsulate the critical elements for ensuring patient safety and procedural compliance in obstetric settings outside the operating theatre.",
    "GP016 Operational Guideline for Admission to Gynaecology & Maternity Ward.txt": "Here are the most clinically significant terms and keywords extracted from the text, critical for understanding the guidance:  \n\n### **General Protocol Keywords:**  \n- **Gynaecology Operational & Escalation Protocol GP016**  \n- **Admission criteria**  \n- **Gynaecology & Maternity wards**  \n- **Brighton & Sussex University Hospitals**  \n- **Professional judgement**  \n- **Guideline compliance**  \n- **Measurable standards for action**  \n- **Ward organization**  \n- **Non-gynaecology patient admissions**  \n- **Medical patient criteria**  \n- **Maternity wards for non-obstetric patients**  \n- **Escalation process (clinically sick patients)**  \n- **Cancellation of operations procedure**  \n- **Compliance monitoring**  \n\n### **Cancellation of Operations Process Keywords:**  \n- **Reasons for cancellation:**  \n  - Lack of equipment/staffing  \n  - Bed capacity  \n- **Steps for cancellation:**  \n  - Contact **Gynaecology Service Manager**  \n  - Agree with **consultant in charge**  \n  - Inform **patient** and provide new surgery date  \n  - Notify **theatres, ward manager/coordinator, clinical site manager**  \n  - Complete **Datix contacts**  \n- **Key Contacts:**  \n  - **Chloe Rogers (Service Manager)**  \n  - **Nicky Van Eerde (Maternity/Gynae Manager PRH)**  \n  - **Dawn Elson (Gynae Manager RSCH)**  \n  - **Gynae Admissions (ext 2863)**  \n  - **Out of hours: Clare Halton (email)**  \n\nThese terms encapsulate the essential clinical, procedural, and administrative elements necessary for understanding and implementing the guideline.",
    "Guideline No. 451 Asymptomatic Endometrial Thickening in Postmenopausal Women.txt": "Clinical guideline, postmenopausal women, endometrial thickening, ultrasound, endometrial cancer, risk factors, postmenopausal bleeding, malignancy, hormone therapy, tamoxifen, endometrial biopsy, complications, hyperplasia, Lynch syndrome, estrogen, progesterone, menopausal hormone treatments, Levonorgestrel intrauterine system, estrogen therapy, tibolone, endometrial thickness, aromatase inhibitors, cervical stenosis, misoprostol, hysteroscopy, complications, ultrasonography, dilation and curettage, vasopressin solution, hysteroscopic morcellator.",
    "UHSx Cord Prolapse Protocol.txt": "Here are the most clinically significant terms and keywords extracted from the **Cord Prolapse Management** guideline:\n\n### **Clinical Definition & Risk Factors**  \n- **Cord prolapse**  \n- **Umbilical cord descent**  \n- **Ruptured membranes**  \n- **Incidence (0.1%\u20130.6%)**  \n- **Risk factors**:  \n  - **Long cord**  \n  - **Breech presentation**  \n  - **Artificial rupture of membranes (ARM)**  \n  - **Balloon induction of labor**  \n\n### **Management & Interventions**  \n- **Antenatal care for high-risk women**  \n- **Obstetric Consultant/Registrar review**  \n- **Immediate action upon diagnosis**  \n- **Summon help**  \n- **Emergency caesarean section (CS)**  \n- **Debriefing (postnatal)**  \n- **Post-traumatic stress disorder (PTSD) prevention**  \n\n### **Training & Governance**  \n- **Obstetric emergency training (annual)**  \n- **Clinical incident reporting**  \n- **Audit (hospital & community settings)**  \n- **NICE (2023) Intrapartum Care standards**  \n\n### **Related Documents & Policies**  \n- **UHSC072 Maternity Education Strategy**  \n- **MP050 Caesarean Section 2022**  \n- **CG120 30 Caesarean Section Birth Guideline 2023**  \n- **Superseded documents: MP047, CG12026**  \n\n### **Approval & Governance**  \n- **Joint Obstetric Guideline Group (JOGG)**  \n- **Women\u2019s and Children Divisional Governance Group**  \n- **Medicines Governance Committee**  \n- **Clinical Document Approval Group**  \n\nThese terms encapsulate the **key clinical, procedural, and governance aspects** of cord prolapse management as outlined in the guideline.",
    "ESHRE - PCOS - 2023.txt": "Keywords and clinically significant terms:\n- Polycystic ovary syndrome (PCOS)\n- International evidence-based guideline\n- Assessment\n- Management\n- Diagnosis\n- Evidence-practice gaps\n- Biochemical hyperandrogenism\n- Clinical hyperandrogenism\n- Ultrasound\n- Polycystic ovarian morphology\n- Anti-M\u00fcllerian hormone (AMH)\n- Ethnic variation\n- Menopause\n- Cardiovascular disease risk\n- Diabetes risk\n- Obstructive sleep apnea\n- Endometrial hyperplasia\n- Cancer\n- Psychological features\n- Lifestyle interventions\n- Behavioral interventions\n- Diet\n- Physical activity\n- Weight stigma\n- Metformin\n- Combined oral contraceptive pills\n- Inositol\n- Shared decision-making\n- Mechanical laser and light therapies\n- Bariatric/metabolic surgery\n- Pregnancy\n- Infertility\n- In vitro fertilization (IVF)\n- Ovarian hyperstimulation syndrome\n- GnRH antagonist protocol\n- Letrozole\n- Conflict of interest\n- Peer-reviewed\n- Data repository",
    "UHSx Obstetric VTE guideline.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance:\n\n### **Core Concepts & Conditions**  \n- **Venous Thromboembolism (VTE)**  \n- **Deep Vein Thrombosis (DVT)**  \n- **Pulmonary Embolism (PE)**  \n- **Thromboprophylaxis**  \n- **Thrombophilia** (e.g., **factor V Leiden**, **protein S deficiency**, **antiphospholipid syndrome**)  \n- **Hyperemesis Gravidarum (HG)**  \n- **Ovarian Hyperstimulation Syndrome (OHSS)**  \n- **COVID-19** (pro-thrombotic risk)  \n\n### **Clinical Management & Interventions**  \n- **Low Molecular Weight Heparin (LMWH)** (primary prophylaxis/treatment)  \n- **Fondaparinux** (alternative, requires hematologist consultation)  \n- **Warfarin** (restricted use in pregnancy)  \n- **DOACs** (avoided in pregnancy/breastfeeding)  \n- **Aspirin** (not for thromboprophylaxis; only if other indications)  \n- **Anti-embolic (TED) stockings**  \n- **Wound drains** (for cesarean section on LMWH)  \n\n### **Risk Assessment & Referral**  \n- **Pre-pregnancy counseling**  \n- **Antenatal/postnatal risk assessment**  \n- **Joint Obstetric Haematology Clinic (JOHC)** (key referral point)  \n- **Maternal Medicine Clinic**  \n- **Immediate referral** (for thrombophilia, recurrent VTE)  \n\n### **Timing & Contraindications**  \n- **Early initiation** (thromboprophylaxis in pregnancy)  \n- **Postpartum LMWH** (start 6 hours after birth)  \n- **Contraindications**:  \n  - Active bleeding  \n  - Labor onset  \n  - LMWH allergy  \n  - Specific bleeding risks  \n\n### **Diagnosis & Monitoring**  \n- **Compression duplex ultrasound** (DVT)  \n- **V/Q scan** or **CTPA** (PE)  \n- **Prompt imaging** (suspected VTE)  \n\n### **Dosing & Administration**  \n- **LMWH dosing**:  \n  - Prophylactic vs. treatment (1mg/kg BD for VTE)  \n  - Syringe strengths (40mg, 60",
    "ANTIMICROBIALS CLICK HERE - Gentamicin, Vancomycin, Amikacin, Daptomycin, Teikoplanin etc (Eolas microguide).txt": "Here are the most clinically significant terms and keywords extracted from the provided guideline text:  \n\n### **Key Terms:**  \n1. **UHSussex Antimicrobial guidance** (the clinical guideline source)  \n2. **Eolas platform** (where the guidance is hosted)  \n3. **Antibiotics listed:**  \n   - Amikacin  \n   - Daptomycin  \n   - Gentamicin  \n   - Teicoplanin  \n   - Vancomycin  \n\nThese terms are critical for understanding:  \n- The **source** of the guidance (UHSussex, Eolas).  \n- The **key antibiotics** covered in the recommendations.  \n\nThe rest of the text (e.g., \"Click here to access\") is procedural and not clinically substantive.",
    "MP065 Neonatal BCG Immunisation Programme.txt": "Here are the most clinically significant terms and keywords extracted from the clinical guideline text, critical for understanding the guidance:\n\n### **Key Clinical Terms and Keywords:**\n1. **Neonatal BCG Immunisation Programme**  \n2. **BCG vaccine**  \n3. **Tuberculosis (TB)**  \n4. **Infants (0-12 months)**  \n5. **TB incidence criteria (40/100,000 or greater)**  \n6. **High-risk populations (parent/grandparent from high-TB-incidence country)**  \n7. **Antenatal identification**  \n8. **Postnatal referral**  \n9. **Vaccination pathway (antenatal & postnatal)**  \n10. **Timely immunisation**  \n11. **Failsafe procedures (database checks, missed referrals)**  \n12. **Reporting requirements (local & national)**  \n13. **Sussex Community Trust (service provider)**  \n14. **Midwives, obstetricians, paediatricians, neonatologists (responsible roles)**  \n15. **High-TB-incidence countries (listed in the text, e.g., India, China, Philippines, Pakistan, etc.)**  \n\n### **Critical Eligibility Criteria:**\n- **Geographic criteria:** Infants in UK areas with TB incidence \u226540/100,000.  \n- **Familial criteria:** Infants with parents/grandparents from countries with TB incidence \u226540/100,000.  \n\nThese terms and keywords capture the essential clinical, procedural, and eligibility aspects of the neonatal BCG immunisation guidance.",
    "UHSx Maternity Escalation Policy.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance:\n\n### **Core Policy & Escalation Framework**  \n- Maternity Divert  \n- Escalation levels (e.g., **Red - MOPEL Level 3**)  \n- Standardized approach  \n- Triggers and actions  \n- Risk assessments  \n- Mitigation of risk reviews  \n\n### **Staff & Operational Procedures**  \n- **Safety huddles** (twice daily, AM/PM, 1 hourly during crisis)  \n- **Staffing concerns** (insufficient staff, daily review)  \n- **Bed capacity** (insufficient beds, peaks in activity)  \n- **Neonatal unit closure** (acuity review)  \n- **Urgent/emergency care** (nearest available unit)  \n- **Clinical Site Manager** (single point of contact)  \n- **Tactical Commander** (liaison)  \n- **Delivery Suite Coordinator** (on-call support)  \n\n### **Key Actions During Escalation**  \n- **Diverting pregnant women** (to other Trusts)  \n- **Communication Checklist** (for unit closure/divert)  \n- **Reopening the unit** (when safe)  \n- **Monitoring compliance** (audit, documentation)  \n- **Patient discharges** (expedite well patients/babies)  \n- **Redeployment of staff**  \n\n### **High-Risk Considerations**  \n- **High-risk women** (e.g., insulin-dependent diabetic, bleeding, premature labor)  \n- **Assessment of callers** (clinical need prioritization)  \n- **A&E referral** (if labor progressing)  \n\n### **Communication & Documentation**  \n- **Notifying service users** (reason for divert, apologies)  \n- **Ambulance Control** (coordination)  \n- **Mutual Aid** (NHS Trust collaboration)  \n- **Record of diverted women** (name, address, contact details)  \n- **Handover documentation** (transfer across sites)  \n\n### **Compliance & Training**  \n- **Dissemination plan** (midwives, obstetricians)  \n- **Training on escalation policy**  \n- **Policy accessibility** (Staffnet/Info-Net)  \n- **Archiving old versions**  \n\nThese terms encapsulate the critical aspects of the **UH Sussex Maternity Escalation Policy**, ensuring clarity on **",
    "UHSx Perinatal Mental Health guideline.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance:\n\n### **Core Concepts and Definitions**  \n- Perinatal mental health  \n- Mental health risk  \n- Care pathways  \n- Anxiety disorders (GAD, OCD)  \n- Postpartum psychosis  \n- Severe mental illness (SMI)  \n- Traumatic birth  \n- Trauma-informed care  \n- PTSD (Post-Traumatic Stress Disorder)  \n- Tocophobia (pathological fear of childbirth)  \n\n### **Risk Factors & Detection**  \n- Disclosure of mental health history  \n- Routine mental health screening  \n- Depression and anxiety screening  \n- Risk factors for mental illness  \n- Antenatal care pathway  \n- Urgent review pathway  \n\n### **Services & Referrals**  \n- **Specialist Perinatal Mental Health Service (SPMHS)**  \n- **NHS Talking Therapy** (Time to Talk, Health in Mind)  \n- **Healthy Futures Team** (early intervention for disadvantaged families)  \n- **Perinatal Bereavement Service** (stillbirth/neonatal loss support)  \n- **Hospital Mental Health Liaison Team**  \n- **The Havens at Mill View** (crisis assessment)  \n- **Sussex Mental Healthline** (crisis support)  \n- **Mental Health Rapid Response Service**  \n- **Adult Mental Health Liaison Service**  \n\n### **Clinical Management & Interventions**  \n- Pre-birth planning meeting (at 32 weeks for high-risk cases)  \n- Skin-to-skin contact  \n- Prevention of mother-baby separation  \n- Pain assessment  \n- Diet and rest  \n- Mental capacity assessments  \n- Safeguarding alerts (moderate to severe cases)  \n- Use of interpreters  \n\n### **Medications in Pregnancy & Breastfeeding**  \n- **Psychotropic medication**  \n- **Mood stabilizers & antipsychotics** (risks in pregnancy)  \n- **SSRIs (preferred):** Sertraline, Citalopram, Fluoxetine  \n- **Contraindicated/High-risk medications:**  \n  - Carbamazepine (neural tube defects)  \n  - Lamotrigine (oral cleft risk)  \n  - Lithium (avoid in first trimester)  \n  - Paroxetine (fetal heart defects)  \n  - Sodium Valproate (absolute contraindication)  \n  - Olanzapine/Quetiapine (weight gain, gestational diabetes)  \n  - Venlafax",
    "SP22007 IM Methotrexate SOP and Competency document.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance:\n\n### **Core Clinical Terms**  \n1. **Methotrexate (IM)** \u2013 Primary drug discussed.  \n2. **Ectopic Pregnancy** \u2013 Key condition treated.  \n3. **Persistent Gestational Trophoblastic Disease (PGTD)** \u2013 Another key condition.  \n4. **Intramuscular Injection (IM)** \u2013 Route of administration.  \n5. **Body Surface Area (BSA)** \u2013 Used for dosage calculation.  \n6. **50 mg/m\u00b2** \u2013 Standard dosage for ectopic pregnancy.  \n\n### **Patient Selection & Safety**  \n7. **Informed Consent** \u2013 Mandatory before administration.  \n8. **Contraindications** \u2013 Includes allergies, renal/liver dysfunction, active bleeding.  \n9. **Abnormal Renal/Liver Function Tests** \u2013 Critical for eligibility.  \n10. **Significant Pain/Bleeding** \u2013 Exclusion criterion for ectopic pregnancy.  \n\n### **Administration & Procedure**  \n11. **Z-track Technique** \u2013 Injection method to prevent leakage.  \n12. **Gluteus Maximus** \u2013 Preferred injection site.  \n13. **Aspiration Before Injection** \u2013 Ensures no intravascular entry.  \n14. **Slow Injection (1 mL/10 sec)** \u2013 Reduces adverse effects.  \n15. **Cytotoxic Sharps Bin** \u2013 Required for disposal.  \n\n### **Monitoring & Risks**  \n16. **Side Effects** \u2013 Injection site reactions, ulceration, photosensitivity.  \n17. **Cytotoxic Spill Kit** \u2013 For accidental exposure.  \n18. **Trained Staff Competency** \u2013 Ensures safe administration.  \n\n### **Documentation & Compliance**  \n19. **Standard Operating Procedure (SOP)** \u2013 Must be followed.  \n20. **Prescription Verification** \u2013 Checks before administration.  \n21. **Competency Assessment** \u2013 Required for staff.  \n\nThese terms encapsulate the critical clinical, procedural, and safety aspects of the guideline. Let me know if you need further refinement!",
    "GP005 Emergency Gynaecology Admissions  GAU READY.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and category:\n\n### **General Protocol & Governance**  \n- Emergency Gynaecology Admissions  \n- GAU Protocol (Gynaecology Assessment Unit)  \n- Guidelines (non-prescriptive, reviewed by clinicians)  \n- Scope (Women\u2019s Directorate, WS&QC members, Protocol and Guideline Group)  \n- Responsibilities (clinicians, nurses, ED staff, management)  \n\n### **Clinical Conditions & Presentations**  \n- Acute gynaecological conditions  \n- Hyperemesis  \n- Pelvic pain  \n- Abnormal bleeding  \n- Early pregnancy problems (<14 weeks gestation)  \n- Ectopic pregnancy  \n- Ovarian torsion (urgent surgery within 6 hours)  \n\n### **Assessment & Management**  \n- Baseline observations  \n- Comprehensive history  \n- Prompt assessment  \n- Registrar referral  \n- Clinical management policies  \n- Urgent surgery  \n- CEPOD pathway (emergency surgery)  \n\n### **Hospital Pathways & Referrals**  \n- RSCH (Royal Surrey County Hospital)  \n- PRH (Princess Royal Hospital)  \n- Transfer process (stabilization, emergency surgery)  \n- Gynaecology admissions to other departments  \n- Daily review & repatriation  \n- Gynaecology white board (for tracking pregnant women)  \n\n### **Gynaecology Assessment Unit (GAU) Features**  \n- 24/7 operational  \n- Ultrasound equipment  \n- Examination tools  \n- Consultation room  \n- Specialist teams access  \n- Diagnostic tests  \n- Referral pathways (ED, GP, pregnancy-related)  \n\n### **Exclusion Criteria for GAU**  \n- Unstable vital signs  \n- Immediate surgery required  \n\n### **Patient Flow & Discharge**  \n- Bed management  \n- Timely assessment  \n- Discharge planning  \n- Communication with patients/families  \n\n### **Staff & Contact Information**  \n- Obstetric & Gynaecological consultants (via switchboard)  \n- SHO & SPR cover (after hours/weekends)  \n- Labour Ward, Central Delivery Suite, Day Assessment Unit  \n- Labour Triage, Early Pregnancy Assessment Unit (EPU)  \n- Gynaecological ward/GAU (EPU booking after hours)  \n\nThese terms encapsulate the critical clinical, operational, and procedural aspects of the guideline.",
    "GTG 2015 - Blood transfusion in Obstetrics.txt": "- Blood transfusion\n- Obstetrics\n- Anaemia\n- Haemoglobin\n- Iron deficiency\n- Recombinant human erythropoietin (rHuEPO)\n- Third stage of labor\n- Consent\n- Group and screen samples\n- Cross-matching\n- ABO\n- RhD\n- Kell\n- Cytomegalovirus (CMV)\n- Autologous blood deposit\n- Intraoperative cell salvage (IOCS)\n- Obstetric hemorrhage\n- Blood components\n- FFP\n- Cryoprecipitate\n- Platelets\n- Tranexamic acid\n- Iron supplements\n- Patient blood management (PBM)\n- Coagulation abnormalities\n- Point of care testing\n- Recombinant activated factor VII\n- Jehovah's Witnesses\n- Anesthesia management",
    "MP051 Recovery Care.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and category:\n\n### **General Protocol & Scope**  \n- **Recovery Care Maternity Protocol (MP051)**  \n- **Regional block / General anaesthetic**  \n- **Caesarean section / Operative obstetric procedure**  \n- **Objective standards**  \n- **Professional judgement**  \n\n### **Staff & Responsibilities**  \n- **Recovery Practitioners**  \n- **Midwives**  \n- **Obstetricians**  \n- **Management (protocol review & accessibility)**  \n- **Trained staff (one-to-one care)**  \n\n### **Recovery Process & Standards**  \n- **Post-anaesthetic recovery**  \n- **Stable, conscious, orientated**  \n- **Discharge criteria**  \n- **Designated recovery area**  \n- **Continuous one-to-one care**  \n\n### **Equipment & Handover**  \n- **Specific equipment (bed area & recovery proximity)**  \n- **Handover details (procedure, anesthesia type, post-op instructions)**  \n\n### **Clinical Monitoring & Interventions**  \n- **Obstetric Haemorrhage emergency pathway**  \n- **MEOWS chart (triggering Obstetric & Anaesthetic review)**  \n- **Pain management (anaesthetist review if inadequate)**  \n- **Hypovolaemic shock (heavy bleeding)**  \n- **Oxygen saturation <95% (oxygen therapy required)**  \n- **Temperature outside normal range (doctor notification)**  \n- **Urinary catheter removal (once mobile)**  \n\n### **Discharge & Transfer Criteria**  \n- **Consciousness**  \n- **Stable cardiovascular system**  \n- **Controlled pain**  \n- **Stable vital signs**  \n- **Anaesthetist informed if criteria not met**  \n- **Clean pads & neat bed (before ward transfer)**  \n- **Qualified handover (midwife/nurse to receiving staff)**  \n\n### **Post-Operative Care & Complications**  \n- **Regular analgesic drugs**  \n- **Opiates \u2192 Regular laxatives (unless bowel injury/ileus)**  \n- **Pain scores (regular measurement)**  \n- **Chronic pain / Depression risk (if pain unmanaged)**  \n- **Obstetric anaesthetist referral (for anesthetic complications)**  \n\n### **Documentation & Follow-Up**  \n- **Obstetric Theatre & Recovery Care Pathway (documentation)**  \n- **Post-operative complications monitoring",
    "Uptodate - 2025 - Preexisting and gestational diabetes - Intrapartum and postpartum glucose management.txt": "- pregnancies complicated by diabetes\n- maternal hyperglycemia\n- adverse pregnancy outcomes\n- glycemic targets\n- metabolic demands of labor\n- dextrose-containing intravenous fluids\n- fetal hypoxemia\n- neonatal hypoglycemia\n- glucose monitoring\n- insulin management\n- continuous glucose monitoring devices\n- intrapartum intravenous insulin\n- neonatal hypoglycemia\n- insulin pumps\n- insulin infusion management\n- food restriction\n- prandial insulin coverage\n- metformin\n- scheduled cesarean birth\n- subcutaneous correctional insulin\n- hyperglycemia\n- insulin degludec\n- breastfeeding\n- insulin regimen\n- follow-up testing\n- target blood glucose levels\n- subcutaneous insulin\n- insulin infusion\n- development of overt diabetes",
    "twin-and-triplet-pregnancy-pdf-66141724389829.txt": "- Twin and triplet pregnancy\n- NICE guideline\n- Gestational age\n- Chorionicity\n- Antenatal care\n- Intrapartum care\n- Multidisciplinary team\n- Estimated fetal weight (EFW) discordance\n- Fetal medicine center\n- Feto-fetal transfusion syndrome\n- Fetal growth restriction\n- Preterm birth\n- Mode of birth\n- Continuous cardiotocography\n- Monitoring\n- Referral\n- Specialist obstetrician\n- Progesterone\n- Cervical length scans\n- Twin anaemia polycythaemia sequence\n- Shared decision-making\n- Senior healthcare professional\n- Fetal scalp electrode\n- Cesarean section\n- Adverse outcomes\n- Specialized care\n- Screening\n- Monitoring\n- Updates\n- Twins and Multiple Births Association",
    "UHSx Retained Placenta protocol.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and section:  \n\n### **General Protocol Information**  \n- **Retained placenta**  \n- **Incidence: 1:100 - 200 births**  \n- **Recurrence rate: 8-10%**  \n- **Active management (30-minute threshold)**  \n- **Physiological management (60-minute threshold)**  \n\n### **Causes of Retained Placenta**  \n- **Trapped separated/partially separated placenta**  \n- **Full bladder**  \n- **Uterine atony**  \n- **Constriction ring**  \n- **Uterine abnormality**  \n- **Morbidly adherent placenta (1 in 1500 births)**  \n  - **Placenta accreta / increta / percreta**  \n\n### **Immediate Management (No Active Bleeding)**  \n- **Labour ward coordinator notification**  \n- **Consent for active management**  \n- **Bladder catheterization (indwelling catheter)**  \n- **Breastfeeding to encourage uterine contraction**  \n- **Upright positioning / walking to toilet**  \n- **Unclamp umbilical cord (allow drainage)**  \n- **Homebirth \u2192 hospital transfer**  \n- **Obstetric registrar notification**  \n- **IV access (16G venflon)**  \n- **Blood tests (group & save, FBC, U&Es)**  \n- **IV crystalloid (Hartmann\u2019s / 0.9% NaCl)**  \n- **Vital signs monitoring (BP, pulse q15min)**  \n- **Nil by mouth (NBM)**  \n- **Avoid IV oxytocin if no bleeding**  \n- **Manual removal under regional/general anesthesia**  \n\n### **Immediate Management (Active Bleeding)**  \n- **Oxytocin infusion (40U in 50ml NaCl at 12.5ml/hr)**  \n- **Manual removal in theatre**  \n- **Consent for procedure (Obstetric registrar/SHO)**  \n- **Crossmatch 2 units blood**  \n- **Anaesthetist notification**  \n- **PPH (postpartum hemorrhage) proforma**  \n- **Theatre team alert**  \n- **Accurate fluid balance (MIS, blood loss tracking)**  \n- **Prophylactic IV Cefuroxime**  \n\nThese terms encapsulate the critical clinical actions, diagnostic criteria, and management steps for retained",
    "BASHH - 2014 - Mx of Vulval Conditions.txt": "Keywords and clinically significant terms:\n- Vulval disorders\n- Vulval lichen sclerosus\n- Vulval lichen planus\n- Vulval eczema\n- Vulval psoriasis\n- Vulval intraepithelial neoplasia (VIN)\n- Vulval pain\n- Vulvodynia\n- Multidisciplinary approach\n- Ultra-potent topical steroids\n- Topical corticosteroids\n- Emollient soap substitute\n- Cognitive behavioral therapy\n- Colposcopy\n- Imiquimod cream\n- Vulvectomy\n- Tricyclic antidepressants\n- Gabapentin\n- Pregabalin\n- Acupuncture\n- Referral guidelines\n- Complications\n- Diagnosis\n- Treatment\n- Follow-up\n- Clinical features\n- Management\n- Psychological support\n- Long-term results\n- Therapeutic approach\n- Pelvic floor muscle assessment\n- Transcutaneous electrical nerve stimulation\n- Vaginal trainers\n- Pain modifiers\n- Pain clinic\n- Treatment-resistant cases\n- Randomized clinical trial",
    "MD086 Maternity Service Staffing.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance:\n\n### **Core Staffing & Roles**  \n- **Midwifery staff**  \n- **Nursing staff**  \n- **Support staff**  \n- **Specialist midwives**  \n- **Supervisors of midwives** (1:15 ratio)  \n- **Trainee supervisors**  \n- **Head of Midwifery**  \n- **Deputy Head of Midwifery**  \n- **Labour Ward (LW) coordinator**  \n- **Manager on-call rota (24/7)**  \n- **Maternity Care Assistants (MCA)**  \n\n### **Care Settings & Services**  \n- **Royal Sussex County Hospital (RSCH)**  \n- **Princess Royal Hospital (PRH)**  \n- **Homebirths**  \n- **Community services**  \n- **Antenatal care**  \n- **Intrapartum care**  \n- **Postnatal care**  \n- **Acute sector**  \n- **Primary care**  \n\n### **Staffing Guidelines & Tools**  \n- **Birthrate Plus** (workforce planning ratios)  \n- **Safer Childbirth** (minimum staffing standards)  \n- **Skill mix rationale**  \n- **Staffing allowances** (travel time, community care hours)  \n- **Required staffing levels**  \n- **Contingency plans**  \n\n### **Operational & Governance Processes**  \n- **24/7 on-call coverage**  \n- **Leave arrangements** (sickness, unplanned workload)  \n- **Bank office staffing**  \n- **Annual staffing review**  \n- **Business case for funding**  \n- **Compliance audits**  \n- **Governance & risk management**  \n\n### **Key Policies & References**  \n- **Managing Sickness Absence Policy**  \n- **CNST (Clinical Negligence Scheme for Trusts)**  \n- **RCOG 2007 (Royal College of Obstetrics & Gynaecology)**  \n\nThese terms encapsulate the critical aspects of maternity staffing, service delivery, and operational management as outlined in the guideline.",
    "CG1198 Management of Hypertensive disorders of pregnancy.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by category for clarity:\n\n### **1. Definitions & Key Conditions**  \n- **Hypertensive disorders of pregnancy**  \n- **Chronic hypertension** (present at booking or before 20 weeks)  \n- **Gestational hypertension** (new hypertension after 20 weeks, no significant proteinuria)  \n- **Pre-eclampsia** (new hypertension after 20 weeks + significant proteinuria)  \n- **Severe pre-eclampsia** (pre-eclampsia + severe hypertension/symptoms)  \n- **Eclampsia** (convulsions associated with pre-eclampsia)  \n- **HELLP syndrome** (haemolysis, elevated liver enzymes, low platelets)  \n\n### **2. Blood Pressure & Proteinuria Assessment**  \n- **Hypertension thresholds**:  \n  - **Mild-moderate**: 140/90\u2013159/109 mmHg  \n  - **Severe**: \u2265160/110 mmHg  \n- **Proteinuria assessment**:  \n  - **Reagent-strip reading device** (avoid first morning void)  \n  - **Urinary protein:creatinine ratio (PCR)**  \n\n### **3. Risk Factors for Pre-eclampsia**  \n- **Moderate risk**:  \n  - Maternal age \u226540  \n  - Nulliparity  \n  - Family history of pre-eclampsia  \n  - BMI \u226535  \n- **High risk**:  \n  - Chronic hypertension  \n  - Previous hypertensive disorder in pregnancy  \n  - Chronic kidney disease  \n  - Autoimmune disease (e.g., SLE)  \n  - Diabetes  \n\n### **4. Monitoring & Management**  \n- **Antenatal care for high-risk women**:  \n  - **Uterine artery Dopplers**  \n  - **Serial ultrasounds**  \n  - **BP monitoring + urinalysis every 2 weeks from 28 weeks**  \n  - **CTG if reduced fetal movements**  \n- **Symptoms of pre-eclampsia**:  \n  - Severe headache  \n  - Vision problems  \n  - Rib pain  \n  - Vomiting  \n  - Sudden swelling  \n\n### **5. Treatment & Targets**  \n- **Antihypertensive medications**:  \n  - **Labetalol (first-line)**  \n  - **Nifedipine**  \n  - **Methyldopa**  \n- **Target BP**: \u2264135/85 mmHg  \n- **Avoid certain medications in pregnancy**  \n\n",
    "CG20015 Parent-to-Baby Skin Contact.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance:  \n\n### **Key Clinical Terms:**  \n1. **Skin-to-skin contact**  \n2. **Kangaroo care** (in neonatal units)  \n3. **Breastfeeding** (stimulation, establishment)  \n4. **Bonding** (mother-baby attachment)  \n5. **Regulation** (heart rate, breathing, digestion, temperature)  \n6. **Oxygen saturation** (improvement in neonates)  \n7. **Stress reduction** (in babies)  \n8. **Growth support** (in preterm/neonatal care)  \n9. **Uninterrupted contact** (immediate post-birth)  \n10. **Antenatal discussions** (promoting skin-to-skin)  \n\n### **Critical Practices & Considerations:**  \n11. **Immediate skin-to-skin after birth** (including **caesarean births**)  \n12. **Instinctive behaviors** (baby\u2019s self-attachment, movement toward breast)  \n13. **Safety monitoring** (clear airway, baby\u2019s well-being)  \n14. **Documentation** (observations of mother and baby)  \n15. **Partner involvement** (support in baby care)  \n16. **Warm blanket** (to maintain temperature)  \n\nThese terms encapsulate the essential clinical and practical aspects of the guideline, ensuring proper implementation and understanding of best practices in maternal and neonatal care.",
    "CG12030 Caesarean Birth Guideline.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and category:\n\n### **General Guideline & Scope**  \n- Caesarean Section (CS)  \n- Evidence-based guidance  \n- Pregnant women/people  \n- Clinical indication  \n- Maternal request  \n- Elective vs. emergency CS  \n- Categories (1, 2, 3, 4)  \n- Breech presentation  \n- HIV and CS  \n- Enhanced recovery programs  \n\n### **Healthcare Professionals Involved**  \n- Midwives  \n- Obstetricians  \n- Anaesthetists  \n- Maternity recovery staff  \n- Operating Department Practitioners  \n- Maternity Assistants  \n- Consultant Obstetrician  \n\n### **Clinical Decision-Making & Documentation**  \n- Category 1 (within 30 minutes)  \n- Category 2 (within 75 minutes)  \n- Maternal/fetal compromise  \n- Consultant involvement  \n- Clear documentation  \n- Pre-operative checklist (MIS, WHO surgical safety checklist)  \n\n### **Preoperative & Intraoperative Management**  \n- Antenatal preoperative assessment  \n- Regional anaesthesia (preferred)  \n- General anaesthesia (rapid sequence induction, cricoid pressure)  \n- Prophylactic antibiotics (before skin incision)  \n- Intravenous crystalloid co-loading  \n- Prophylactic vasopressors  \n- Fluid warming device  \n- Intra-operative cell salvage  \n- Carbetocin (for postpartum haemorrhage prevention)  \n- Surgical techniques for CS at term  \n\n### **Postoperative Care & Recovery**  \n- Immediate recovery care  \n- Skin-to-skin contact  \n- Breastfeeding support  \n- Pain relief (TAP blocks, morphine, diclofenac, paracetamol, NSAIDs)  \n- Avoid codeine in breastfeeding  \n- Discharge medication (paracetamol, ibuprofen, senna)  \n- Wound care monitoring  \n- Urinary catheter removal (12-24 hours)  \n- Thromboembolic prophylaxis  \n\n### **Risks & Complications**  \n#### **Increased with CS:**  \n- Peripartum hysterectomy  \n- Maternal death  \n- Placenta accreta (future pregnancy)  \n- Uterine rupture (future pregnancy)  \n- Neonatal mortality  \n- Asthma (childhood)  \n- Childhood obesity  \n\n#### **Decreased with CS:**  \n- Urinary incontinence (>1 year post-birth)  \n- Faecal incontinence (>1 year post-birth vs. assisted vaginal birth)",
    "MP011 Obesity In Pregnancy.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and category:\n\n### **General Protocol & Scope**  \n- Obesity in pregnancy  \n- BMI \u226530, BMI \u226535, BMI \u226540, BMI \u226550  \n- Multidisciplinary care (MDT)  \n- Professional judgment  \n\n### **Clinical Complications**  \n- Diabetes (GDM)  \n- Hypertension  \n- Increased hospital attendance  \n- Difficulties with clinical procedures  \n- VTE (venous thromboembolism) risk  \n- Nutritional deficiencies (post-bariatric surgery)  \n\n### **Management & Care Recommendations**  \n- **BMI-based care:**  \n  - **BMI \u226530:** Counseling, thromboprophylaxis, MDT care  \n  - **BMI \u226535:** Obstetric referral, additional scans, antenatal consultations  \n  - **BMI \u226540:** Obstetric anesthetic plan, tissue viability assessment  \n  - **BMI \u226550:** Anesthetic referral, specialist equipment  \n\n- **Labour & Birth:**  \n  - Obstetric unit birth (recommended)  \n  - Continuous CTG monitoring  \n  - Suturing during C-section  \n  - Home birth considerations (access, evacuation, birthing pool risks)  \n\n- **Postnatal Care:**  \n  - VTE risk assessment  \n  - Breastfeeding support  \n  - Weight management  \n\n### **Bariatric Surgery & Pregnancy**  \n- **Preconception:**  \n  - Delay pregnancy (first year post-surgery)  \n  - Contraception (LARC preferred, COC less effective)  \n\n- **Nutrition:**  \n  - Dietician referral  \n  - Supplements (Folic acid 5mg, B12, Vitamin D, beta-carotene)  \n\n- **Antenatal Management:**  \n  - Nutritional blood tests (FBC, LFTs, Ca, Folate, B12, Ferritin, Vitamin D)  \n  - GDM screening (BM monitoring instead of OGTT)  \n  - Serial growth scans (32 & 34 weeks)  \n  - Anesthetic referral if BMI >50  \n\n- **Surgical Complications:**  \n  - Internal hernia (Petersen\u2019s space)  \n  - Gastric band slippage (vomiting, short interval post-surgery)  \n\n- **Intrapartum & Postnatal:**  \n  - No evidence for early induction/C-section preference  \n  - Post-bariatric follow-up (band adjustments, body contouring advice)  \n\n",
    "CG14020 Female Genital Mutilation (FGM).txt": "Here are the most clinically significant terms and keywords extracted from the FGM guideline, organized by category for clarity:\n\n### **Core Definitions & Concepts**  \n- **Female Genital Mutilation (FGM)**  \n- **Clitoridectomy**  \n- **Excision**  \n- **Infibulation**  \n- **Non-medical reasons**  \n- **No health benefits**  \n- **Significant harm**  \n\n### **Legal & Professional Obligations**  \n- **Mandatory reporting** (under 18)  \n- **Legal responsibilities**  \n- **UK health professionals**  \n- **Police reporting**  \n- **Safeguarding measures**  \n- **FGM Information Sharing system**  \n- **Data collection** (FGM datasets)  \n- **Patient objections respected**  \n\n### **Clinical & Risk Management**  \n- **Recognition of FGM**  \n- **Management of FGM**  \n- **Prevalence** (high in certain countries, >200 million globally)  \n- **Risk assessment tool** (for under 18s)  \n- **Indicators of risk**  \n- **Significant/immediate risk** (refer to Social Services/CAIT/Police/MASH)  \n- **Emergency measures** (if harm imminent)  \n- **Health complications of FGM**  \n\n### **Documentation & Referrals**  \n- **Healthcare record documentation**  \n- **Referrals to safeguarding**  \n- **Named Nurse/Safeguarding Lead**  \n- **Share information with GP**  \n- **FGM Information Leaflet** (for at-risk individuals)  \n\n### **Special Populations & Contexts**  \n- **Maternity-specific guidance**  \n- **Children under 18**  \n- **Family risk assessment**  \n- **Defibrillation** (offered at 20 & 30 weeks if declined) *(Note: This appears to be an unrelated error in the text and may not belong to FGM guidelines.)*  \n\n### **Support & Resources**  \n- **Professional support** (consult agencies)  \n- **Audit guidelines**  \n- **Support resources for professionals**  \n\nThese terms encapsulate the critical aspects of the guideline, ensuring clarity on definitions, legal duties, clinical actions, and risk management protocols. Let me know if you'd like further refinement!",
    "MP004 Antenatal Screening - Infectious Diseases HIV.txt": "Here are the most clinically significant terms and keywords extracted from the clinical guideline text, organized by relevance and importance:\n\n### **Core Concepts & Screening Principles**  \n- **Antenatal screening for HIV**  \n- **Mother-to-child transmission (MTCT)**  \n- **Early pregnancy screening (ideally by 10 weeks)**  \n- **Universal screening (regardless of prior results)**  \n- **Late booking / unbooked women (still eligible for screening)**  \n- **Re-screening for known HIV-positive women**  \n- **Specialist referral for positive diagnosis**  \n\n### **Declining Screening & Follow-Up**  \n- **Optional screening (right to decline)**  \n- **Booking blood test declined form**  \n- **Documentation in hand-held notes**  \n- **Re-offer screening at 28 weeks**  \n- **SMRHW (Specialist Midwife for Reproductive Health and Wellbeing) follow-up at 32 weeks**  \n\n### **Sample Collection & Processing**  \n- **Sample taken by midwife/practice nurse**  \n- **Proper labeling (according to lab guidelines)**  \n- **Unacceptable samples (repeat within 10 working days)**  \n- **Results available within 5 working days**  \n- **Follow-up responsibility (within 10 working days)**  \n- **Notification for women who terminate/miscarry**  \n\n### **Test Results & Management**  \n- **Negative result (does not confer protection, repeat test offered)**  \n- **HIV-positive result (confirmatory testing in Brighton pathology lab)**  \n- **Equivocal result**  \n- **Specialist Midwife & Health Advisors notified**  \n- **Confidentiality rights**  \n- **Informed consent for disclosure**  \n\n### **Ongoing Care & Protocols**  \n- **BSUH protocols (Brighton and Sussex University Hospitals)**  \n- **Specialist assessment within 10 working days**  \n\n### **Audit, Monitoring & Compliance**  \n- **Minimum auditable standards (e.g., uptake, declines, new diagnoses)**  \n- **Annual audit of women\u2019s notes**  \n- **Mandatory midwife training on antenatal screening**  \n- **Incident reporting for screening errors**  \n- **Care pathway adherence (screening at booking, follow-up within 10 days)**  \n\n### **Key Personnel & Systems**  \n- **SMRHW (Specialist Midwife for Reproductive Health and Wellbeing)**  \n- **Designated Health Advisors",
    "SP23003 Caring for a friend or relative SOP.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance:  \n\n### **Key Clinical and Operational Terms:**  \n1. **Maternity SOP** (Standard Operating Procedure)  \n2. **Pregnant women and people**  \n3. **Midwives**  \n4. **Friends or relatives**  \n5. **Supervision framework**  \n6. **Personal accountability**  \n7. **Conflicts of interest**  \n8. **Appropriate boundaries**  \n9. **Antepartum care**  \n10. **Intrapartum care**  \n11. **Postpartum care**  \n12. **Adverse outcomes** (mother or baby)  \n13. **Midwife wellbeing**  \n14. **Compliance monitoring**  \n15. **Annual appraisals**  \n16. **PMA supervision checks** (Professional Midwifery Advocate)  \n\nThese terms capture the core clinical, ethical, and procedural aspects of the guideline. Let me know if you need further refinement!",
    "CG21009 Maternity Fluid Management as an In-patient or in Labour.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, categorized for clarity:\n\n### **Core Concepts & Conditions**  \n- **Hyponatraemia** (including prevention, diagnosis, management)  \n- **Fluid balance management** (positive fluid balance, thresholds)  \n- **Electrolyte balance** (sodium monitoring, sodium levels)  \n- **Labour** (midwife-led care, induction of labour, high-risk pregnancy)  \n- **Ketonuria** (mild/moderate/severe, dehydration, ketosis)  \n- **Eclampsia** (fluid monitoring)  \n\n### **Diagnostic & Monitoring Terms**  \n- **Sodium monitoring** (venous sample, blood gas machine, lab testing)  \n- **Peripartum Sodium Monitoring Pathway** (reference for repeat testing)  \n- **Blood sodium levels** (thresholds: <125 mmol/L, <130 mmol/L, \u2265130 mmol/L)  \n- **Fluid balance chart** (oral/IV intake, urine output, losses)  \n- **Ketones** (urine dipstick, hypoglycemia)  \n\n### **Clinical Interventions**  \n- **IV fluids** (volumetric pumps, ml/hour, restrictions for ketosis)  \n- **Oxytocin cessation** (if Na <125 mmol/L, consultant review)  \n- **Insulin and dextrose infusions** (6\u20138 hourly sodium checks)  \n- **Severe hyponatremia management** (2.7% saline, furosemide, HDU/ICU transfer)  \n- **Fluid restriction** (for symptomatic hyponatremia)  \n\n### **High-Risk Scenarios & Actions**  \n- **Symptomatic hyponatremia** (medical emergency, senior team involvement)  \n- **Postpartum monitoring** (paediatric alert for hyponatremic mothers, discharge criteria)  \n- **Ketosis management** (carbohydrate intake, Nutricia Pre-op)  \n\n### **Thresholds & Protocols**  \n- **>1500 mL positive fluid balance** (triggers sodium monitoring)  \n- **IV fluid thresholds** (hourly intake recording)  \n- **Sodium critical values** (125 mmol/L, 130 mmol/L)  \n\nThese terms encapsulate the guideline\u2019s critical elements for clinical decision-making, risk mitigation, and patient management.",
    "NICE - 2021 - Antenatal Care.txt": "- Antenatal care\n- NICE guideline\n- Routine antenatal clinical care\n- Information and support\n- Pregnant women\n- Partners\n- Common problems during pregnancy\n- Minority ethnic backgrounds\n- Deprived areas\n- Female genital mutilation\n- Cardiac conditions\n- Obstetrician\n- Long-term medicines\n- Domestic abuse\n- Venous thromboembolism\n- Gestational diabetes\n- Pre-eclampsia\n- Blood pressure\n- Proteinuria\n- Fetal growth restriction\n- Symphysis fundal height\n- Ultrasound scan\n- Babies' movements\n- Stillbirth rates\n- Breech presentation\n- Fetal movement awareness\n- Peer support\n- Sleep position\n- Nausea and vomiting\n- Ginger\n- Antiemetics\n- Hyperemesis gravidarum\n- Heartburn\n- Pelvic girdle pain\n- Physiotherapy\n- Vaginal discharge\n- Lumbopelvic belt\n- Unexplained vaginal bleeding\n- Neonatal unit care\n- England and Wales\n- Complications\n- Evidence reviews\n- Committee discussions\n- NICE topic page\n- Update information",
    "2020-10 SECAmb Suspected Preterm Labour Guidance v0.0.1.txt": "- Suspected Preterm Labour\n- Frontline Clinicians\n- Babies born very premature\n- Expert care\n- Extremely preterm births\n- Labour ward\n- Neonatal units\n- Gestational age\n- Clinical status\n- Transfers\n- Necessary level of care",
    "CG13019 Triage of Maternity Patients Guideline.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance:\n\n### **Core Concepts & Systems**  \n- **Triage** (Maternity Triage, Antenatal Triage)  \n- **BSOTS system** (standardized assessment, prioritization)  \n- **MEOWS** (Modified Early Obstetric Warning Score)  \n- **Urgency categories**: **Red/Orange/Yellow/Green**  \n- **SBAR tool** (structured handover)  \n- **Antenatal Triage Assessment Card (TAC card)**  \n- **Symptom-specific algorithms**  \n\n### **Clinical Assessments & Protocols**  \n- **Initial assessment within 15 minutes**  \n- **Vital signs**: Temperature, Pulse, Respirations, Blood Pressure, Pain levels  \n- **Fetal assessment**: Lie, Presentation, Fetal movements, Fetal heart rate  \n- **Urinalysis**  \n- **VTE Risk Assessment** (thromboprophylaxis for COVID+ patients)  \n- **Red flag symptoms**:  \n  - O2 saturations **<93%**  \n  - **Blue lips**, **audible wheeze**, **chest pain**  \n  - **Unable to complete a sentence at rest**  \n- **Growth scan & ANC follow-up**  \n\n### **Key Processes & Responsibilities**  \n- **Telephone triage** (BSOTS standard form, referral criteria)  \n- **Escalation pathway** (Labour Ward Co-ordinator, MDT decision)  \n- **Handover** (direct communication, in-person/telephone)  \n- **Antenatal Day Assessment Unit (ADAU)** (documentation in MIS)  \n- **Neonatal referrals** (community pathway)  \n\n### **High-Risk Conditions & Interventions**  \n- **APH** (Antepartum Hemorrhage)  \n- **SROM** (Spontaneous Rupture of Membranes)  \n- **IOL** (Induction of Labour)  \n- **COVID-19 management**:  \n  - **Thromboprophylaxis** (10 days post-discharge)  \n  - **Hydration & mobility** advice  \n  - **High temperature (>37.8\u00b0C)** \u2192 **call 111/A&E**  \n\n### **Staff & Workflow Requirements**  \n- **Midwife/Obstetrician roles** (BSOTS-trained)  \n- **Staffing adjustments**",
    "MP036 Care of Women with Haemoglobinopathies.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and category:  \n\n### **General Terms**  \n- **Haemoglobinopathies**  \n- **Protocol**  \n- **Professional judgement**  \n- **Childbearing women**  \n- **Midwives**  \n- **Obstetricians**  \n- **Antenatal screening coordinator midwife**  \n- **Partner testing**  \n\n### **Thalassaemia-Specific Terms**  \n- **Thalassaemia trait** (no maternal/fetal hazards)  \n- **Thalassaemia major** (increased risks)  \n- **Thalassaemia intermedia** (increased risks)  \n- **Haematologist involvement**  \n\n### **Sickle Cell Disease-Specific Terms**  \n- **Sickle cell disease in pregnancy**  \n- **Crisis (third trimester)**  \n- **Intravenous infusion** (prevent dehydration)  \n- **Pre-eclampsia risk**  \n- **Fetal growth restriction**  \n\n### **Management Terms**  \n- **Antenatal sickle cell crisis management**:  \n  - **Admit to delivery suite**  \n  - **Obstetric referral**  \n  - **Anesthetic team referral**  \n  - **Adequate analgesia**  \n\n- **Labour management**:  \n  - **No contraindication to normal obstetric practice**  \n  - **Continuous electronic fetal monitoring**  \n\n- **Postnatal management**:  \n  - **High risk for venous thromboembolism (VTE)**  \n  - **Low-molecular-weight heparin (LMWH) prophylaxis**  \n\nThese terms capture the essential clinical and management aspects of the guideline. Let me know if you'd like further refinement!",
    "UHSussex - MP049 - Assisted Vaginal Birth.txt": "Assisted Vaginal Birth, Protocol, Professional Judgement, Midwives, Obstetricians, Management, Assisted Instrumental Vaginal Birth, Morbidity, Indications, Contraindications, Risks, Ventouse, Forceps, Informed Consent, Location, Analgesia, Bladder Care, Hygiene, Neonatal Resuscitation, Ventouse, Kiwi Cup, Forceps, Episiotomy, Perineal Care, Aftercare, Post-Delivery Documentation, Debriefing, Traumatic Birth Experience.",
    "UHS Intrahepatic Cholestasis(ICP) protocol.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance to diagnosis, management, and monitoring:\n\n### **Diagnosis & Assessment**  \n- **Intrahepatic Cholestasis of Pregnancy (ICP)**  \n- **Pruritus (itching)**  \n- **Raised bile acids**  \n- **Liver Function Tests (LFTs)**  \n- **Bile acid measurement**  \n- **Exclude other causes of itching/liver dysfunction**  \n\n### **Risk Factors & Complications**  \n- **Maternal risks**  \n- **Perinatal risks**  \n- **Severe ICP (bile acids >100 \u00b5mol/L)**  \n- **Moderate ICP**  \n\n### **Management & Treatment**  \n- **Consultant-led care**  \n- **Vitamin K (10mg water-soluble if PT elevated or fat malabsorption)**  \n- **Timing of birth (planned by consultant obstetrician)**  \n  - **38-39 weeks (moderate ICP)**  \n  - **35-36 weeks (severe ICP)**  \n- **Continuous electronic fetal monitoring (if bile acids \u2265100 \u00b5mol/L)**  \n- **Progesterone-only or non-hormonal contraception (for previous ICP)**  \n\n### **Postnatal Care & Follow-up**  \n- **Itch resolves after birth**  \n- **LFTs normalize within weeks**  \n- **Postnatal bile acids & LFTs at 4 weeks**  \n- **Investigate persistent abnormalities**  \n\n### **Recurrence & Future Pregnancies**  \n- **Risk of recurrence**  \n- **Consultant-led care in future pregnancies if symptoms develop**  \n\n### **Audit & Compliance**  \n- **Proportion offered guideline-compliant timing of birth**  \n- **Proportion offered continuous fetal monitoring**  \n\nThese terms encapsulate the critical aspects of ICP diagnosis, risk stratification, management, and follow-up as per the guideline.",
    "MP008 Infections in Pregnancy.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by topic for clarity:  \n\n### **General Protocol Terms**  \n- **Infections in Pregnancy**  \n- **Maternity Protocol MP008**  \n- **Key Principles**  \n- **Professional judgement**  \n- **Scope (childbearing women, suspected/confirmed infection)**  \n- **Responsibilities (Midwives, Obstetricians, Management)**  \n\n### **Group B Streptococcus (GBS) in Pregnancy**  \n- **Routine screening not recommended**  \n- **IV antibiotic prophylaxis in labour**  \n- **Intrapartum management (previous GBS pregnancies)**  \n- **GBS-specific IAP (Intrapartum Antibiotic Prophylaxis)**  \n- **Risks and benefits summary**  \n- **Intrapartum antibiotics guidelines**  \n- **Protocol if antibiotics declined**  \n\n### **Herpes Simplex in Pregnancy**  \n#### **Antenatal Management**  \n- **Primary genital herpes infection**  \n- **Recurrent genital herpes**  \n- **Caesarean section (active ulcers at birth)**  \n- **Daily suppressive aciclovir (from 36 weeks)**  \n- **HIV-positive women with genital herpes**  \n- **PCR testing (week 34+)**  \n\n#### **Delivery & Intrapartum Management**  \n- **First episode within 6 weeks of delivery \u2192 Caesarean recommended**  \n- **Invasive procedures avoided (vaginal delivery with lesions)**  \n- **IV acyclovir during labor**  \n- **Neonatal team involvement (testing, neonatal acyclovir)**  \n- **Recurrent herpes \u2192 Vaginal delivery (if no other indications for C-section)**  \n\n#### **Preterm Premature Rupture of Membranes (PPROM)**  \n- **Primary infection with active lesions \u2192 C-section**  \n- **IV acyclovir during conservative PPROM management**  \n\n#### **Postnatal HSV Transmission**  \n- **Hand hygiene (washing before touching baby)**  \n- **Avoid kissing if cold sores present**  \n- **Breastfeeding encouraged (unless nipple lesions)**  \n\nThese terms capture the essential clinical actions, recommendations, and considerations for managing **GBS** and **herpes simplex virus (HSV)** in pregnancy, labor, and postpartum care.",
    "Lipid Lowering Therapy in Pregnancy.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance:  \n\n### **Key Conditions & Populations**  \n- **Pregnancy**  \n- **Breastfeeding**  \n- **Familial hypercholesterolaemia (FH)**  \n- **Severe hypertriglyceridaemia**  \n- **Hypertriglyceridemia**  \n- **Pancreatitis (history of)**  \n- **Genetic disorders (causing high triglycerides)**  \n- **Dyslipidaemia in children**  \n\n### **Key Medications & Therapies**  \n- **Statins** (contraindicated in pregnancy)  \n- **Ezetimibe**  \n- **PCSK9 inhibitors (PCSK9i)**  \n- **Bile acid sequestrants** (safe in breastfeeding)  \n- **Fibrates (e.g., fenofibrate)**  \n- **Omega-3 fish oils (e.g., OMACOR)**  \n- **Icosapent ethyl**  \n\n### **Key Clinical Actions & Recommendations**  \n- **Specialist care (for FH in pregnancy)**  \n- **Limited treatment options (for severe hypertriglyceridemia)**  \n- **Counseling & referral**  \n- **Maternal medicine & lipidology services involvement**  \n- **Continuation of icosapent ethyl (if already on it)**  \n- **High-dose omega-3 (caution advised)**  \n- **Theoretical risks vs. benefits of statins in pregnancy**  \n\n### **Key Themes**  \n- **Lipid control in pregnancy**  \n- **Medication safety in pregnancy/breastfeeding**  \n- **Risk assessment & multidisciplinary care**  \n\nThese terms encapsulate the core clinical considerations for managing lipid disorders in pregnancy and breastfeeding.",
    "MD089 Labour Ward Staffing.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, which are critical for understanding the guidance:\n\n### **General Terms**  \n- Protocol  \n- Measurable standards  \n- Objective standards  \n- Professional judgement  \n- Scope  \n- Responsibilities  \n\n### **Staff Roles & Responsibilities**  \n- **Midwives & Obstetricians**  \n  - Access, read, understand, follow guidance  \n  - Professional judgement in protocol application  \n\n- **Management Team**  \n  - Protocol review (Trust & National recommendations)  \n  - Accessibility (parents & staff)  \n\n- **Labour Ward Coordinators**  \n  - Safe & effective staffing  \n  - Day-to-day management  \n  - Escalation of concerns  \n  - Referrals (obstetric team, anaesthetic team, midwifery management, supervisor of midwives)  \n\n- **Consultant Obstetricians**  \n  - Physical presence on labour ward  \n  - Resource for staff  \n  - Support for doctors in training, midwives, students  \n  - Attendance in emergencies  \n\n- **Anaesthetic Cover**  \n  - Duty anaesthetist (24/7 coverage)  \n  - Anaesthetic service for procedures & emergencies  \n  - Availability (24 hours/day, 7 days/week)  \n\n### **Key Operational Terms**  \n- Labour ward staffing  \n- Maternity units  \n- Emergency situations  \n- Obstetric emergencies  \n- Escalation process  \n\nThese terms encapsulate the core clinical, operational, and governance aspects of the guideline.",
    "MP043 Prevention of Acid Aspiration.txt": "Here are the most clinically significant terms and keywords extracted from the guideline text, which are critical for understanding the guidance:  \n\n1. **Acid Aspiration Syndrome**  \n2. **Late pregnancy**  \n3. **Labor**  \n4. **Peri-partum anesthesia**  \n5. **Neuraxial anesthetic technique**  \n6. **High-risk women**  \n7. **Elective caesarean section**  \n8. **Emergency caesarean section**  \n9. **Low-risk factors**  \n10. **High-risk factors**  \n11. **Intervention in labor**  \n12. **Aspiration in labor**  \n13. **Antacid prophylaxis**  \n14. **Oral medications**  \n15. **Dietary restrictions**  \n16. **Fluid intake guidelines**  \n\nThese terms capture the key clinical considerations, risk factors, and management strategies outlined in the guideline.",
    "CG18006 NIPE SOP.txt": "Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance:\n\n### **Core Screening Program & Objectives**  \n- **Newborn and Infant Physical Examination (NIPE)**  \n- **Congenital abnormalities** (heart, hips, eyes, testes)  \n- **Early assessment & intervention**  \n- **Mortality & morbidity reduction**  \n- **Screening within 72 hours of birth**  \n\n### **Eligibility & Referrals**  \n- **University Hospitals Sussex (UH Sussex) NHS Trust**  \n- **St. Richard\u2019s (SRH) & Worthing (WH) Hospitals**  \n- **Referral pathways** (based on location)  \n- **NICU (Neonatal Intensive Care Unit)**  \n- **SCBU (Special Care Baby Unit)**  \n\n### **Performance & Compliance**  \n- **Key Performance Indicators (KPIs)**  \n- **Quarterly reporting** (PHE, SIT team)  \n- **Missed screenings** (parental decline, illness, preterm <34+0 weeks)  \n- **Escalation for screening pathway failures**  \n- **Serious incident reporting**  \n\n### **Training & Practitioner Requirements**  \n- **Accredited NIPE training**  \n- **Competent practitioners** (doctors, midwives)  \n- **E-learning modules & annual updates**  \n- **Minimum screening numbers for certification**  \n\n### **Hip Screening & Developmental Dysplasia of the Hip (DDH)**  \n- **RACH Baby Hip Ultrasound Clinic**  \n- **Developmental Dysplasia of the Hip (DDH)**  \n- **Risk factors** (breech, family history, abnormal exam)  \n- **Ultrasound scan at 4-6 weeks**  \n- **\"One-stop shop\" model for assessment**  \n- **Treatment protocols for DDH**  \n- **6-8 week GP hip recheck**  \n- **Failed appointment follow-up**  \n\n### **Documentation & Follow-Up**  \n- **Badgernet (maternity IT system)**  \n- **CRIS IT system (neonatal/child death notifications)**  \n- **Stillbirth & neonatal death protocols**  \n- **Parental decline documentation**  \n- **USS (ultrasound) appointment tracking**  \n\n### **Key Abbreviations**  \n- **ANNB** (Antenatal and Newborn)  \n- **CHIS** (Child Health Information Services)  \n",
    "CG1122 Maternal Transfer & Onsite Handover of Care.txt": "- Maternal transfer\n- Onsite handover of care\n- Antenatal\n- Intrapartum\n- Postnatal\n- Multidisciplinary\n- Informed consent\n- SBAR\n- Obstetricians\n- Midwives\n- ITU/HDU transfers\n- Neonatal readmissions\n- Health visitors\n- Maternity SBAR Transfer Form\n- Shift changes\n- Monitoring and audit\n- Discharge forms\n- Postnatal concerns\n- Antenatal Clinic\n- Community Midwives\n- Labour Ward\n- Bramber Ward\n- Safeguarding\n- Bereavement Multidisciplinary Team",
    "Eclampsia prompt card ED RSCH PRH.txt": "Here are the most clinically significant terms and keywords extracted from the **Eclampsia Prompt Card** guideline, critical for understanding and implementing the guidance:\n\n### **Emergency Management**  \n- **2222 obstetric & neonatal emergency call**  \n- **Airway, Breathing, Circulation (ABC)**  \n- **Oxygen (O\u2082) 10L via face mask**  \n- **BP & Sats monitoring**  \n- **2 x Grey Cannulas (IV access)**  \n\n### **Magnesium Sulfate (MgSO\u2084) Therapy**  \n- **Loading Dose: 4g MgSO\u2084 (8ml of 50% solution) IV over 5 mins (doctor-administered)**  \n- **Maintenance Dose: 10g MgSO\u2084 (20ml) in 50ml total volume @ 5ml/hour via Alaris pump**  \n- **Seizure recurrence: Bolus 2g MgSO\u2084 IV over 3 mins**  \n- **Check Mg blood levels**  \n- **Calcium gluconate (on standby for toxicity)**  \n\n### **Blood Pressure Control (Labetalol Protocol)**  \n- **IV Labetalol Bolus: 10-20mg every 10 mins (max 200mg)**  \n- **IV Labetalol Infusion: 300mg in 60ml (start at 4ml/hr, double every 30 mins, max 32ml/hr)**  \n- **Continuous BP monitoring**  \n\n### **Supportive Measures**  \n- **Fluid restriction**  \n- **Catheter with urometer (strict fluid balance)**  \n- **Fetal assessment post-seizure**  \n- **Delivery consideration (once maternal stabilization)**  \n\nThese terms encapsulate the **key actions, medications, dosages, and monitoring** required for managing eclampsia per the guideline."
}